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“Cancer in Germany” is published every two years 
by the Association of Population-based Cancer 
Registries in Germany (GEKID) and the German 
Centre for Cancer Registry Data (ZfKD) at the Robert 
Koch Institute.
This eighth edition includes data supplied in 
anonymised form by the regional cancer registries 
under the Federal Cancer Registry Data Act. The 
data is processed and evaluated by the German Cen-
tre for Cancer Registry Data, which was newly esta-
blished at the beginning of 2010. Data for 2007 and 
2008 was received for all federal states (Laender) 
with the exception of Baden-Württemberg, which 
only began registration in 2009. They have contri-
buted to the results presented here according to the 
estimated completeness of registration for each can-
cer site. 
Although some new elements are included, the 
overall structure of “Cancer in Germany” has been 
retained.
The basic principles are outlined in this introduc-
tory chapter, which includes a section on cancer 
registration in Germany provided by representatives 
of GEKID. This is followed by a chapter on metho-
dology and an overview of the results. Following 
this, the results and epidemiological data for the 
most important cancer diseases are presented on a 
series of double-page spreads, together with an 
account of key risk factors and available early detec-
tion measures. As in previous editions, these two 
chapters were contributed by co-workers of the Can-
cer Information Service. The final chapter on can-
cers in childhood is written by the German Child-
hood Cancer Registry.
This edition includes additional sections on liver 
cancer, cancer of the bladder and biliary tract, and 
multiple myeloma. This means that the results now 
cover about 93 % of all new cases of cancer in Ger-
many (not including non-melanoma skin cancers).
For the first time, this report presents tumour 
stages (T stage) for all sites for which sufficient data 
is available. In addition, pooled survival rates have 
been evaluated with data fromeight federal states. 
Even though the data do not cover Germany as a 
whole (the inclusion criteria are described in the 
chapter on methodology), the use of the broader 
database means it is possible to make much more 
representative statements about the survival pros-
pects of cancer patients in Germany than were pos-
sible in the past.
Methodological developments in the estimation 
of incidence have also shifted the focus of the trends 
for incidence and mortality. This edition of the 
report concentrates on the developments over the 
past decade. These can be presented and assessed 
more accurately because modelling has largely been 
dispensed with and the database has become much 
broader since about 1999. The changed methodo-
logy will also ensure a smooth transition from “esti-
mating” to “counting” the frequency of cases in Ger-
many. However, this will only be possible when suf-
ficiently complete data are received from all federal 
stateson their cases of cancer. In addition to the age-
standardised rates, the report also shows the deve-
lopment of absolute numbers for incidence and 
mortality. The figures indicate in particular how 
demographic changes are affecting the impact 
which cancer has on society.
As well as presenting the results up to 2008, this 
edition includes a prognosis of the numbers of new 
cases of cancer for 2012. Current trends for the vari-
ous cancer sites according to age and sex are also 
taken into consideration. 
There is usually a period of two to three years in 
population-based cancer registries between the 
deadline for the receipt of reports covering a diagno-
sis year and the publication of the relevant statistics. 
This is due in part to the delays in reporting and in 
part to the extent of the data processing in the regis-
tries. The incoming data has to be compared conti-
nually with the existing data and also with death 
reports and causes of death. By bringing deadlines 
for the delivery of cancer registry data forward by 
about three months and shortening the processing 
time in ZfKD, it will in future be possible be publish 
“Cancer in Germany” some six months earlier. In 
addition, an annual update of key results will be pro-
vided in an interactive database on the ZfKD Web-
site (www.krebsdaten.de). In the near future, more 
detailed results about epidemiological cancer deve-
lopments in Germany will be available sooner than 
in the past.
A key goal of the German Centre for Cancer 
Registry Data with this report, with further planned 
publications and the restructuring of the Website is 
to provide better data about cancer epidemiology in 
Germany. 
An important contribution is also made by the 
population-based cancer registries of the federal sta-
teswith their regular publication of regional results. 
1 About this report
1 1 Introduction 
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 ▶ Predicting the future number of new cancer 
cases is important for requirement planning in 
the health service. The population-based cancer 
registries provide the data needed for this.
The data from population-based cancer registries 
not only serve to describe the incidence of cancer in 
the population, they are also used for scientific 
research into the causes of cancer and for research 
on healthcare effectiveness. Such studies (case-con-
trol studies, cohort studies, etc.) investigate issues 
such as:
 ▶ What are the causes of childhood leukaemia?
 ▶ Do women who take hormone-replacement the-
rapy for menopausal problems have a higher 
risk of developing breast cancer?
 ▶ Do people in certain occupational groups deve-
lop lung cancer more frequently?
 ▶ Are diagnosis, therapy and aftercare being car-
ried out according to the latest standards?
Population-based cancer registries make it possi-
ble for all cases of the disease that have occurred in 
a defined population to be taken into account in 
research projects. This ensures that the findings of 
such studies usually apply not only to a specific hos-
pital or group of patients, but to the entire popula-
tion. Population-based case-control studies and 
cohort studies use data from population-based can-
cer registries for research into the causes and risks 
of cancer. 
 ▶ Does mammography screening lead to a decrea-
se in the discovery of tumours at late stages, thus 
reducing breast cancer mortality?
The data from population-based cancer registries 
with complete coverage can be used to objectively 
assess the effectiveness of preventive and screening 
programmes. For example, a possible decline in the 
numbers of advanced cases of cancer in the popula-
tion can be assessed on the basis of data from popu-
lation-based registries. The aim is to show the desi-
red reduction in mortality among the participants of 
such a measure by linking the registry data with the 
screening programme.
The degree of completeness of data capture that 
has now been reached in many registries has also 
led to an increase in the use of the registry data. For 
example:
 ▶ Analyses of survival prospects after contracting 
cancer 
 ▶ A study of the oncological care and long-term 
quality of life of cancer patients
1 2 Aims and tasks of population-based 
cancer registries
Population-based cancer registries are institutions 
for the collection, storage, processing, analysis and 
interpretation of epidemiological data on the occur-
rence and frequency of cancers within defined regis-
tration areas (e.g. the inhabitants of a German fede-
ral state). The data from the cancer registries are 
also indispensable as a basis for further research 
into the causes of cancer and for efforts to improve 
patient care.
Findings from population-based cancer regist-
ries include:
 ▶ The prostate, intestines and lungs are the most 
common cancer sites among men.
The incidence of cancers (i.e. how frequently they 
occur annually in a certain population) can be 
described with the data from population-based can-
cer registries. The incidence is broken down accor-
ding to cancer type, patient age and sex, and other 
characteristics. Reliable information on incidence is 
indispensable for describing the extent and type of 
the burden that cancer places on a population.
 ▶ For some years there have been as many new 
cases of lung cancer among women under the 
age of forty as among men in the same age 
group. 
The development (trend) of incidence over time 
can only be observed with the data from population-
based cancer registries. The registries have a key 
function for health reporting in this context 
 ▶ Regional differences in the incidence of malig-
nant melanoma of the skin can be observed in 
Europe and in Germany.
Population-based cancer registries can analyse 
the regional distribution of types of cancer. It is also 
their task to examine observed cancer clusters and 
their causes, which usually involves more detailed 
analytical studies.
 ▶ The survival expectations of men with testicular 
cancer have improved markedly over the last 
quarter century.
Population-based cancer registries conduct survi-
val analyses of all cancer patients in their registra-
tion region. Population-based survival rates are an 
important parameter for assessing the effectiveness 
of the diagnosis, therapy and aftercare of cancers.
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lish a link between the data and the individual. How-
ever, in order to safeguard patients' privacy and their 
right to control what happens to their data, all popu-
lation- based registries are required under state 
legislation to adopt extensive precautions to protect 
and secure personal data.
Undistorted evaluation of the data is only possi-
ble if more than 90 % of all new cancer cases are 
registered. The cooperation of all physicians and 
dentists involved in diagnosis, treatment and after-
care is therefore crucial for the informational value 
of data from a population-based cancer registry. Pati-
ents are also requested to take an active part in can-
cer registration. Ask your doctor to report your case 
to the cancer registry! This way you too can make a 
contribution to the assessment of cancer trends and 
to cancer research and help to improve cancer detec-
tion, treatment and aftercare. 
1 3 Developments of cancer registration 
in Germany
After the expansion of the cancer registry of Baden-
Württemberg to cover the whole federal state, new 
cases of cancer can now be registered systematically 
throughout Germany on the basis of regional legis-
lation. The current situation of population-based 
cancer registration is very good. The long-standing 
cancer registries of many federal states have also 
achieved considerable improvements in their rates 
of registration since the last issue of “Cancer in Ger-
many” in 2010.
Whereas for 2005/2006 only seven federal state-
sand the administrative district of Muenster in 
North Rhine-Westphaliawere estimated to have 
achieved complete registration, by 2008 this was the 
case for ten federal states, together with four out of 
five administrative districts of North Rhine-West-
phalia. This means that reliable data about new 
cases of cancer is now available for more than 60 % 
of the population. Germany has thus caught up with 
the leading group of nations. 
Numerous individual initiatives in the federal 
states have contributed to the improved perfor-
mance of the cancer registries. The Federal Govern-
ment has also provided further support for the 
population-based cancer registration, with the Fede-
ral Cancer Registry Data Act of 2009 and the estab-
lishment of the German Centre for Cancer Registry 
Data (ZfKD) in the Robert Koch Institute. Since the 
end of 2010, all regional cancer registries have been 
supplying their data to the ZfKD in a uniform for-
mat. These data form the basis for the analysescar-
ried out by the ZfKD which are presented in this 8th 
edition of “Cancer in Germany”. 
The International Agency for Research on Cancer of 
theWorld Health Organisation (IARC, Lyon/F) once 
 ▶ An evaluation of pilot projects on mammogra-
phy screening, quality-assured breast cancer dia-
gnostics, and skin-cancer screening
 ▶ A study of the connection between social strata 
and cancer incidence and mortality
 ▶ Cooperation with the cancer centres, e.g. in the 
assessment of the long-term survival of treated 
patients
 ▶ A study on the effectiveness of colonoscopy 
screening
 ▶ (for a detailed list see: www.gekid.de).
The evaluation of the screening measures intro-
duced in Germany presents a special challenge for 
the population-based cancer registries. Among 
other things, the focus is on assessing mammogra-
phy screening, which has been introduced nation-
wide. The population-based cancer registries have 
already provided detailed basic data for the first eva-
luation report on mammography screening (www. 
mammo-programm.de), and this is being used for 
quality assurance and an initial assessment of the 
programme. A new task here is the identification of 
interval carcinomas. 
In 2008, the statutory health insurers introduced 
screening for skin cancer, and the effects of this on 
the incidence of skin cancer and mortality can also 
be investigated with the data from the cancer regist-
ries. The National Cancer Plan emphasised the key 
role of cancer registration for assessing the effects of 
organised programmes for the early detection of 
cancer. A number of measures were recommended 
to ensure improved harmonisation between the 
early recognition programmes and the information 
collected in the cancer registries.
A longer-term task of the population-based can-
cer registries is examining the effectiveness of the 
vaccination programme for girls aged between 12 
and 17 against human papilloma viruses (HPV) with 
the aim of significantly reducing the number of new 
cases of cervical cancer.
In order to establish nationwide health monito-
ring and an on-going comparative analysis of cancer, 
it is necessary to have population-based cancer 
registries covering all federal states. This goal was 
achieved with the inclusion of Baden-Württemberg 
in 2009. The Federal Cancer Registry Data Act, 
which came into force in the same year, further 
improved the scope for collecting and evaluating the 
anonymised cancer registry data at the national level 
by the newly established German Centre for Cancer 
Registry Data at the Robert Koch Institute. 
In order to be able to pool information about an 
individual's cancer condition from different sour-
ces, the data are collected in such a way that multiple 
reports on the same person are recognizable. For 
research purposes it should be possible to re-estab-
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get “Evaluation of cancer screening using the data of 
the regional cancer registries”, and it is also closely 
involved in the sub-section “Clinical cancer registra-
tion”. Together with the German Tumour Centres 
Working Group (ADT) a basic uniform dataset is 
being developed for cancer registration. The reports 
and recommendations (in German)can be accessed 
on the Website of the Federal Ministry of Health 
(www.bundesgesundheitsministerium.de). 
Overall, cancer registration and data utilisation 
are developing satisfactorily and the prospects for 
the future are positive. If the doctors and patients 
remain willing to report, and with the necessary 
financial and political support for the cancer regist-
ries, the goal of comprehensive, nationwide cancer 
registration in Germany will soon be reached.
The improved and internationally accepted can-
cer registration in Germany marks the start of a new 
era of utilisation of the data from cancer registries 
for oncological research and treatment, to the bene-
fit of patients with cancer.
2 Methodology
2 1 Completeness of cancer registration
The usefulness of population-based data on cancer 
depends to a large extent on how completely new 
cases of cancer are registered. Therefore the Robert 
Koch Institute (RKI) regularly checks the complete-
ness of the data from the population-based cancer 
registries in Germany. For 2008, data was available 
for all the federal states with the exception of Baden-
Württemberg, where registration only began in 
2009. There are various ways of estimating the 
completeness of population-based cancer registrati-
on. A simple and reliable method is the determina-
tion of the DCO-percentage, i.e. the proportion of 
cancer cases which are only ascertained from death 
certificates. A high DCO-percentage is generally an 
indication of incomplete registration of cases at an 
earlier stage. However, if a registry has only been 
gathering data over a relatively short period, a DCO-
case could be linked to a cancer diagnosis which pre-
ceded the start of registration. New methods to esti-
mate completeness, e.g. the ‘flow method’ develo-
ped in Great Britain, cannot be implemented with 
the dataset currently available to the German Centre 
for Cancer Registry Data (ZfKD), among other 
things because of the lack of details about the dateof 
first registration. However, these methods have not 
yet proved to be superior.
The German Centre for Cancer Registry Data 
therefore estimates the degree of completeness 
using another internationally accepted indicator, 
namely the ratio of mortalityto incidence. Assuming 
that diagnostics and treatment and thus the survival 
again called on the German cancer registries to con-
tribute to the 2012 edition of “Cancer Incidence in 
Five Continents” (Vol. X), and they transferred their 
anonymised datasets on new cancer cases to the 
IARC. In the previous issue, data was presented 
from seven German cancer registries, but with the 
improved quality of the data gathered in Germany it 
is now possible for further federal states’registries to 
meet the strict criteria of the IARC and qualify for 
inclusion in the WHO’s central publication series. 
The Association of Population-based Cancer 
Registries in Germany (GEKID), which has cancer 
epidemiologists as members in addition to all the 
population-based cancer registries, has continued to 
work intensively over the past two years on the 
improved use of the cancer registry data. An impor-
tant result is the new interactive cancer atlas of 
GEKID on cancer incidence and mortality. The atlas 
is available on the Website of GEKID (www.gekid.
de), with maps offering interactive regional compa-
risons for 23 cancer sites. Important agreements 
were also reached on the methodology for calcula-
ting survival rates, with the aim of improving the 
transparency and comparability of this important 
parameter. 
In addition to presenting the cancer registry data, 
the population-based cancer registries and GEKID 
have also been involved in planning and carrying 
out research projects, in particular within the 
“Cancer epidemiology” funding programme of the 
German Cancer Aid (Deutsche Krebshilfe). These 
research projects have already led to a number of 
important international publications, for example 
on survival after cancer in Germany or on the con-
nections between research and cancer registry data. 
Information about further research projects and 
current publications is provided on the GEKID 
Website. 
These examples show clearly that the focus of 
cancer registration in Germany is shifting towards 
the active utilisation of the data. This development 
is essential, because without scientific utilisation of 
the laboriously gathered data, cancer registration 
would amount to little more than meaningless 
countingexercises. In addition to the research, the 
cancer registries have also made numerous signifi-
cant contributions to public health reporting. 
Finally, the pooled anonymised datasets from the 
registries can now also be used by external scientists 
(on application to the German Centre for Cancer 
Registry Data). 
Within the framework of the National Cancer 
Plan, both the German Centre for Cancer Registry 
Data and the population-based cancer registries, 
through GEKID,havetaken active roles. In the field 
“Further development of the early detection of can-
cer”, GEKID is playing a leading role in the sub-tar-
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i.e. by summing the observed and expected values 
for all individual sites.
The results presented in this report for individual 
sites showed some shifts in comparison with previ-
ous estimates, but for the majority of registries the 
values calculated retrospectively for 2006 using the 
new method only differed very slightly (<2 %) from 
the previous estimates. Therefore, despite the 
change in the methodology, it seems justifiable to 
make a direct comparison between the earlier and 
the current estimates when assessing the complete-
ness of registration (Figure 2.1.1). However, the new 
method for estimating completeness also has its 
limitations, in particular if the mortality of a type of 
cancer is low, either in absolute terms or relative to 
the incidence (e.g. testicular cancer, malignant 
melanomas, thyroid gland cancer) or if the introduc-
tion of screening measures affects the ratio of mor-
tality to incidence differently for different regions. 
This is the case in particular for breast cancer. The 
national Mammography Screening Programme was 
introduced successively across Germany between 
2005 and 2008, so that in particular in the early sta-
ges of screening the anticipated spike in incidence 
showed marked regional differences over time, 
which in turn impacted on the M/I indices and thus 
also on the estimates of completeness. Taking this 
into account, two registries were assessed as com-
plete which had reached a completeness of more 
than 90 % in the previous estimate (which had been 
largely unaffected by screening effects), although 
they did not reach this value in the current estima-
tes. In a few years’ time, assuming comparable 
levels of participation in screening programmes in 
all German federal states, this limitation will no lon-
ger apply for the estimation of completeness of 
registration of new cases of breast cancer.
According to the current estimate for 2008, 
already ten federal states and four out of five admi-
nistrative districts of North Rhine-Westphalia 
reached an estimated completeness of at least 90 %. 
Of these, eight federal states (and the eastern part of 
NRW) achieved more than 95 % in comparison with 
the above-mentioned reference registries. This 
marks a considerable increase in completeness 
within 6-8 years (Figure 2.1.1). However, while this 
development is very positive, it should be noted that 
in two federal states with well-established registra-
tion the degree of completeness remains only 
slightly above 80 %. 
Using the new method, some differences remain 
in the completeness for specific cancer sites. Regis-
tration is best for thyroid gland carcinomas and 
breast cancer, with 12 and 13 of the federal states 
regarded as complete, respectively. The deficits are 
greatest for cancers of the liver, gall bladder and pan-
creas, with only six federal states having complete 
prospects of cancer patients do not differ signifi-
cantly throughout Germany and that regionally vary-
ing cancer risks are reflected in the official cause-of-
death statistics, the incidence in each region can be 
estimated using the mortality /incidence ratio in the 
reference registry in combination with the regional 
mortality. The incidence in the catchment area of a 
cancer registry is estimated on the basis of the data 
from another cancer registry in which registration is 
known to be complete. This figure is then compared 
with data actually collected.
In a working group made up of ZfKD personnel, 
representatives of the registries and external scien-
tists, key modifications were made in 2011 to aspects 
of the method used to estimate completeness, while 
retaining the mortality to incidence ratio. The fol-
lowing inclusion criteria were agreed on for a new 
reference region:
 ▶ Comprehensive data over at least 10 years (i.e. at 
present since 1999)
 ▶ Completeness for cancer overall as a mean since 
1999 of more than 90 % (using the previous 
method) and more than 80 % for all individual 
years 
 ▶ DCO-proportion for cancer overall as a mean 
since 1999 or from the sixth year since the foun-
ding of the registry of less than 15 %.
These criteria were met by Saarland (the previous 
reference region) and also by registries from Ham-
burg, Bremen, Saxony and the Münster administra-
tive district (NRW). It will be possible to extend this 
‘reference pool’ of registries step by step over the 
coming years as further registries meet the criteria. 
The completeness of the registries in the reference 
region can now also be estimated by comparison 
with the expected values. Assuming a largely cons-
tant M/I ratio across Germany with respect to site, 
age group, and sex, the expected incidence values 
are calculated for six age groups (for men and 
women in each case) and for 24 cancer sites as well 
as for the group of ‘other sites’. In contrast to the 
previous models, only (log)-linear trends over time 
are used for modelling (smoothing) the expected 
values, since a shortened period does not offer suf-
ficient data for more complex models. Furthermore, 
in order to allow for occasional fluctuations, the 
observed incidence values are also smoothed. 
If the age-, sex- and site-specific mortality in the 
investigation region was less than 50 fatalities over 
the 10-year period of investigation, then instead of 
the ratio of mortality and incidence we used the 
modelled incidence in the reference region to calcu-
late the expected number of new cases of cancer.
The completeness for cancer overall was calcula-
ted for the first time by means of an additive method, 
10 Cancer in Germany
throughout Germany, it was required that the new 
method should ensure a smooth transition from 
estimating to counting the number of new cases of 
cancer every year in Germany, while also making it 
possible to assess trends over time. The figures pre-
sented in this report are still based on the estimates 
of completeness. In contrast to the previous method, 
modelling is dispensed with as far as possible. The 
numbers of new cases by site and diagnosisyear are 
derived from the summation of the results of the 
‘complete’ registries and the expected values from 
the estimates for the federal states which were jud-
ged not to be complete, or for which data was not yet 
available (Baden-Württemberg). DCO cases were 
also included for the registries estimated to be com-
plete, but only beginning with the sixth year of com-
prehensive registration. For the first five years, the 
DCO-proportions(by site, age, and sex) for the refe-
rence region were used.
reporting. For most sites, reporting to between eight 
and ten registries was rated as complete for 2008, so 
that the estimates of incidence for Germany now 
have a very broad basis, and have correspondingly 
become more reliable and stable.
2 2 Estimating incidence and numbers of 
new cases, with results for Germany 
up to 2008
On the basis of the data from the population-based 
cancer registries in Germany, the German Centre 
for Cancer Registry Data estimates the numbers of 
all new cases of cancer in Germany every year. The 
modification of the method used to estimate the 
completeness of registration also made it necessary 
to adapt the method previously used to estimate the 
incidences. As a result of the steady extension of the 
data base, particularly since 1999, and the medium-
term perspective of complete cancer registration 
Figure 2 1 1
Development of the estimated completeness of the population-based cancer registries in Germany, 2000 to 2002 and 2008,  
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steady. For women, an increase in incidence rates is 
found after 2005. This is mainly attributable to the 
start of the Mammography Screening Programme 
for the early detection of breast cancer. The increase 
was expected and can be interpreted as a first indica-
tion of the effectiveness of screening. The increase 
in the number of cases discovered in the early stages 
of the programme suggests that many tumours are 
being discovered at a much earlier stage than in the 
past. Given the staggered introduction of screening 
across Germany between 2005 and 2008 it is dif-
ficult to estimate at present whether the increase in 
incidence rates will continue. In the Muenster admi-
nistrative district, where the programme was intro-
duced in 2005, there were already reports of a slight 
decline for 2009, whereas in Hamburg the rates in 
the same year showed a further marked increase 
(www.krebs- register-nrw.de and www.krebsregister-
hamburg. de). The experience in other countries 
after the introduction of screening suggests that in 
the long term the incidence rates in the relevant age 
group (50-69 years) will be higher than the level 
before the start of screening. By linkage with the 
data from the early detection units, the data from the 
population-based cancer registries will contribute in 
the coming years to the evaluation of the screening 
programme in particular regardingany reduction in 
mortality from breast cancer. 
When the intensive screening programme for 
skin cancer was launched in mid-2008 it already led 
in the same year to a marked increase in the repor-
ted incidence rates for malignant melanomas. How-
ever, it is once again difficult to predict the future 
developments, especially because in this case there 
is no comparable experience from other countries, 
in contrast to mammography screening. 
There is no ready explanation for the increasing 
incidence of thyroid gland cancer in recent years, 
although similar trends can be observed in some 
other European countries and the USA. Screening 
programmes as such do not play any role but it may 
well be possible that diagnostic procedures have 
meanwhile become more intensive, leading to the 
increased discovery of smaller, slowly growing 
tumours. This is supported by the fact that mortality 
is also continuing to decline slightly, although from 
a low level. 
Other trends, such as the falling rates of stomach 
cancer, of lung and bladder cancer for men, or the 
increasing rates of lung cancer for women, have 
already been observed over a longer period and can 
be attributed, among other factors, to changes in 
smoking habits. 
The improved data situation also makes it possi-
ble to make more reliable statements about regional 
variations in the frequency of cancer in Germany. 
Stable differences, both in mortality and incidence, 
In contrast to earlier estimates, for which the 
incidence was modelled over the full period of obser-
vation, the data is now only smoothed slightly by 
means of the log-linear modelled expectation values, 
and this will be used less and less as growing num-
bers of registries provide complete reporting. The 
incidence trend therefore increasingly resembles 
‘counted’ values for mortality from the cause of 
death statistics andthe trends reported from the 
registries,and includes random fluctuations from 
year to year. 
A key advantage of the modified method is the 
more precise presentation, which allows improved 
assessment of current trends, for example those that 
arose in recent years as a result of the introduction of 
screening programmes, in particular for breast can-
cer and malignant melanoma. However, it is not yet 
possible to present long-term trends. The new 
methods can only be used to estimate completeness 
and incidences since 1999 and the results of the ear-
lier estimates are not directly comparable. Long term 
trends are therefore not presented in this report, but 
in some cases qualitative comments are included. 
A further advantage is that the new method is 
more stable. The results for the years presented here 
will now only change significantly if amendments 
are made to the data in the registries themselves 
(due to late reports or corrections). This applies pri-
marily of course to the last year of diagnosis.
As expected, the methodological alterations have 
led to some changes in comparison to the figures 
published in 2010 for the diagnosis years up to 
2006. The estimates for the numbers of new cases 
of cancer for 2006 for the oesophagus, the ovaries, 
testicles, and the central nervous system are now 
some 15-20 % lower, for tumours in the oral cavity 
and pharynx, the larynx, and for leukaemia and lym-
phoma they are some 10-15 % higher. The new over-
all estimates for 2006are higher by 3 % for men and 
6 % for women, and this is attributable to a more 
realistic estimate of the cancer sites which are not 
considered individually in this report, e.g. tumours 
of bone and articular cartilage, of the efferent uri-
nary tract, or of the reproductive organs. The inci-
dence rates for these rare cancer sites can now be 
calculated using the new method. In particular for 
these cases the broader data base offers much better 
opportunities for interpretation than the extrapola-
tion of results from individual registries. This 
applies both for the assessment of current trends 
and for the comparison with international results. 
The nationwide estimates of incidences for these 
sites will in future be presented on the ZfKD Web-
site or in special publications. 
After age-standardisation, mortality rates for 
men and women have declined since1999 and inci-
dence rates for men have remained more or less 
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Table 2 2 1
Estimated numbers of new cases of cancer in Germany 2008
No  of incident cases Incidence rate¹
Cancer site ICD-10 Men Woman Men Woman
Oral cavity and pharynx C00-C14 9,520 3,490 19.1 5.9
Oesophagus C15 4,800 1,380 9.0 2.1
Stomach C16 9,210 6,660 16.8 8.6
Colon and rectum C18-21 35,350 30,040 63.0 39.4
Liver C22 5,270 2,340 9.4 3.2
Gallbladder and biliary tract C23-24 2,270 2,890 4.0 3.6
Pancreas C25 7,390 7,570 13.4 9.8
Larynx C32 3,610 510 6.9 0.9
Lung C33-34 33,960 15,570 60.6 24.3
Malignant melanoma of the skin C43 8,910 8,890 17.1 16.6
Breast C50 520 71,660 1.0 123.1
Cervix C53 4,880 9.5
Uterus C54-55 11,280 17.2
Ovaries C56 7,790 12.2
Prostate C61 63,440 110.9
Testis C62 3,970 9.5
Kidney C64 8,960 5,540 16.5 8.2
Bladder C67 11,460 4,510 20.1 5.6
Central nervous system C70-72 3,810 2,990 7.7 5.3
Thyroid gland C73 1,710 4,160 3.5 8.6
Hodgkin's lymphoma C81 1,160 920 2.7 2.0
Non-Hodgkin lymphomas C82-85 7,270 6,430 13.7 9.8
Multiple myeloma C90 2,980 2,650 5.3 3.6
Leukaemias C91-95 6,340 5,080 12.4 7.9
Other cancer sites 14,760 15,870 27.3 22.5
Total cancer² C00-C97 w/o C44 246,700 223,100 450 0 349 9
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1 Age-standardised(European Standard)  2 Not including non-melanoma skin cancer
Figure 2 2 1
The most frequent tumour sites as a percentage of all new cases of cancer in Germany 2008  
(not including non-melanoma skin cancer)
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Table 2 2 2
Number of deaths from cancer in Germany 2008
Source: Official cause of death statistics, Federal Statistical Office, Wiesbaden
No  of deaths Mortality rate¹
Cancer site ICD-10 Men Woman Men Woman
Oral cavity and pharynx C00-C14 3,776 1,170 7.4 1.8
Oesophagus C15 3,655 1,135 6.8 1.6
Stomach C16 5,929 4,581 10.5 5.6
Colon and rectum C18-21 13,726 12,936 24.0 14.7
Liver C22 4,523 2,539 7.9 3.1
Gallbladder and biliary tract C23-24 1,153 2,092 2.0 2.6
Pancreas C25 7,327 7,508 13.0 9.2
Larynx C32 1,275 209 2.4 0.3
Lung C33-34 29,505 12,841 52.3 19.2
Malignant melanoma of the skin C43 1,365 1,135 2.5 1.6
Breast C50 136 17,209 0.2 24.6
Cervix C53 1,596 2.6
Uterus C54-55 2,420 3.0
Ovaries C56 5,529 7.6
Prostate C61 12,134 20.6
Testis C62 153 0.3
Kidney C64 3,060 2,041 5.4 2.5
Bladder C67 3,611 1,921 6.2 2.0
Central nervous system C70-72 3,008 2,554 5.8 4.0
Thyroid gland C73 279 429 0.5 0.5
Hodgkin's lymphoma C81 193 148 0.4 0.2
Non-Hodgkin lymphomas C82-85 2,926 2,658 5.2 3.2
Multiple myeloma C90 1,882 1,786 3.3 2.2
Leukaemias C91-95 3,908 3,400 6.9 4.2
Other cancer sites 12,346 11,735 22.0 14.1
Total cancer² C00-C97 w/o C44 115,870 99,572 205 6 130 5
1 Age-standardised (European Standard)  2 Not including non-melanoma skin cancer
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Figure 2 2 2
Most frequent tumour sites when cancer was the cause of death in Germany 2008 
Source: Official cause of death statistics, Federal Statistical Office, Wiesbaden
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tation of the age-specific incidence for men and 
women in this report shows, the incidence rate usu-
ally increases considerably with age, so that before 
comparing incidence or mortality in various coun-
tries and regions, or in the same population at diffe-
rent times, it is important to carry out age-standardi-
sation to allow for the differences in age structure. 
This involves weighting and then summing the age-
specific rates. The frequency of a disease or a cause 
of death is then presented for a total of 100,000 peo-
ple with a defined age structure, in this report the 
European Standard (WHO, 1976).  
Cancer incidence and mortality risks 
Age-specific incidence rates and mortality rates can 
be interpreted as measures for the age- and sex-spe-
cific risk of developing or dying from a specific mali-
gnant tumour within a year. To clarify the presentati-
on of this form of risk communication, we calculated 
the risk which 40-, 50-, 60- and 70-year-old men and 
women have of developing and/ or dying of a specific 
cancer within the next ten years and also at any time 
in their life. The results are presented both as a per-
centage and as one in N individuals of the same age 
and sex. “Competing risks” were also considered, e.g. 
there is a certain probability that a 70-year-old man 
might die from some other disease within the next 
ten years. Furthermore, the “lifetime risk” was also 
calculated, i.e. the risk of developing a tumour during 
the lifespan of an average person. However the calcu-
lations are only based on current rates (incidence 
and mortality rates and the general life expectancy). 
No prediction is made about the future development 
of these values. Furthermore, these risks relate to the 
entire population (according to age and sex), but an 
individual’s risk can vary considerably depending on 
the presence or absence of specific risk factors. The 
Devcan program developed by the US National Can-
cer Institute was used for the calculations. 
International comparison
The estimated cancer incidence and the cancer mor-
tality in Germany were compared with current age-
standardised incidence and mortality rates in the 
countries bordering on Germany and also the Uni-
ted Kingdom, Finland, and the USA (sources are 
given in the appendix). Where the relevant figures 
were available at the end of 2011, the results repre-
sent the mean for 2007 and 2008, otherwise the 
latest available results were used for the comparison 
(France: 2005, Switzerland: mean value 2004-2008, 
Belgium: mortality only for 2008). For some types 
of cancer (e.g. bladder cancer, renal cancer) the 
grouping of diagnoses in accordance with ICD-10 in 
some countries differs from the grouping in Germa-
ny, which slightly limits comparability in some 
cases. 
can still be observed between western and eastern 
Germany (higher rates for stomach and bladder can-
cer in the east, or for breast cancer in the west). In 
the case of thyroid gland cancer and liver cancer the 
rates are higher in the south and south-east, respec-
tively, whereas for lung cancer the ratesare lower in 
both regions.
An overview of the figures for cancer incidence 
and mortality for 2008 in Germany are provided in 
the Tables and Figures 2.2.1 and 2.2.2. There were 
approximately470,000 new cases of cancer in 2008. 
This further increase is due at least in part to the 
further rise in the number of older people in the 
German population. With an almost constant num-
ber of deaths caused by cancer (approx. 215,000 in 
2008), the numbers of new cases of cancer in the 
years 1999 to 2008 increased more for men than for 
women, although the age-standardised rates only 
rose for women, as mentioned above. This is partly 
due to the demographic development in Germany. 
There has been a marked increase in the proportion 
of the elderly in the male population over recent 
decades and this can be interpreted as an indirect 
effect of World War II. In 1999, the demographic 
statistics clearly showed the war losses in the male 
cohorts born between 1920 and 1925. Today’s 75- to 
80-year-old male cohort is no longer directly affected 
by the effects of war in this way. Therefore in future 
the number of new cases of cancer among men will 
most probably not increase as much as in the previ-
ous two or three decades. However, the demogra-
phic statistics indicate that for both sexes the num-
bers of new cases will continue to increase for seve-
ral decades, even though the age-specific incidence 
rates remain constant. 
2 3 Indicators and graphical presentations 
This section provides details of the indicators used 
and explanations of the graphical presentations.
Age-specific rate
The age-specific rate is determined by dividing the 
number of cases of cancer or deathsin a certain age 
group by the number of men or women in this 
group in the population. The graphical presentation 
of these rates shows the relationship between age 
and incidence for men and women. The age-specific 
incidence and mortality rates are expressed as annu-
al rates per 100,000 inhabitants for the age group in 
question. 
Age-standardised rates
In descriptive epidemiology, one may compare the 
frequencies (incidence or mortality) of a certain type 
of cancer in the populationsofvarious regions or at 
various times within a singleregion. As the presen-
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phalia, DCO-cases had only been registered fully for 
a few years, so these are not yet included in their cal-
culations. The completeness of case registration in 
the population-based cancer registries is indicated 
by colour-coding in the graphs and tables. An esti-
mated degree of completeness for 2008 below 90 % 
is denoted by a lighter shade of the incidence bar. 
The age-standardised mortality according to site and 
sexfor all federal states was presented in comparison 
with the national mortality, using figures from the 
German Federal Statistical Office (www.gbe-bund.
de).
Crude rates 
For a specific cancer site and population, a crude 
rate of incidence or mortality is calculated by divi-
ding the total number of new cases of cancer repor-
ted (incidence) or the number of deaths due to can-
cer (mortality) in a given period by the total number 
of people in the relevant population (here: residenti-
al population of Germany). The result is usually 
expressed as the rate per 100,000 residents per year. 
In contrast to the age-standardised rate, crude rates 
are highly dependent on the age-structure of a popu-
lation, particularly in the case of cancer. 
Survival rates
The results of survival analyses in this report descri-
be the average survival prospects of people over the 
age of 15 years after diagnosis witha specific form of 
cancer. Absolute and relative survival rates were cal-
culated. Absolute survival rates present the proporti-
on of patients who are still alive at a certain time 
after their diagnosis. For example, an absolute 5-year 
survival rate of 80 % means that 80 people out of 
100 diagnosed with a type of cancer have survived 
the first five years after their diagnosis. 
The relative survival rate takes into account the 
fact that only a part of the mortality rate of cancer 
patients is attributable to cancer, and that some mor-
tality is expected among people of the same age and 
sexdue to other causes. Relative survival rates pre-
sent the cancer-related mortality in terms of the abso-
lute survival rate of cancer patients divided by the 
expected survival rates in the general population. For 
example, a relative 5-year survival rate of 80 % means 
that the proportion of the cancer patients surviving 
five years after diagnosis is 80 % of the expected pro-
portion of survivors among the general population of 
the same age and sexwithout cancer. The relative sur-
vival rate is always higher than the corresponding 
absolute rate. The expected rate of survival was calcu-
lated using the EdererII method and the national life 
tables of the German Federal Statistical Office.
In order to make up-to-date estimates of survival 
prospects the so-called “period” method was used. 
This takes into account the survival of people with 
The international results were not checked 
further for completeness or plausibility. It is there-
fore possible that the incidence is underestimated in 
a country if new cases are underreported. As a rule, 
if a neighbouring country shows a marked deviation 
from the mortality / incidence ratio in Germany this 
can indicate underestimation. If the incidence rate 
is lower than the mortality rate for a specific cancer 
site this indicates underreporting. 
Median age at diagnosis 
The age at which a specific cancer develops is 
expressed in terms of the median age at diagnosis 
for all cases included for the diagnosis years 2007 
and 2008 by the registries with complete reporting. 
Here, the inclusion of DCO-cases, for which the age 
at death is used instead of the age at diagnosis, ine-
vitably leads to a slight overestimation. However, 
excluding DCO-cases, which generally account for a 
much larger proportion for sites with shorter survi-
val periods in old age, would have ledto a marked 
underestimation. 
Mortality 
The cancer mortality is based on the annual number 
of deaths dueto cancer according to the official 
cause-of-death statistics. The deaths are attributedto 
the underlying cause of death and grouped in terms 
of age and sex. The mortality rate is usually expressed 
as the annual number of deaths per 100,000 people. 
In this report, both the absolute number of deaths 
from 1999 to 2008 and the age-standardised morta-
lity rates European Standard) are presented.
Predicting incidences for 2012
The incidence rates and numbers of cases of cancer 
were predicted for 2012 by extrapolating linear 
trends of the estimated age-, sex- and site-specific 
logarithmic incidence rates for Germany over the 
past ten years, drawing on the current demographic 
extrapolations fromthe German Federal Statistical 
Office. In the case of female breast cancer, as an 
exception, it was assumed that for the age groups 
between 50 and 69 years (target group of the mam-
mography screening programme) the incidence 
rates will remain constant from 2008 onwards. For 
prostate cancer, constant incidence rates were assu-
med for all age groups. 
Regional comparison
The mean age-standardised incidence rates for 
2007 and 2008 (European Standard) in 15 federal 
stateswere presented in comparison with the corre-
sponding national estimates. In Baden-Württem-
berg the cancer registry has only recorded new cases 
of cancer since 2009, so that population-based data 
is not yet available. In Hesse and North Rhine-West-
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was not presented. According to past estimates, the 
presented range probably only reflects differences in 
the quality of treatment to a very small extent. Diffe-
rences in the data quality or in the proportion of 
DCO cases can play a role, as can random fluctua-
tions, above all in the smaller federal states. Metho-
dological differences between the registries may 
influence the results, in particular the efforts made 
to follow back DCO cases. Overall, it can be assumed 
that the estimated survival rates forGermany are 
slightly overestimated, but this is probably the case 
for most international results too.
Distribution of stages of tumours 
The extent of newly diagnosed solid malignant 
tumours is categorised by means of the TNM-classi-
fication: T refers to the size of the tumour, N to the 
regional lymph nodes that are involved, and M to 
distant metastases. For 2007 and 2008 the 6th edi-
tion of this classification was valid. 
Given the data situation, only the T stages are pre-
sented here. For each cancer site the registries were 
included which had less than 50 % of reports mis-
sing (including DCO-cases). For NRW and Hesse 
the DCO-proportion was estimated on the basis of 
reports from other registries with comparable com-
pleteness. If fewer than five registries met the crite-
ria for a cancer site then the T-stages were not pre-
sented.
5-year prevalence
The 5-year prevalence refers to the number of people 
living at a given time (here: 31.12.2008) who had 
been newly diagnosed with cancer within the previ-
ous five years, i.e. between 2004 and 2008. The pre-
valence is calculated using the Pisani method from 
the estimated incidence rates for Germany and the 
absolute survival rates calculated using the period 
method (according to age, sex, site, and calendar 
year) for the regions listed in the Survival rates sub-
section above. 
cancer who have lived within some recent time 
period. Here the 1- to 5-year period survival was cal-
culated for 2007 – 2008. 
Because the accuracy of the survival analyses is 
highly dependent on the quality of the available data, 
registries were required to meet two criteria for 
inclusion in the current calculations. Firstly, DCO-
cases should not account for more than 15 % of all 
malignant cancers (C00-C97 not including C44) for 
the period being considered. Since there is no date 
of diagnosis for DCO cases (which are only recorded 
by the death certificate), they have to be excluded 
from the survival analysis. This can lead to an overe-
stimation of survival rates, because many studies 
have shown that DCO-cases tend to include patients 
with short survival times.
The second criterion concerns the quality of data on 
the vital status of patients . International studies 
show a very poor prognosis for patients diagnosed 
with pancreatic cancer or lung cancer with metasta-
ses. Furthermore, the average survival prospects for 
patients with these diagnoses have not changed sub-
stantially over a long period. This means that if a 
cancer registry reports a large proportion of survi-
ving patients with these types of cancer it indicates 
deficiencies in the quality of the data (a substantial-
proportion of ‘missed’ deaths). Therefore, registries 
were only included in the evaluation if patients dia-
gnosed with pancreatic cancer or metastasised lung 
cancer showed an average relative 5-year survival 
rate of not more than 7.5 %. 
After applying these two criteria, the cancer regist-
ries of Hamburg, Lower Saxony, Bremen, and Saar-
land were used in the evaluations, as well as the data 
from the Joint Cancer Registry for Brandenburg, 
Mecklenburg-West Pomerania, Saxony and Thurin-
gia. The lowest andhighest values are presented for 
five year survival for the individual regions, and regi-
ons wereonly taken into account if they had at least 
50 patients included in the analysis. If this criterion 
wasnot met by at least five regions then the range 
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Epidemiology
‘All cancer sites’ refers here to all malignant neo-
plasms including lymphomas and leukaemias, but 
omitting non-melanoma skin cancer in line with 
international practice. A conservative estimate on 
the basis of data from the German cancer registries 
for 2008 suggests between 160,000 and 170,000 
new cases of these so-called ‘non-melanoma skin 
cancers’ (mostly basal cell carcinomas). However, 
despite this large number of cases, these diseases 
only result in about 600 deaths each year, far fewer 
than for the much rarer malignant melanoma.
For the first time, the incidence estimatesof the 
Robert Koch Institute for Germany usedirect measu-
rements in those cancer registries with sufficiently 
complete records. These are augmented by estima-
ted values for the federal states in which diagnosed 
cases are not yet registered with sufficient complete-
ness. The figures were calculated for the years 1999 
to 2008. In comparison with the previous incidence 
estimates for2006, the newly calculated figures for 
the same year for all cancer sites differ by about + 3 
% for men and + 6 % for women, for methodological 
reasons. In 2008, breast cancer is still the most com-
mon form for women, with approx. 71,700 cases. For 
men the most common form is still prostate cancer, 
with approx. 63,400 diagnosed cases.
The number of newly diagnosed cases of cancer 
in Germany increased between 1980 and 2006 by 
35 % for women and by more than 80 % for men, 
while the age-standardised incidence rates increased 
by 15 % and 23 %, respectively. The changing demo-
graphic structure has led to these marked increases 
in incidence and mortality, particularly in the case of 
men. Since 1990, the incidence rates for 55- to 
80-year-old men and 45- to 70-year-old women have 
increased, whereas the incidence rates for the 
younger age groups have decreased. This century, 
the number of cases of newly diagnosed cancer 
among men has increased more than for women, 
although the annual numbers of deaths caused by 
cancer have remainedalmost unchanged. Age-stan-
dardisedmortality rates have been decreasing for 
men and women since 1999, and incidence rates for 
men have beenmore or less constant. After 2005, 
there was an increase in the age-standardizedinci-
dence for women, most probably due to the start of 
the mammography screening programme. 
Cancer can occur in a wide range of bodily organs, 
and can originate from various cell types. Most cases 
of cancer originate at the internal and external sur-
faces of the body. Some 70 % are adenocarcinomas 
in glandular tissue. A further 10 % are squamous epi-
thelial carcinomas or small-cell carcinomas, which 
occur for example in the lungs. In addition to leuka-
emias and lymphomas there are also rarer forms of 
cancer occurring for example in the nervous system 
or pigment-producing cells (melanomas). Rarer 
types of cancer include forms originating in the con-
nective tissue, e.g. mesothelioma, and various sarco-
mas.  
People in Germany are diagnosed with cancer at 
a median age of 69 years. Women die of cancer at a 
median age of 76 years, and men at73 years. Every 
second man and 43 % of all women develop cancer 
in the course of their life, but the age-pattern of inci-
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 243,900 215,100 246,700 223,100 258,000 228,200
Crude incidence rate1 605.5 512.5 613.0 532.7 646.9 551.1
Standardised incidence rate1.² 453.1 338.2 450.0 349.9 441.2 350.0
Median age at diagnosis 69 69 69 69
Deaths 113,121 98,137 115,870 99,572
Crude mortality rate1 280.8 233.8 288.0 237.8
Standardised mortality rate1.² 205.9 129.8 205.6 130.5
5-year prevalence 650,700 637,400 669,200 658,500 697,900 698,000
Absolute 5-year survival rate (2007–2008)3 50 (44-52) 57 (50-59)
Relative 5-year survival rate (2007–2008)3 59 (52-60) 64 (57-66)
Table 3 1 1
Overview of key epidemiological parameters for Germany, ICD-10 C00-97 without C44
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 Results
3 1 All cancer sites
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dence differs considerably between the sexes. Whe-
reas the age-specific incidence rate for women below 
55 yearsofage is higher than the corresponding rate 
for men, above the age of 70 the incidence rate for 
men is nearly double that for women. For men, only 
13 % of all cases of cancer are diagnosed before the 
age of 55, compared with 21 % for women. 
The relative 5-year survival rates range from above 
90 % for malignant melanoma of the skin, testicular 
cancer, and meanwhile also prostate cancer, to survi-
val rates of less than 20 % for lung and oesophagus 
cancer, and below 10 % for pancreatic cancer. Com-
pared to the survival rates from the 1980s in Saar-
land(50 % to 53 % for women and 38 % to 40 % for 
men), the recent survival rates of cancer patients in 
Germany have shown considerable improvements. 
Using the period method and including data from 
eight federal states for patients diagnosed in 2007 
and 2008, 5-year relative survival rates of 59 % for 
men and 64 % for womenwere estimated. The 
improved overall cancer survival rates are due in part 
to shifts in the localisation spectrum, for example the 
decline in cases of stomach cancer and lung cancer 
among men (for which the prognoses are poor) and 
a larger proportion of colon, breast, and prostate can-
cer with better prognoses.
Risk factors and early detection
The aetiology of many cancers is not known, and in 
other cases, known risk factors cannot be influ-
enced. Prevention strategies are therefore only 
available for a few tumour types. However, these 
include types of cancer which affect large numbers 
of people. The World Health Organization estimates 
that more than 30 % of all cancer cases could be avo-
idedwithpreventive measures. 
Among avoidable risk factors, tobacco consump-
tion is the most important. Also the roles of excess 
weight andlack of exercise have long been known 
from observational epidemiological investigations. 
Possible underlying biological mechanisms are 
being revealed by on-going research into the meta-
bolic syndrome. This chronic “metabolic imbalance” 
is linked with hypertension, high blood cholesterol 
and hyperglycaemia. Inflammatory processes in adi-
pose tissue are also suspected of being involved in 
the development of cancer. Avoidable risk factors 
also include exposure to ultra-violet radiation.
Among nutrition-related factors, alcohol con-
sumption plays an important role. Insufficient fruit, 
vegetables, and dietary fibre, often combined with a 
high intake of red meat, have been identified as risk 
factors for a number of types of cancer. However it 
has not always been possible in observational studies 
to separate the influence of specific foodstuffs and 
their constituentsfrom that of the energy balance.
Many people, particularly in Germany, overesti-
mate the influence of hazardoussubstances and 
impurities in foodstuffs, as well as environmental 
influences or exposure at the workplace. However, 
in certain cases these factors can also play a substan-
tialrole in the development of cancer. An example is 
the regionally occurring noble gas radon, which is 
thought to be responsible for five to ten per cent of 
the lung cancer cases in Germany. Nor can the influ-
ence of medical procedures be generalised. Potential 
risks include diagnostic procedures and therapies 
involving exposure to radiation, cytostatic agents 
aschemotherapy, andhormone replacement therapy 
for menopausal women, which has been identified 
as a risk factor for breast cancer. 
Chronic infections are now known to be risk fac-
tors for some widespread forms of cancer, and vac-
cinations or the treatment of causal factors can con-
tribute to the reduction of cancer risk. This has been 
established for vaccinations against hepatitis viruses 
as a risk factor for liver cancer, and it is also hoped 
that vaccination against human papilloma viruses-
will reduce the cervical carcinoma rate. 
The relevant risk factors for specific types of can-
cer are presented in more detail in the individual 
sections.  
The early detection programmes supported by 
the statutory health insurance companies in Ger-
many screen for cancer of the skin and colon, cancer 
of the uterus and breast for women, and prostate 
cancer for men. These early detection measures are 
presented in the individual sections.
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Figure 3 1 2
Distribution of T-stages at first diagnosis by sex 
Not included because tumour stages are site-specific.
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Figure 3 1 1b 
Absolute numbers of incident cases and deaths,  
ICD-10 C00 – 97 without C44, Germany, 1999 – 2008
Figure 3 1 1a 
Age-standardised incidence and mortality rates,  
ICD-10 C00 – 97 without C44, Germany, 1999 – 2008 
100,000 (European standard)
Figure 3 1 3a
Absolute survival rates up to 5 years after first diagnosis by sex, 
ICD-10 C00 – 97 without C44, Germany,
2007 – 2008
Figure 3 1 3b
Relative survival rates up to 5 years after first diagnosis by sex, 
ICD-10 C00 – 97 without C44, Germany,
2007 – 2008                                
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Figure 3 1 4















Table 3 1 2
Age-specific incidence rates in Germany by sex, ICD-10 C00 – 97 without C44, 2007 – 2008  
per 100,000
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 21.7 11.0 10.9 20.7 34.1 48.4 60.5 85.4 127.5 238.2 442.1 805.5 1,325.7 1,854.6 2,344.0 2,758.3 3,034.1 2,963.8
Woman 19.5 10.0 9.9 19.0 28.4 50.6 87.7 146.3 239.7 379.5 526.4 711.4 954.0 1,134.4 1,240.4 1,467.7 1,690.5 1,845.3
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 1.9 % (1 in 52) 51.0 % (1 in 2) 0.6 % (1 in 160) 26.3 % (1 in 4)
50 years 6.4 % (1 in16) 50.9 % (1 in 2) 2.4 % (1 in 41) 26.3 % (1 in 4)
60 years 15.8 % (1 in 6) 49.8 % (1 in 2) 5.9 % (1 in 17) 25.6 % (1 in 4)
70 years 25.4 % (1 in 4) 44.8 % (1 in 2) 10.9 % (1 in 9) 23.1 % (1 in 4)
Lifetime risk 50.7 % (1 in 2) 25.9 % (1 in 4)
Women aged in the next ten years ever in the next ten years ever
40 years 3.2 % (1 in 31) 42.1 % (1 in 2) 0.6 % (1 in 160) 20.2 % (1 in 5)
50 years 6.6 % (1 in 15) 40.5 % (1 in 2) 1.8 % (1 in 55) 19.8 % (1 in 5)
60 years 11.2 % (1 in 9) 36.9 % (1 in 3) 3.7 % (1 in 27) 18.6 % (1 in 5)
70 years 14.9 % (1 in 7) 30.3 % (1 in 3) 6.5 % (1 in 15) 16.2 % (1 in 6)
Lifetime risk 42.8 % (1 in 2) 20.2 % (1 in 5)
Table 3 1 3 
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – 97 without C44, database 2008
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Figure 3 1 5
Registered age-standardised incidence rates in German federal states, ICD-10 C00 – 97 without C44, 2007 – 2008
per 100,000 (European standard)
Figure 3 1 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C00 – 97 without C44, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
1 without DCOcases   2 no incidence data
1 Including other tumours, e.g. benign brain neoplasms
22 Cancer in Germany | Oral cavity and pharynx
Epidemiology
Cancer of the oral cavity and the pharynx is made up 
of a heterogeneous group of malignant neoplasms. 
In 2008, some 13,000 new cases were diagnosed in 
Germany. More than 90 % were squamous epitheli-
al carcinomas, but in the salivary gland region the 
majority were adenocarcinomas.
The relative 5-year survival rate for women, is 
60 %, compared with 46 % for men. This difference 
is due in part to the fact that fewer women suffer 
from cancers of the floor of the mouth, tongue, and 
hypopharynx: Theseare all linked to tobacco and 
alcohol consumption and have less favourable prog-
noses than other malignant tumours e.g. those 
affecting the lips or salivary glands. In addition, 
every fourth tumour in women is diagnosed at an 
early stage (T1) compared with only every fifth 
tumour in men.
The fact that men are affected more frequently 
than women and are diagnosed at a younger median 
age is also linked to the risk factors tobacco and alco-
hol consumption. Women are diagnosed at a median 
age of 66 years, 5 years later than men.
The incidence rates for cancer of the oral cavity 
and pharynx have increased since the year 2000, 
while the age-standardised mortality rate has remai-
ned constant for women and has declined slightly 
for men. The highest incidence and mortality rates 
for women in Germany are reported from Hamburg 
and Bremen, and for men in Mecklenburg-West 
Pomerania. In an international comparison, France 
has the highest incidence rate among men.
Risk factors 
The most important triggers for cancer of the oral 
cavity and pharynx are tobacco and alcohol con-
sumption, and these reinforce one another. Further 
possible risk factors can be insufficient intake of 
fruit and vegetables, inadequate oral hygiene, and 
mechanical irritations, for example due to poorly fit-
ting dentures. Exposure to sunlight can contribute 
to carcinoma of the lips. Regular or occupational 
contact with sawdust or some chemicals can increa-
se the risk of developing tumours, in particular in 
the nasopharynx.
New light has been cast on the origins of cancer 
of the oral cavity and pharynx by research into the 
role of viruses, in particular in cases where known 
risk factors are not involved (e.g. non-smokers or 
teetotallers). Tumours caused by human papilloma 
viruses (HPV) may have a different course and a bet-
ter prognosis. Epstein-Barr viruses are regarded as a 
further viral risk factor, in particular for nasopharyn-
geal carcinoma. People with Type II diabetes, a 
marked immunodeficiency or previous infection 
with some rare diseases may also have an increased 
risk, possibly linked in particular with the risk of an 
HPV infection.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 9,260 3,340 9,520 3,490 10,100 3,800
Crude incidence rate1 23.0 8.0 23.7 8.3 25.3 9.1
Standardised incidence rate1.² 18.7 5.7 19.1 5.9 19.2 6.2
Median age at diagnosis 61 65 61 66
Deaths 3,650 1,127 3,776 1,170
Crude mortality rate1 9.1 2.7 9.4 2.8
Standardised mortality rate1.² 7.3 1.8 7.4 1.8
5-year prevalence 23,000 9,500 23,700 9,900 25,200 10,900
Absolute 5-year survival rate (2007–2008)3 42 (40-45) 54 (50-59)
Relative 5-year survival rate (2007–2008)3 46 (43-50) 60 (56-65)
Table 3 2 1
Overview of the key epidemiological parameters for Germany, ICD-10 C00 – 14
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 2  Oral cavity and pharynx
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Figure 3 2 3b
Relative survival rates up to 5 years after diagnosis, 
ICD-10 C00 – 14, Germany, 2007 – 2008
Figure 3 2 3a
Absolute survival rates up to 5 years after diagnosis, 
ICD-10 C00 – 14, Germany, 2007 – 2008
















Figure 3 2 2
Distribution of T-stages at first diagnosis (top: all cases; bottom: valid reports)  
ICD-10 C00 – 14, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information       DCO
Women
Men
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Figure 3 2 1b 
Absolute numbers of new cases and deaths,  
ICD-10 C00 – 14, Germany, 1999 – 2008
per 100,000
Figure 3 2 1a 
Age-standardised incidence and mortality rates,  
ICD-10 C00 – 14, Germany, 1999 – 2008
per 100,000 (European standard)
24
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 540) 1.7 % (1 in 58) 0.1 % (1 in 1,700) 0.7 % (1 in 140)
50 years 0.5 % (1 in 200) 1.6 % (1 in 63) 0.2 % (1 in 530) 0.7 % (1 in 150)
60 years 0.6 % (1 in 160) 1.2 % (1 in 86) 0.2 % (1 in 400) 0.5 % (1 in 190)
70 years 0.4 % (1 in 250) 0.6 % (1 in 155) 0.2 % (1 in 530) 0.3 % (1 in 310)
Lifetime risk 1.7 % (1 in 58) 0.7 % (1 in 140)
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,900) 0.6 % (1 in 160) <0.1 % (1 in 7,700) 0.2 % (1 in 440)
50 years 0.1 % (1 in 730) 0.6 % (1 in 170) <0.1 % (1 in 2,500) 0.2 % (1 in 460)
60 years 0.2 % (1 in 500) 0.5 % (1 in 210) 0.1 % (1 in 1,700) 0.2 % (1 in 540)
70 years 0.2 % (1 in 650) 0.3 % (1 in 330) 0.1 % (1 in 1,600) 0.1 % (1 in 720)
Lifetime risk 0.7 % (1 in 150) 0.2 % (1 in 440)
 Cancer in Germany | Oral cavity and pharynx
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.1 0.1 0.1 0.5 0.5 0.8 1.1 3.4 10.2 26.8 45.1 60.3 67.9 62.0 49.7 41.6 51.8 36.7
Woman 0.0 0.1 0.3 0.3 0.3 0.6 0.7 1.8 3.2 7.3 12.4 15.3 18.7 21.0 15.5 16.8 19.6 20.9
Table 3 2 2
Age-specific incidence rates in Germany by sex, ICD-10 C00 – 14, 2007 – 2008
per 100,000
Table 3 2 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C00 – 14, database 2008
Figure 3 2 4 
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Figure 3 2 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C00 – 14, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
































Figure 3 2 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C00 – 14, 2007 – 2008
per 100,000 (European standard)










































1 without DCO cases  2 no incidence data yet
26 Cancer in Germany | Oesophagus
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 4,860 1,330 4,800 1,380 5,300 1,400
Crude incidence rate1 12.1 3.2 11.9 3.3 13.2 3.5
Standardised incidence rate1.² 9.3 2.0 9.0 2.1 9.1 2.2
Median age at diagnosis 67 69 67 69
Deaths 3,725 1,120 3,655 1,135
Crude mortality rate1 9.3 2.7 9.1 2.7
Standardised mortality rate1.² 7.0 1.6 6.8 1.6
5-year prevalence 6,200 1,700 6,300 1,800 6,700 1,900
Absolute 5-year survival rate (2007–2008)3 14 (8-21) 17 (7-27)
Relative 5-year survival rate (2007–2008)3 16 (10-24) 20 (8-30)
Table 3 3 1
Overview of the key epidemiological parameters for Germany, ICD-10 C15
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 3  Oesophagus
Epidemiology
In Germany, cancer of the oesophagus accounts for 
about 3 % of all deaths due to cancer in men, and 
some 1 % in women. Four to five-times more men in 
Germany are diagnosed with this cancer than 
women, which is attributable to the most important 
risk factors alcohol and tobacco consumption. In 
addition, men are diagnosed at a median age of 67 
years with cancer of the oesophagus, which is two 
years earlier than women. 
The age-standardised incidence and mortality 
rates have increased slightly for women since the 
start of this millennium and have remained more or 
less unchanged for men.
Despite considerable improvements in recent 
years, the survival prospects for patients with cancer 
of the oesophagus are still not favourable. The rela-
tive 5-year survival rates are currently 16 % for men 
and 20 % for women. This is partly due to the fact 
that only some 7 % of all cases are diagnosed at an 
early stage (T1). 
Squamous epithelial carcinomas account for 50 
% to 60 % of all cases of cancer of the oesophagus., 
Adenocarcinomas, which are mainly found in the 
lower third of the oesophagus, showed a marked 
increase in recent years and now account for 25 % to 
30 % of cases. 
Risk factors
The most important risk factors for the development 
of the more frequent squamous epithelial carcinoma 
in the oesophagus include alcohol and tobacco con-
sumption. In combination, the two factors reinforce 
one another. Studies have also shown a possible pro-
tective effect of vegetables and fruit. For squamous 
epithelial carcinomas at the transition between sto-
mach and oesophagus,changes to the mucous lining 
as a result of long-term infection with Helicobacter 
pylori bacteria can also play a part.
Adenocarcinomas frequently originate in connec-
tion with a gastro-oesophageal reflux disease (long-
term flow of gastric juices back into the oesophagus, 
chronic heartburn). This leads to changes to the 
mucous lining of the lower part of the oesophagus, 
causing a Barrett oesophagus, which is regarded as a 
precursor to cancer. 
Recently, adenocarcinomas of the oesophagus 
have been associated with smoking and with smo-
kingand possibly also with overweight and Type II 
diabetes. Diet-related risk factors also play an impor-
tant but possibly indirect role for adenocarcinomas 
risk factors. Family clusters of cases are known, but 
these may possibly be attributable to shared lifestyle 
risks. A possible influence of the human papilloma 
viruses is a topic of debate.
27
















Figure 3 3 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C15, Germany, 2007 – 2008
Figure 3 3 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C15, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information        DCO
Women
Men
Figure 3 3 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports) 
ICD-10 C15, Germany, 2007 – 2008
Figure 3 3 1b
Absolute numbers of new cases and deaths, 
ICD-10 C15, Germany, 1999 – 2008


































Figure 3 3 1a
Age-standardised incidence and mortality rates, 
ICD-10 C15, Germany, 1999 – 2008
per 100,000 (European standard)
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,100) 0.9 % (1 in 110) <0.1 % (1 in 3,200) 0.7 % (1 in 140)
50 years 0.2 % (1 in 560) 0.9 % (1 in 110) 0.1 % (1 in 790) 0.7 % (1 in 140)
60 years 0.3 % (1 in 310) 0.8 % (1 in 130) 0.2 % (1 in 410) 0.6 % (1 in 160)
70 years 0.3 % (1 in 290) 0.6 % (1 in 180) 0.3 % (1 in 370) 0.5 % (1 in 220)
Lifetime risk 0.9 % (1 in 110) 0.7 % (1 in 140)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 9,400) 0.3 % (1 in 370) <0.1 % (1 in 16,000) 0.2 % (1 in 440)
50 years <0.1 % (1 in 2,200) 0.3 % (1 in 380) <0.1 % (1 in 3,800) 0.2 % (1 in 450)
60 years 0.1 % (1 in 1,200) 0.2 % (1 in 440) 0.1 % (1 in 1,800) 0.2 % (1 in 490)
70 years 0.1 % (1 in 1,400) 0.2 % (1 in 650) 0.1 % (1 in 1,400) 0.2 % (1 in 620)
Lifetime risk 0.3 % (1 in 370) 0.2 % (1 in 440)
Table 3 3 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C15, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.8 2.3 6.3 14.2 23.4 33.9 38.2 42.2 39.3 42.0 37.2
Woman 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 1.6 3.0 5.8 8.5 8.7 7.3 8.4 11.0 10.9
Table 3 3 2
Age-specific incidence rates in Germany by sex, ICD-10 C15, 2007 – 2008 
per 100,000
Figure 3 3 4 
Age-specific incidence rates in Germany by sex  ICD-10 C15, 2007 – 2008
per 100,000
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Figure 3 3 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C15, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 3 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C15, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C15 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
30 Cancer in Germany | Stomach
Epidemiology
For more than 30 years in Germany – as in other 
industrialised nations – there has been a steady dec-
line in the incidence and mortality rates for stomach 
cancer. Men are diagnosed at a median age of 71 
years, women at 76 years. This is above all due to the 
greater life expectancy of women and the larger 
number of older women in the population. One in 
74 women and one in 51 men can currently expect to 
develop stomach cancer. 
The survival prospects with stomach cancer have 
improved recently, but in comparison with other 
types of cancer they remain less favourable. The rela-
tive 5-year survival rates are about 30 %. The stage of 
the tumour at diagnosis is only reported in just over 
half the cases – and of these most cases in men and 
in women are diagnosed in stages T2 or T3.
Histologically various forms of adenocarcinomas 
predominate in the stomach, some of which are only 
found there, for example signet ring cell carcinoma 
(15 %) or certain neuroendocrinal carcinomas. 
Particularly for men, there are appreciable higher 
incidence and mortality rates in the federal states of 
eastern Germany than in western Germany; similar 
differences are also found between the eastern and 
western neighbours of Germany. 
Risk factors
A bacterial infection of the stomach with Helicobac-
ter pylori is the most important risk factor, and this 
can probably reinforce the effects of other risks. A 
diet low in fresh fruit and vegetables, and the fre-
quent consumption of meat, heavily salted, grilled, 
pickled or smoked foods can also increase the inci-
dence of stomach cancer. In addition, smoking and 
excessive alcohol consumption clearly exert an unfa-
vourable influence. There are indications that chro-
nic heartburn or gastro-oesophageal reflux increases 
the risk for certain forms of tumour at the transition 
from the stomach to the oesophagus. Overweight 
can also promote these carcinomas. It is not possible 
at present to quantify the contributions of the known 
risks. Many people with stomach cancer have no 
signs of risk factors in the medical history. 
First-degree relatives of patients have twice or 
three-times the risk of the normal population. How-
ever, it is not always clear whether this is due to a 
shared lifestyle, the transfer of Helicobacter pylori 
within the family, or hereditary gene mutations. In 
the case of young patients it can be appropriate for 
the relatives to receive genetic counselling, also for 
members of families with rare hereditary bowel can-
cer (HNPCC, Lynch syndrome). Pernicious anaemia, 
Ménétrier’s disease and other diseases predispose to 
cancer, but only affect relatively few people. Among 
the mostly benign stomach polyps only the rare ade-
noma is regarded as a cancer precursor.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 9,570 6,840 9,210 6,660 9,100 6,200
Crude incidence rate1 23.7 16.3 22.9 15.9 22.8 14.9
Standardised incidence rate1.² 17.8 8.9 16.8 8.6 15.7 7.7
Median age at diagnosis 71 76 71 76
Deaths 5,846 4,641 5,929 4,581
Crude mortality rate1 14.5 11.1 14.7 10.9
Standardised mortality rate1.² 10.6 5.7 10.5 5.6
5-year prevalence 15,700 11,300 15,800 11,200 15,400 10,400
Absolute 5-year survival rate (2007–2008)3 25 (15-30) 26 (15-36)
Relative 5-year survival rate (2007–2008)3 30 (18-36) 31 (19-42)
Table 3 4 1
Overview of the key epidemiological parameters for Germany, ICD-10 C16
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 4  Stomach
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Figure 3 4 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C16, Germany, 2007 – 2008
Figure 3 4 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C16, Germany, 2007 – 2008
Figure 3 4 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C16, Germany, 2007 – 2008
Figure 3 4 1b
Absolute numbers of new cases and deaths,  
ICD-10 C16, Germany, 1999 – 2008
Figure 3 4 1a
Age-standardised incidence and mortality rates,  
ICD-10 C16, Germany, 1999 – 2008
per 100,000 (European standard)
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Table 3 4 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C16, database 2008
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,200) 2.0 % (1 in 50) <0.1 % (1 in 2,500) 1.4 % (1 in 72)
50 years 0.3 % (1 in 380) 2.0 % (1 in 51) 0.1 % (1 in 820) 1.4 % (1 in 73)
60 years 0.5 % (1 in 210) 1.8 % (1 in 55) 0.3 % (1 in 390) 1.3 % (1 in 75)
70 years 0.8 % (1 in 130) 1.6 % (1 in 63) 0.6 % (1 in 180) 1.3 % (1 in 79)
Lifetime risk 2.0 % (1 in 51) 1.4 % (1 in 73)
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,900) 1.3 % (1 in 74) <0.1 % (1 in 3,400) 1.0 % (1 in 110)
50 years 0.1 % (1 in 850) 1.3 % (1 in 76) 0.1 % (1 in 1,500) 0.9 % (1 in 110)
60 years 0.2 % (1 in 470) 1.2 % (1 in 81) 0.1 % (1 in 790) 0.9 % (1 in 110)
70 years 0.4 % (1 in 230) 1.1 % (1 in 90) 0.3 % (1 in 350) 0.8 % (1 in 120)
Lifetime risk 1.3 % (1 in 74) 1.0 % (1 in 110)
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.3 0.5 1.5 2.2 5.7 12.1 20.2 35.4 46.3 58.5 76.5 110.6 144.9 158.4
Woman 0.0 0.0 0.0 0.2 0.3 0.6 1.4 2.0 3.5 6.7 9.8 13.9 19.0 25.8 40.5 57.2 80.6 109.2
Table 3 4 2
Age-specific incidence rates in Germany by sex, ICD-10 C16, 2007 – 2008
per 100,000













Figure 3 4 4 
Age-specific incidence rates in Germany by sex  ICD-10 C16, 2007 – 2008
per 100,000 
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Figure 3 4 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C16, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 4 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C16, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
34 Cancer in Germany | Colon and rectum
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 34,960 30,300 35,350 30,040 38,300 31,100
Crude incidence rate1 86.8 72.2 87.9 71.7 95.9 75.1
Standardised incidence rate1.² 63.7 40.2 63.0 39.4 63.0 39.3
Median age at diagnosis 71 75 71 75
Deaths 13,385 13,048 13,726 12,936
Crude mortality rate1 33.2 31.1 34.1 30.9
Standardised mortality rate1.² 24.0 15.2 24.0 14.7
5-year prevalence 100,300 87,200 103,100 87,800 109,400 88,600
Absolute 5-year survival rate (2007–2008)3 52 (40-54) 52 (43-56)
Relative 5-year survival rate (2007–2008)3 63 (49-64) 62 (52-65)
Table 3 5 1
Overview of the key epidemiological parameters for Germany, ICD-10 C18 – 21
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 5  Colon and rectum
Epidemiology
About every seventh case of cancer in Germany ori-
ginates in the bowel, and in 2008 some 35,000 men 
and 30,000 women were diagnosed, in addition to 
some 4,500 in situ tumours. Nearly two thirds of 
tumours were located in the large intestine, some 
30% affecting the rectum, the remainder are located 
at the transition between the colon and rectum (rec-
tosigmoid) or the anus. The very rare upper intesti-
nal tumours (C17) are not included in this group, in 
line with international practice. Histologically, ade-
nocarcinomas predominate, with the exception of 
the squamous epithelial carcinomas of the anus and 
the rare neuroendocrinal tumours (approx. 1 %). 
The risk of developing disease increases steadily 
with advancing age. More than half the cases were 
diagnosed after the age of 70 years, only about 10 % 
before 55 years of age. The age-standardised inci-
dence rates for women have recently shown a slight 
downward trend. Rates for men have remained 
fairly stable, although due to demographic effects 
there has been an increase in the absolute number 
of cases. The age-standardised mortality rates for 
men and women have declined by more than 20 % 
over the past ten years. In 2008, some 3,000 fewer 
women died of bowel cancers than in 1999, while 
the number for men remained about the same. 
Colorectal cancer has a moderately good prognosis, 
and five years after diagnosis about half the patients 
are still alive. 
Risk factors
The risk of suffering colorectal cancer is increased by 
being overweight, by insufficient exercise, and by a 
diet which is low in fibres and rich in fats, with a 
high proportion of red meat and processed meats 
and a low proportion of vegetables. Regular con-
sumption of alcohol or tobacco also has an unfavou-
rable effect. People with first degree relatives with 
bowel cancer are themselves more frequently affec-
ted. There is an elevated risk of developing cancer in 
early years in the cases of the very rare familial ade-
nomatous polyposis (FAP) and the hereditary Lynch 
syndrome (non-polyposis colorectal cancer). Chronic 
inflammatory bowel diseases also slightly increase 
the risk of developing cancer. 
Early detection 
Under the screening programmes of the statutory 
health insurance companies, people aged 50 to 54 
years can have an annual test for blood in stool. From 
the age of 55 years they are entitled to a colonoscopy 
investigation, in the course of which colon polyps, 
which may develop into malignant tumours, can also 
be removed. If there are no pathological findings, 
they canhave a repeat examination after ten years.
Alternatively the above-mentioned test for blood 
in stool can be repeated every two years above the age 
of 55 years, with a follow-up colonoscopy where cla-
rification is required. Special provisions are made for 
people with an increased risk.
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Figure 3 5 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C18 – 21, Germany, 2007 – 2008
Figure 3 5 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C18 – 21, Germany, 2007 – 2008
Figure 3 5 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C18 – 21, Germany, 2007 – 2008
Figure 3 5 1b
Absolute numbers of new cases and deaths,  
ICD-10 C18 – 21, Germany, 1999 – 2008
Figure 3 5 1a
Age-standardised incidence and mortality rates,  
ICD-10 C18 – 21, Germany, 1999 – 2008
per 100,000 (European standard)
36 Cancer in Germany | Colon and rectum
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 470) 7.6 % (1 in 13) 0.1 % (1 in 2,000) 3.2 % (1 in 31)
50 years 0.8 % (1 in 120) 7.6 % (1 in 13) 0.2 % (1 in 430) 3.3 % (1 in 31)
60 years 2.0 % (1 in 49) 7.3 % (1 in 14) 0.7 % (1 in 150) 3.3 % (1 in 31)
70 years 3.3 % (1 in 30) 6.3 % (1 in 16) 1.4 % (1 in 73) 3.0 % (1 in 33)
Lifetime risk 7.5 % (1 in 13) 3.2 % (1 in 31)
Women aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 540) 6.1 % (1 in 16) <0.1 % (1 in 2,300) 2.8 % (1 in 36)
50 years 0.6 % (1 in 180) 6.0 % (1 in 17) 0.1 % (1 in 700) 2.8 % (1 in 36)
60 years 1.1 % (1 in 88) 5.7 % (1 in 18) 0.4 % (1 in 280) 2.7 % (1 in 37)
70 years 2.1 % (1 in 48) 4.9 % (1 in 20) 0.8 % (1 in 120) 2.6 % (1 in 39)
Lifetime risk 6.1 % (1 in 17) 2.7 % (1 in 36)
Table 3 5 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C18 – 21, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.1 0.0 0.5 0.9 1.5 3.2 7.2 12.9 27.2 56.3 111.6 178.0 250.8 353.0 441.9 526.0 531.3
Woman 0.0 0.0 0.0 0.7 0.7 1.3 2.9 6.4 11.8 22.8 45.9 64.6 103.3 135.4 191.6 270.5 345.2 424.7
Table 3 5 2
Age-specific incidence rates in Germany by sex, ICD-10 C18 – 21, 2007 – 2008
per 100,000













Figure 3 5 4 
Age-specific incidence rates in Germany by sex  ICD-10 C18 – 21, 2007 – 2008
per 100,000
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Figure 3 5 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C18 – 21, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 5 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C18 – 21, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
38 Cancer in Germany | Liver
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 5,170 2,130 5,270 2,340 6,000 2,400
Crude incidence rate1 12.8 5.1 13.1 5.6 15.2 5.9
Standardised incidence rate1.² 9.5 2.9 9.4 3.2 9.9 3.2
Median age at diagnosis 69 73 70 73
Deaths 4,469 2,358 4,523 2,539
Crude mortality rate1 11.2 5.6 11.1 6.1
Standardised mortality rate1.² 8.1 2.9 7.9 3.1
5-year prevalence 5,200 2,000 5,300 2,100 5,900 2,300
Absolute 5-year survival rate (2007–2008)3 13 (5-15) 11 (5-16)
Relative 5-year survival rate (2007–2008)3 15 (6-17) 13 (6-18)
Table 3 6 1
Overview of the key epidemiological parameters for Germany, ICD-10 C22
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 6  Liver
Epidemiology 
Liver cancer, which is included for the first time, is 
relatively uncommon, but in view of the poor prog-
nosis it is among the ten most frequent causes of 
deaths due to cancer for both men and women. In 
Germany, some 7,600 new cases are diagnosed eve-
ry year, with roughly the same number of deaths. 
The median age at diagnosis is 70 years for men and 
73 years for women. Only about 4 % of cases are dia-
gnosed before 50 years of age. One in 92 men and 
one in 210 women in Germany develop a malignant 
liver tumour in the course of their life.  
Some 70 % of liver tumours develop from liver 
cells (hepatocellular carcinoma), others above all 
from epithelial cells in the intrahepatic bile ducts 
(cholangiocarcinoma).
Since 1980, the mortality rate for men has risen 
steadily, even after age-standardisation, while it has 
remained more or less unchanged for women. The 
age-standardised incidence rate for men has also 
increased slightly over the past 10 years.
Currently, incidence and mortality rates in the 
north-western federal states are somewhat lower 
than in the rest of Germany. 
The survival prospects for liver cancer depend on 
the stage of the tumour at diagnosis and the state of 
the liver (cirrhosis). Only slightly more than 10 % of 
patients survive the first five years after diagnosis. 
The prognosis is only worse for malignant pancrea-
tic tumours.
Risk factors
Proven risk factors for liver cancer are chronic infec-
tion with the hepatitis-B or hepatitis-C virus. There is 
also a relationship between regular high alcohol con-
sumption and the risk of developing liver cancer. 
Foodstuffs contaminated with aflatoxin B1 (produced 
by the fungi Aspergillus parasiticus and A. flavus) 
represents a further risk factor. Tobacco consumpti-
on is associated with an increased risk. Lifestyle rela-
ted risk factors also include type II diabetes mellitus 
and obesity. Finally, hereditary metabolic diseases 
such as haemochromatosis increase the risk for liver 
cancer. 
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Figure 3 6 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C22, Germany, 2007 – 2008
Figure 3 6 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C22, Germany, 2007 – 2008
Figure 3 6 2
Distribution of T-stages at first diagnosis 
Not presented due to the large proportion of missing data.
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Figure 3 6 1b
Absolute numbers of new cases and deaths,  
ICD-10 C22, Germany, 1999 – 2008 
Figure 3 6 1a
Age-standardised incidence and mortality rates,  
ICD-10 C22, Germany, 1999 – 2008
per 100,000 (European standard
40 Cancer in Germany | Liver
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 5,000) 1.1 % (1 in 91) <0.1 % (1 in 6,800) 1.0 % (1 in 103)
50 years 0.1 % (1 in 760) 1.1 % (1 in 91) 0.1 % (1 in 1,000) 1.0 % (1 in 102)
60 years 0.3 % (1 in 310) 1.0 % (1 in 96) 0.3 % (1 in 380) 1.0 % (1 in 105)
70 years 0.5 % (1 in 190) 0.8 % (1 in 120) 0.4 % (1 in 220) 0.8 % (1 in 125)
Lifetime risk 1.1 % (1 in 92) 1.0 % (1 in 104)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 7,400) 0.5 % (1 in 220) <0.1 % (1 in 11,000) 0.5 % (1 in 190) 
50 years <0.1 % (1 in 2,000) 0.5 % (1 in 220) <0.1 % (1 in 3,000) 0.5 % (1 in 190) 
60 years 0.1 % (1 in 1,000) 0.4 % (1 in 240) 0.1 % (1 in 1,200) 0.5 % (1 in 200) 
70 years 0.2 % (1 in 610) 0.4 % (1 in 280) 0.2 % (1 in 520) 0.5 % (1 in 220) 
Lifetime risk 0.5 % (1 in 210) 0.5 % (1 in 190) 
Table 3 6 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C22, database 2008
Table 3 6 2
Age-specific incidence rates in Germany by sex, ICD-10 C22, 2007 – 2008
per 100,000
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.6 0.0 0.2 0.1 0.2 0.3 0.4 0.4 1.6 2.7 8.9 19.3 29.7 38.7 58.2 64.3 63.1 52.1
Woman 0.4 0.0 0.1 0.2 0.1 0.1 0.2 0.2 0.9 1.7 3.4 5.5 8.2 10.3 16.3 18.3 25.1 26.7













Figure 3 6 4 
Age-specific incidence rates in Germany by sex  ICD-10 C22, 2007 – 2008
per 100,000
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Figure 3 6 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C22, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 6 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C22, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
42
Epidemiology
In Germany, some 5,200 new cases of malignant 
tumours were diagnosed in 2008 in the gall bladder 
(accounting for about 40 % of all cases) and the bili-
ary tract outside the liver (60 %). Women develop 
gall bladder carcinomas more frequently, whereas 
tumours in the extrahepatic biliary tracts are diag-
nosed more frequently for men. As with liver cancer, 
the risk of developing disease increases steadily with 
age. The lifetime risk is about 0.5 % for women and 
0.6 % for men.
Histologically, some 95 % of malignant tumours 
of the gall bladder and extrahepatic biliary tract are 
adenocarcinomas. Other histological variants such 
as squamous epithelial carcinomas, neuroendocrine 
tumours, and sarcomas are rare. 
Since 1999 the age-standardised incidence rate 
in Germany has declined for women and remained 
largely unchanged for men. The age-standardised 
mortality rates have decreased markedly for both 
genders over this period. Due to special demogra-
phic effects in the older male population, the abso-
lute number of new diagnosed cases has increased 
while the number of mortalities has decreased 
slightly.  
The survival prospects with malignant tumours 
of the gall bladder and biliary tract are as a rule poor, 
but better than for liver cancer. The relative 5-year 
survival rates were 16 % for women and 21 % for 
men.
Risk factors
The triggers for gall bladder carcinomas are not 
clear. Possible risk factors cited in the literature 
include the presence of gallstones, chronic inflamm-
atory diseases of the biliary tract, such as a primary 
sclerosing cholangitis (PSC), the inflammatory 
bowel disease ulcerative colitis, liver diseases as a 
result of the high consumption of alcohol, hepatitis-
C virus infection, and HIV infection. As lifestyle-
related risk factors, obesity and smoking are suspec-
ted of increasing the risk of biliary tract carcinomas. 
Diabetes can also increase the risk, however available 
studies do not clearly show if this applies for both 
type I and type II diabetes. Above all in Asia, infec-
tion with the parasitic liver flukes Clonorchis sinen-
sis or Opisthorchis viverrini is a further risk factor.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 2,170 3,130 2,270 2,890 2,400 2,700
Crude incidence rate1 5.4 7.5 5.6 6.9 6.1 6.6
Standardised incidence rate1.² 4.0 4.0 4.0 3.6 4.0 3.3
Median age at diagnosis 71 75 72 76
Deaths 1,208 2,245 1,153 2,092
Crude mortality rate1 3.0 5.4 2.9 5.0
Standardised mortality rate1.² 2.2 2.8 2.0 2.6
5-year prevalence 2,800 3,300 2,900 3,100 3,200 2,900
Absolute 5-year survival rate (2007–2008)3 18 (12-25) 13 (8-16)
Relative 5-year survival rate (2007–2008)3 21 (14-30) 16 (10-20)
Table 3 7 1
Overview of the key epidemiological parameters for Germany, ICD-10 C23 – 24
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 7  Gall bladder and biliary tract
 Cancer in Germany | Gall bladder and biliary tract
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Figure 3 7 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C23 – 24, Germany, 2007 – 2008
Figure 3 7 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C23 – 24, Germany, 2007 – 2008
Figure 3 7 2
Distribution of T-stages at first diagnosis 
Not presented due to the large proportion of missing data.


































Figure 3 7 1b
Absolute numbers of new cases and deaths,  
ICD-10 C23 – 24, Germany, 1999 – 2008
Figure 3 7 1a
Age-standardised incidence and mortality rates,  
ICD-10 C23 – 24, Germany, 1999 – 2008
per 100,000 (European standard)
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44 Cancer in Germany | Gall bladder and biliary tract
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 5,600) 0.5 % (1 in 200) <0.1 % (1 in 26,000) 0.3 % (1 in 370)
50 years <0.1 % (1 in 2,100) 0.5 % (1 in 200) <0.1 % (1 in 5,800) 0.3 % (1 in 360)
60 years 0.1 % (1 in 810) 0.5 % (1 in 210) 0.1 % (1 in 1,800) 0.3 % (1 in 360)
70 years 0.2 % (1 in 470) 0.4 % (1 in 240) 0.1 % (1 in 860) 0.3 % (1 in 390)
Lifetime risk 0.5 % (1 in 210) 0.3 % (1 in 370)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 13,000) 0.6 % (1 in 170) <0.1 % (1 in 23,000) 0.4 % (1 in 230)
50 years <0.1 % (1 in 2,500) 0.6 % (1 in 170) <0.1 % (1 in 4,500) 0.4 % (1 in 230)
60 years 0.1 % (1 in 930) 0.6 % (1 in 170) 0.1 % (1 in 1,600) 0.4 % (1 in 230)
70 years 0.2 % (1 in 480) 0.5 % (1 in 200) 0.2 % (1 in 640) 0.4 % (1 in 250)
Lifetime risk 0.6 % (1 in 170) 0.4 % (1 in 230)
Table 3 7 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C23 – 24, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.4 1.3 2.1 2.9 4.5 12.9 12.8 24.0 28.9 39.2 35.5
Woman 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.2 0.3 1.8 2.6 5.3 8.7 13.3 24.4 26.8 36.6 45.3
Table 3 7 2
Age-specific incidence rates in Germany by sex, ICD-10 C23 – 24, 2007 – 2008
per 100,000













Figure 3 7 4 
Age-specific incidence rates in Germany by sex, ICD-10 C23 – 24, 2007 – 2008
per 100,000
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Figure 3 7 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C23 – 24, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 7 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C23 – C24, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
1 no comparable data
46 Cancer in Germany | Pancreas
Epidemiology
The pancreas produces hormones (endocrinal func-
tion) as well as digestive juices (exocrinal function). 
Tumours originate most frequently in the exocrinal 
portion of the pancreas, and these account for 
approx. 95 % of all pancreatic carcinoma. 
In 2008, some 15,000 people were diagnosed 
with pancreatic cancer, making the pancreatic carci-
noma one of the ten most common tumours in Ger-
many. The prognosis is unfavourable and it accounts 
for 6.3 % of all deaths due to cancer for men and 7.5 
% for women – the fourth most frequent cause of 
cancer deaths. 
The incidence and mortality rates are about equal 
due to the poor prognosis for pancreatic cancer, and 
the rates have remained fairly constant since the end 
of the 1990s. 
In the early stages, malignant neoplasms of the 
pancreas frequently cause few or only unspecific 
symptoms, so that the tumour is not recognised 
until it has reached an advanced stage. The relative 
5-year survival rate is correspondingly unfavourable, 
and in Germany it is 8 % for men and 7 % for 
women. The pancreatic carcinoma has the lowest 
survival rates of all types of cancer.
The median age at diagnosis is 70 years for men 
and 76 years for women. The lifetime risk is 1.5 % 
for both genders. 
Risk factors and early detection
Definite risk factors are tobacco consumption, inclu-
ding passive smoking, and obesity. The influence of 
further lifestyle-related factors, in particular diet, is 
not clear. It is therefore not possible to make definite 
recommendations for the prevention of a pancreatic 
carcinoma, with one exception: alcohol should be 
avoided if possible. At least high levels of alcohol 
consumption clearly increase the risk.
The probability of developing pancreatic cancer is 
also higher for patients with type 2 diabetes mellitus 
or with long-term chronic inflammation of the pan-
creas (pancreatitis).
First degree relatives of patients with a pancreatic 
carcinoma have a statistically higher risk of themsel-
ves developing the cancer, although it is not clear if 
this is due to a hereditary genetic predisposition or 
to a shared lifestyle. A hereditable risk seems to play 
a role for at least some patients. People with two or 
more first-degree relatives with pancreatic cancer are 
at a much higher risk than the normal population.
It is not yet clear what role is played by environ-
mental factors or occupational exposure to harmful 
substances.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 7,300 7,250 7,390 7,570 7,800 7,600
Crude incidence rate1 18.1 17.3 18.4 18.1 19.5 18.3
Standardised incidence rate1.² 13.5 9.4 13.4 9.8 13.2 9.5
Median age at diagnosis 70 76 70 76
Deaths 6,904 7,541 7,327 7,508
Crude mortality rate1 17.1 18.0 18.2 17.9
Standardised mortality rate1.² 12.6 9.3 13.0 9.2
5-year prevalence 5,600 5,600 5,800 5,800 6,100 6,000
Absolute 5-year survival rate (2007–2008)3 7 (3-9) 6 (4-10)
Relative 5-year survival rate (2007–2008)3 8 (3-10) 7 (4-11)
Table 3 8 1
Overview of the key epidemiological parameters for Germany, ICD-10 C25
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 8  Pancreas
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Figure 3 8 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C25, Germany, 2007 – 2008
Figure 3 8 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C25, Germany, 2007 – 2008
Figure 3 8 2
Distribution of T-stages at first diagnosis 
Not presented due to the large proportion of missing data.


































Figure 3 8 1b
Absolute numbers of new cases and deaths,  
ICD-10 C25, Germany, 1999 – 2008
Figure 3 8 1a
Age-standardised incidence and mortality rates,  
ICD-10 C25, Germany, 1999 – 2008
100.000 (European standard)
48 Cancer in Germany | Pancreas
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,800) 1.6 % (1 in 64) <0.1 % (1 in 2,200) 1.6 % (1 in 62)
50 years 0.2 % (1 in 520) 1.6 % (1 in 64) 0.2 % (1 in 610) 1.6 % (1 in 63)
60 years 0.5 % (1 in 220) 1.5 % (1 in 69) 0.4 % (1 in 240) 1.5 % (1 in 65)
70 years 0.6 % (1 in 160) 1.2 % (1 in 85) 0.7 % (1 in 140) 1.3 % (1 in 76)
Lifetime risk 1.5 % (1 in 65) 1.6 % (1 in 64)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 3,000) 1.5 % (1 in 65) <0.1 % (1 in 4,300) 1.6 % (1 in 64)
50 years 0.1 % (1 in 860) 1.5 % (1 in 66) 0.1 % (1 in 1,000) 1.6 % (1 in 64)
60 years 0.3 % (1 in 320) 1.5 % (1 in 69) 0.3 % (1 in 360) 1.5 % (1 in 66)
70 years 0.6 % (1 in 170) 1.2 % (1 in 81) 0.6 % (1 in 180) 1.3 % (1 in 75)
Lifetime risk 1.5 % (1 in 66) 1.5 % (1 in 65)
Table 3 8 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C25, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.2 0.1 0.2 1.0 3.4 7.4 13.4 25.2 41.4 55.8 66.6 86.0 94.0 113.3
Woman 0.0 0.0 0.0 0.2 0.3 0.2 0.3 0.5 1.6 4.8 7.8 14.4 26.9 37.8 51.7 72.6 86.1 93.2
Table 3 8 2
Age-specific incidence rates in Germany by sex, ICD-10 C25, 2007 – 2008
per 100,000













Figure 3 8 4 
Age-specific incidence rates in Germany by sex  ICD-10 C25, 2007 – 2008
per 100,000
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Figure 3 8 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C25, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
Figure 3 8 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C25, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
50 Cancer in Germany | Larynx
Epidemiology
Men are affected by laryngeal cancer considerably 
more frequently than women due to their higher 
consumption of tobacco and alcohol. Currently one 
in 150 men in Germany develops laryngeal cancer, 
but only one in 1,000 women (lifetime risk). Both 
men and women are diagnosed at a median age of 
65 years, which is four years earlier than the average 
for all types of cancer.
Since the 1980s the incidence and mortality rates 
for men have been declining, in particular for the 
under 50-year-olds. The rates for women have 
remained unchanged after a marked increase in the 
1980s and 1990s. This resulted after the year 2000 
in an increase in the numbers of deaths and diag-
nosed cases for women, in particular in the higher 
age groups – while the numbers of cases diagnosed 
for men remained unchanged.
The relative 5-year survival rates of men and 
women differ little from one another (62 % and 60 
%, respectively). In contrast to many other types of 
cancer, tumours of the larynx are more frequently 
diagnosed at an early stage (T1) for men than for 
women (40 % and 34 %, respectively). Malignant 
neoplasms of the larynx are almost exclusively squa-
mous epithelial carcinomas.
Risk factors
Smoking is the most-important risk factor for the 
development of laryngeal cancer. Alcohol consump-
tion also increases the probability of developing the 
cancer, and the combination of both factors is parti-
cularly harmful. The influences of lifestyle, nutriti-
on, or environmental factors are not yet clear, 
because in the majority of cases the influence of 
tobacco and alcohol consumption overshadows other 
effects. However, there are indications of a protective 
effect of eating carotene-rich vegetables and fruit. 
There is a known link between tumours of the larynx 
and occupational exposure to asbestos, nickel or 
polycyclical aromatic hydrocarbons. Infection with 
human papilloma viruses (HPV) can also play a role 
in the development of laryngeal cancer. First-degree 
relatives of patients have a higher risk of developing 
the cancer, but it is not clear in detail whether this is 
attributable to genes which are directly involved in 
the development of the tumour or to genes which 
determine the individual susceptibility to carcino-
gens. 
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 3,550 520 3,610 510 3,600 600
Crude incidence rate1 8.8 1.2 9.0 1.2 9.0 1.4
Standardised incidence rate1.² 6.9 0.9 6.9 0.9 6.5 0.9
Median age at diagnosis 66 64 66 64
Deaths 1,263 220 1,275 209
Crude mortality rate1 3.1 0.5 3.2 0.5
Standardised mortality rate1.² 2.4 0.4 2.4 0.3
5-year prevalence 11,600 1,600 11,700 1,600 11,600 1,750
Absolute 5-year survival rate (2007–2008)3 55 (37-61) 55
Relative 5-year survival rate (2007–2008)3 62 (42-68) 60
Table 3 9 1
Overview of the key epidemiological parameters for Germany, ICD-10 C32
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 9  Larynx
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Figure 3 9 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C32, Germany, 2007 – 2008
Figure 3 9 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C32, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information        DCO
Women
Men
Figure 3 9 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C32, Germany, 2007 – 2008 


































Figure 3 9 1b
Absolute numbers of new cases and deaths,  
ICD-10 C32, Germany, 1999 – 2008
Figure 3 9 1a
Age-standardised incidence and mortality rates,  
ICD-10 C32, Germany, 1999 – 2008
per 100,000 (European standard)
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52 Cancer in Germany | Larynx
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,400) 0.7 % (1 in 150) <0.1 % (1 in 11,000) 0.3 % (1 in 380)
50 years 0.2 % (1 in 610) 0.7 % (1 in 150) <0.1 % (1 in 2,200) 0.3 % (1 in 380)
60 years 0.2 % (1 in 410) 0.5 % (1 in 190) 0.1 % (1 in 1,200) 0.2 % (1 in 430)
70 years 0.2 % (1 in 430) 0.3 % (1 in 290) 0.1 % (1 in 1,000) 0.2 % (1 in 560)
Lifetime risk 0.7 % (1 in 150) 0.3 % (1 in 380)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 12,000) 0.1 % (1 in 1,000) <0.1 % (1 in 63,000) <0.1 % (1 in 2,400)
50 years <0.1 % (1 in 4,300) 0.1 % (1 in 1,100) <0.1 % (1 in 16,000) <0.1 % (1 in 2,500)
60 years <0.1 % (1 in 3,700) 0.1 % (1 in 1,500) <0.1 % (1 in 8,600) <0.1 % (1 in 2,800)
70 years <0.1 % (1 in 4,600) <0.1 % (1 in 2,300) <0.1 % (1 in 9,400) <0.1 % (1 in 3,900)
Lifetime risk 0.1 % (1 in 1,000) <0.1 % (1 in 2,400)
Table 3 9 3
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C32, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.3 2.0 5.9 14.2 20.5 24.6 27.0 27.0 28.3 21.8 19.4
Woman 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.8 0.9 2.0 3.2 2.4 3.0 2.4 2.7 2.6 2.8
Table 3 9 2
Age-specific incidence rates in Germany by sex, ICD-10 C32, 2007 – 2008
per 100,000













Figure 3 9 4 
Age-specific incidence rates in Germany by sex  ICD-10 C32, 2007 – 2008
per 100,000
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Figure 3 9 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C32, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 9 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C32, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases 2 no incidence data yet
54 Cancer in Germany | Lung
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 33,650 15,280 33,960 15,570 33,700 17,700
Crude incidence rate1 83.5 36.4 84.4 37.2 84.4 42.7
Standardised incidence rate1.² 61.4 24.0 60.6 24.3 55.9 26.8
Median age at diagnosis 69 68 69 68
Deaths 29,143 12,379 29,505 12,841
Crude mortality rate1 72.3 29.5 73.3 30.7
Standardised mortality rate1.² 52.7 18.5 52.3 19.2
5-year prevalence 39,200 19,200 39,500 20,000 38,600 22,900
Absolute 5-year survival rate (2007–2008)3 13 (10-15) 18 (15-23)
Relative 5-year survival rate (2007–2008)3 15 (11-18) 19 (16-25)
Table 3 10 1
Overview of the key epidemiological parameters for Germany, ICD-10 C33 – 34
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 10  Lung
Epidemiology 
Lung cancer is the third most common form of can-
cer both for men and women. In 2008 about 34,000 
men and 15,500 women were newly diagnosed with 
lung cancer, and for approx. 29,500 men and 13.000 
women it was the cause of death. This means that 
lung cancer accounts for 26 % of cancer-related 
deaths for menin Germany, by far the most com-
mon cause, and 13 % for women, the third most 
common cause of cancer-related deaths. 
While the age-standardised incidence and morta-
lity rates for men are continually declining, since the 
end of the 1990s both rates have increased for 
women by some 30 %. Similar trends are also found 
in other European industrialised countries. This 
contrary development is attributable to the changing 
smoking habits of both sexes.
The prognosis for lung tumours is rather unfavo-
urable. In Germany, the relative 5-year survival rate 
for men is 15 % and for women 19 %. 
The stage distribution at diagnosis for men and 
women is very similar, with a high proportion of T4 
cases (approx. 40 %). The median age at diagnosis 
is about 69 years for men and 68 years for women 
and roughly corresponds to the average figure for 
cancer cases overall.
Risk factors and early detection
Exposure to tobacco smoke has long been recognised 
as the main risk factor for lung cancer. For men at 
least nine out of ten cases of lung cancer, and for 
women at least six out of ten cases are attributable to 
active smoking. Passive smoke inhalation also incre-
ases the cancer risk and is a major contributor to 
indoor pollution. 
Other risk factors play a relatively minor role. Bet-
ween 9 and 15 out of 100 lung cancer cases are attri-
butable to exposure to various carcinogenic substan-
ces, including asbestos and quartz dust, polycyclical 
aromatic hydrocarbons, and nickel dust. In areas 
with a high natural exposure to radon in buildings 
the lung cancer risk is higher for residents, particu-
larly for dwellings near ground level. The risk is also 
increased by occupational exposure to radon or other 
sources of ionising radiation. Diesel exhaust fumes 
are the most important risk factor among air pollu-
tants. The impact of other environmental pollutants 
(e.g. particulate matter) is a matter for further 
research. The same applies for the influence of gene-
tic factors. There is also a relationship between an 
infection with a human papilloma virus (HPV) or 
Epstein Barr virus (EBV) and the development of 
lung carcinomas. Higher consumption of vegetables 
and fruit has a protective effect, but in smokers it 
cannot make up for the tobacco-related increase in 
risk.
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Figure 3 10 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C33 – 34, Germany, 2007 – 2008
Figure 3 10 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C33 – 34, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no Information        DCO
Women
Men
Figure 3 10 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C33 – 34, Germany, 2007 – 2008


































Figure 3 10 1b
Absolute numbers of new cases and deaths,  
ICD-10 C33 – 34, Germany, 1999 – 2008
Figure 3 10 1a
Age-standardised incidence and mortality rates,  
ICD-10 C33 – 34, Germany, 1999 – 2008
je 100,000 (European standard)
 ICD-10 C33 – 34 | Cancer in Germany 
56 Cancer in Germany | Lung
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 530) 7.1 % (1 in 14) 0.2 % (1 in 660) 6.3 % (1 in 16)
50 years 0.9 % (1 in 110) 7.1 % (1 in 14) 0.7 % (1 in 140) 6.3 % (1 in 16)
60 years 2.1 % (1 in 48) 6.6 % (1 in 15) 1.8 % (1 in 57) 6.0 % (1 in 17)
70 years 3.1 % (1 in 32) 5.3 % (1 in 19) 2.8 % (1 in 36) 4.9 % (1 in 20)
Lifetime risk 7.0 % (1 in 14) 6.2 % (1 in 16)
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 670) 3.0 % (1 in 34) 0.1 % (1 in 910) 2.5 % (1 in 40)
50 years 0.5 % (1 in 200) 2.9 % (1 in 35) 0.4 % (1 in 260) 2.4 % (1 in 41)
60 years 0.8 % (1 in 120) 2.4 % (1 in 41) 0.6 % (1 in 160) 2.1 % (1 in 47)
70 years 1.0 % (1 in 100) 1.7 % (1 in 58) 0.8 % (1 in 120) 1.6 % (1 in 63)
Lifetime risk 3.0 % (1 in 34) 2.5 % (1 in 40)
Table 3 10 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C33 – 34, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.2 0.3 1.3 0.8 3.2 7.9 28.2 66.1 119.1 189.5 259.6 329.2 422.0 480.6 332.9
Woman 0.0 0.0 0.0 0.3 0.3 0.3 1.5 3.4 8.3 20.5 41.1 61.5 85.1 87.8 97.1 119.6 116.3 92.3
Table 3 10 2
Age-specific incidence rates in Germany by gender, ICD-10 C33 – 34, 2007 – 2008 
per 100 .000













Figure 3 10 4 
Age-specific incidence rates in Germany by gender  ICD-10 C33 – 34, 2007 – 2008
per 100,000
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Figure 3 10 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C33 – 34, 2007 – 2008 or latest available year (details and sources, see Annex)
per 100,000 (European standard)










































Figure 3 10 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C33 – 34, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
58 Cancer in Germany | Malignant melanoma of the skin
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 7,340 7,740 8,910 8,890 9,200 8,400
Crude incidence rate1 18.2 18.4 22.1 21.2 23.0 20.2
Standardised incidence rate1.² 14.3 14.4 17.1 16.6 16.9 15.6
Median age at diagnosis 65 60 66 60
Deaths 1,368 1,099 1,365 1,135
Crude mortality rate1 3.4 2.6 3.4 2.7
Standardised mortality rate1.² 2.6 1.6 2.5 1.6
5-year prevalence 28,600 32,600 30,900 34,200 36,100 37,000
Absolute 5-year survival rate (2007–2008)3 77 (71-82) 83 (76-85)
Relative 5-year survival rate (2007–2008)3 87 (84-94) 91 (82-94)
Table 3 11 1
Overview of the key epidemiological parameters for Germany, ICD-10 C43
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 11  Malignant melanoma of the skin
Epidemiology
Nearly 18,000 people were diagnosed in 2008 with 
a malignant melanoma of the skin (men and women 
in near equal parts), with in addition some 5,000 in 
situ melanomas. Malignant skin melanomas are 
distinguished in terms of their growth behaviour. 
The most common type is the superficial spreading 
melanoma (SSM), for which the prognosis is good.
The median age of women at diagnosis is 60 
years, which is comparatively young. Men are diag-
nosed at a median age of 66 years. This corresponds 
to higher risks of developing disease among younger 
women and older men. Only about one in 440 
women and one in 350 men in Germany die of a 
malignant melanoma of the skin.  
Since the 1980s, the age-standardised incidence 
rates have more than tripled. The mortality rates of 
women have declined by about 10 %, whereas mor-
tality rates for men have increased to a similar extent. 
Since the end of the 1990s the mortality rates have 
been unchanged, but the incidence rates increased 
in 2008 alone by 15-20 %. This was the year in which 
the new screening programme for skin cancer was 
introduced.
Currently, the relative 5-year survival rate in Ger-
many for women with malignant melanoma of the 
skin is above 90 % and for men is 87 %. The survival 
rates are favourable in part due to the fact that every 
second melanoma is discovered at an early stage (T1).
Risk factors
More than half of all skin melanomas develop on 
skin without previous noticeable changes, while the 
remainder originate from existing skin pigmenta-
tions. People with a light skin type, or with a large 
number of skin pigmentations (moles, birth marks, 
or dysplastic naevi) have a higher risk of developing 
a melanoma, and genetic factors can therefore also 
play a part. High-risk genes have been identified 
which are linked to rare family clusters of melano-
ma, other genes are associated with a medium risk, 
and some increase the likelihood of “spontaneously” 
developing malignant melanomas as a result of 
other risk factors.
The most important exogenous risk factor is exposu-
re to natural sunlight or artificial UV-radiation in 
solariums, in particular during childhood and youth. 
A further risk factor is exposure to ultraviolet radiati-
on at the workplace, e.g. during welding.
Early detection
In 2008, new screening regulations were introduced 
in Germany for all forms of skin cancer within the 
framework of the legislation on the early detection of 
cancer. Men and women above 35 years of age with 
statutory health insurance are entitled to a medical 
examination by a suitably trained doctor (dermatolo-
gist, general practitioner, etc.).
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Figure 3 11 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C43, Germany, 2007 – 2008
Figure 3 11 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C43, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
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Figure 3 11 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C43, Germany, 2007 – 2008 


































Figure 3 11 1b
Absolute numbers of new cases and deaths,  
ICD-10 C43, Germany, 1999 – 2008
Figure 3 11 1a
Age-standardised incidence and mortality rates,  
ICD-10 C43, Germany, 1999 – 2008
per 100,000 (European standard)
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60 Cancer in Germany | Malignant melanoma of the skin
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 640) 1.6 % (1 in 63) <0.1 % (1 in 5,900) 0.3 % (1 in 350)
50 years 0.3 % (1 in 390) 1.5 % (1 in 68) <0.1 % (1 in 2,900) 0.3 % (1 in 370)
60 years 0.5 % (1 in 210) 1.3 % (1 in 76) 0.1 % (1 in 1,600) 0.3 % (1 in 390)
70 years 0.6 % (1 in 170) 1.0 % (1 in 100) 0.1 % (1 in 920) 0.2 % (1 in 440)
Lifetime risk 1.7 % (1 in 58) 0.3 % (1 in 350)
Women aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 420) 1.4 % (1 in 74) <0.1 % (1 in 6,300) 0.2 % (1 in 450)
50 years 0.3 % (1 in 390) 1.1 % (1 in 88) <0.1 % (1 in 4,000) 0.2 % (1 in 480)
60 years 0.3 % (1 in 310) 0.9 % (1 in 110) <0.1 % (1 in 2,600) 0.2 % (1 in 530)
70 years 0.3 % (1 in 290) 0.6 % (1 in 160) 0.1 % (1 in 1,600) 0.2 % (1 in 610)
Lifetime risk 1.6 % (1 in 61) 0.2 % (1 in 440)
Table 3 11 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C43, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.1 0.0 1.1 3.7 5.1 7.7 11.2 13.3 15.2 20.6 27.0 39.6 52.2 64.5 64.4 66.7 71.7
Woman 0.1 0.1 0.1 2.1 8.1 11.5 15.6 18.9 23.0 21.3 22.3 25.1 31.2 33.6 34.4 34.5 36.8 39.7
Table 3 11 2
Age-specific incidence rates in Germany by gender, ICD-10 C43, 2007 – 2008
per 100,000













Figure 3 11 4 
Age-specific incidence rates in Germany by gender  ICD-10 C43, 2007 – 2008
per 100,000
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Figure 3 11 6
International comparison of age-standardised incidence and mortality rates 
ICD-10 C43, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 11 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C43, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
62 Cancer in Germany | Breast 
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 520 66,490 520 71,660 600 74,500
Crude incidence rate1 1.3 158.4 1.3 171.1 1.5 180.0
Standardised incidence rate1.² 0.9 114.4 1.0 123.1 1.0 124.7
Median age at diagnosis 69 66 68 65
Deaths 249 16,780 136 17,209
Crude mortality rate1 0.6 40.0 0.3 41.1
Standardised mortality rate1.² 0.5 24.3 0.2 24.6
5-year prevalence 1,800 260,000 1,900 273,000 2,100 300,900
Absolute 5-year survival rate (2007–2008)3 63 (52-64) 78 (75-79)
Relative 5-year survival rate (2007–2008)3 76 (61-77) 86 (83-87)
Table 3 12 1
Overview of the key epidemiological parameters for Germany, ICD-10 C50
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 12  Breast 
Epidemiology
With some 72,000 new cases diagnosed annually, 
breast cancer is by far the most frequent type of can-
cer in women; there are annually also an additional 
6,500 in situ tumours. According to current figures, 
about one woman in eight will develop breast cancer 
in the course of herlife. Of these, a quarter of the 
women are younger than 55 years at diagnosis, and 
one in ten is younger than 45 years old.
In 2008, twice as many women were diagnosed 
as in 1980. The age-standardised incidence rate has 
since increased by 50 %. The current incidence and 
mortality rates are comparable with the results for 
neighbouring countries. However, they are still 
some 25 % lower across eastern Germany than in 
the western federal states. 
With the gradual introduction of mammography 
screening across the country, beginning in 2005, the 
incidence rates initially spiked. This indicates that in 
the first phase of the programme many tumours 
were diagnosed at a much earlier stage than they 
would have been without screening. However, it is 
also possible that some tumours were diagnosed that 
would otherwise have gone unrecognised for the 
whole life of the patient (over-diagnosis). There has 
been an appreciable increase in the proportion of 
smaller tumours (T1) in the screening age group. 
Despite the increased incidence, fewer women 
die of cancer now than 20 years ago. The survival 
prospects have been improved considerably by 
advances in therapy. It will not be possible to tell if 
screening leads to a further reduction in breast can-
cer mortality before 2015 at the earliest.
Risk factors
Early first menses and late last menses, no children 
or a late first child are associated with an increased 
risk of breast cancer in women. Conversely, several 
or early births and longer periods of breast-feeding 
reduce the risk of breast cancer. Hormone replace-
ment therapy with oestrogen, either alone or in com-
bination with progestogen during and after meno-
pause increase the risk of breast cancer. Ovulation 
inhibitors containing hormones (the “Pill”) only 
have a slight influence. 
Studies have shown an increased risk with over-
weight and a lack of exercise after menopause, and 
alcohol is also a proven risk factor. There is increa-
sing evidence that the risk is increased by smoking 
and passive exposure to tobacco smoke. 
Women with very dense breast tissue or with cer-
tain benign neoplasms (lobular neoplasias and atypi-
cal ductal hyperplasias) have an increased risk, the 
same applies if there are cases of breast or ovary can-
cer in the family. However, so-called “breast cancer 
genes” (BRCAs) can only be identified in some 5 to 
10 % of patients; other genes play a part in the deve-
lopment of mammary carcinomas. 
Early detection
Under the early detection programme, women above 
the age of 30 years are offered an annual palpation 
examination by a physician. Between 2005 und 
2008, the Mammography Screening Programme 
was introduced in Germany, and women between 50 
and 69 years are invited to an x-ray examination of 
the breasts every two years. 
63 ICD-10 C50 | Cancer in Germany 

















Figure 3 12 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C50, Germany, 2007 – 2008
Figure 3 12 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C50, Germany, 2007 – 2008
T1       T2        T3       T4       
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Figure 3 12 2
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)  
ICD-10 C50, Germany, 2007 – 2008


































Figure 3 12 1b
Absolute numbers of new cases and deaths,
ICD-10 C50, Germany, 1999 – 2008
Figure 3 12 1a
Age-standardised incidence and mortality rates, 
ICD-10 C50, Germany, 1999 – 2008
per 100,000 (European standard)
64 Cancer in Germany | Breast 
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 30,000) 0.1 % (1 in 670) <0.1 % (1 in 46,000) 0.1 % (1 in 1,500)
50 years <0.1 % (1 in 8,800) 0.1 % (1 in 670) <0.1 % (1 in 24,000) 0.1 % (1 in 1,500)
60 years <0.1 % (1 in 3,300) 0.1 % (1 in 680) <0.1 % (1 in 7,900) 0.1 % (1 in 1,500)
70 years 0.1 % (1 in 730) 0.1 % (1 in 730) 0.1 % (1 in 1,500) 0.1 % (1 in 1,500)
Lifetime risk 0.1 % (1 in 680) 0.1 % (1 in 1,500)
Women aged in the next ten years ever in the next ten years ever
40 years 1.5 % (1 in 68) 13.0 % (1 in 8) 0.2 % (1 in 570) 3.4 % (1 in 30)
50 years 2.7 % (1 in 37) 11.8 % (1 in 8) 0.4 % (1 in 240) 3.3 % (1 in 31)
60 years 4.1 % (1 in 24) 9.7 % (1 in 10) 0.8 % (1 in 130) 2.9 % (1 in 34)
70 years 3.4 % (1 in 29) 6.3 % (1 in 16) 1.0 % (1 in 100) 2.4 % (1 in 42)
Lifetime risk 13.3 % (1 in 8) 3.4 % (1 in 29)
Table 3 12 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C50, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.5 1.0 1.5 3.0 4.0 4.8 5.6 7.6 7.6
Woman 0.0 0.0 0.0 0.3 1.5 8.0 25.9 55.9 110.4 181.3 228.1 283.5 378.8 409.6 333.8 325.3 348.6 361.5
Table 3 12 2
Age-specific incidence rates in Germany by gender, ICD-10 C50, 2007 – 2008
per 100,000













Figure 3 12 4 
Age-specific incidence rates in Germany by gender  ICD-10 C50, 2007 – 2008
per 100,000
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Figure 3 12 6
International comparison of age-standardised incidence and mortality rates, only women,  
ICD-10 C50, 2007 – 2008 or latest available year (details and sources, see appendix) 
per 100,000 (European standard)






















Figure 3 12 5 
Registered age-standardised incidence rates in German federal states, only women ICD-10 C50, 2007 – 2008
per 100,000 (European standard)
1 ohne DCO-Fälle  2 noch keine Inzidenzdaten
66 Cancer in Germany | Cervix
Epidemiology
In Germany some 4,900 women were diagnosed 
with a cervical carcinoma in 2008. About three-
quarters of the invasive cervical tumours are squa-
mous epithelial carcinomas. Adenocarcinomas 
(approx. 20 %) have a higher origin at the transition 
from uterus to cervix. 
The incidence rates of invasive (fully developed) 
cervical carcinoma are continuing to decline among 
women. Since the 1990s, however, the rate of dec-
line has slowed down. The highest incidence rates 
are currently for 40- to 49-year-old women. In the 
1980s, older women had the highest relative inci-
dence rates. The median age at diagnosis for inva-
sive cancer is 52 years, in comparison with 69 years 
for all types of cancer. The median age at diagnosis 
for in situ carcinomas is 36 years. These are some 
three to four times more frequent than invasive car-
cinomas, a result of the early detection programme 
that is aimed at the identification and treatment of 
cancer precursors. The mortality rates have also dec-
lined markedly since 1980. Overall in Germany, one 
in 340 women dies as a result of cervical cancer, 
which corresponds to nearly 1,600 deaths every year 
– 30 years ago it was twice as many.
The relative 5-year survival rate after diagnosis of 
an invasive cervical tumour is 68 %. More than half 
of every invasive carcinoma is diagnosed at an early 
stage (T1). 
Risk factors and early detection 
Cervical cancer is mostly the result of sexually trans-
mitted infection with human papilloma viruses 
(HPV). The majority of women are infected with 
HPV at some stage in their life. Usually, the infection 
heals without further effects, but in some cases it 
persists and a cervical carcinoma can develop, above 
all with virus subtypes from the high risk group (e.g. 
HPV 16 and 18). Further risk factors are smoking, 
infections in the genital area with sexually transmit-
ted pathogens such as herpes simplex or chlamydia, 
multiple births, or a severely impaired immune sys-
tem. Taking old-generation oral contraceptives is 
also associated with a slightly increased incidence 
risk. However there are not yet any reliable findings 
concerning new generations of the “Pill”.
Women in Germany aged 20 years and above are 
entitled to an annual cervical smear test (PAP smear) 
as part of the statutory cancer screening arrange-
ments. In March 2007, the German Standing Com-
mittee on Vaccination Recommendations (STIKO) 
proposed inoculating girls between 12 and 17 years of 
age against HPV 16 and 18, which are responsible for 
some 70 % of all cervical carcinomas. It has been 
proved that the vaccination can prevent the develop-
ment of preliminary stages of cervical cancer. Howe-
ver, the vaccination does not render the PAP-smear 
test superfluous, because it only protects against the 
more common high-risk papilloma viruses.
 
 2007 2008 Prediction for 2012
 Woman Woman Woman
Incident cases 4,780 4,880 4,600
Crude incidence rate1 11.4 11.6 11.0
Standardised incidence rate1.² 9.4 9.5 9.0
Median age at diagnosis 52 52
Deaths 1,566 1,596
Crude mortality rate1 3.7 3.8
Standardised mortality rate1.² 2.6 2.6
5-year prevalence 16,700 17,000 16,400
Absolute 5-year survival rate (2007–2008)3 65 (53-72)
Relative 5-year survival rate (2007–2008)3 68 (56-75)
Table 3 13 1
Overview of the key epidemiological parameters for Germany, ICD-10 C53
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 13  Cervix
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Figure 3 13 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C53, Germany, 2007 – 2008
Figure 3 13 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C53, Germany, 2007 – 2008
T1       T2        T3       T4       no information        DCO Women
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
Figure 3 13 2
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)  
ICD-10 C53, Germany, 2007 – 2008






























Figure 3 13 1b
Absolute numbers of new cases and deaths,  
ICD-10 C53, Germany, 1999 – 2008
Figure 3 13 1a
Age-standardised incidence and mortality rates,  
ICD-10 C53, Germany, 1999 – 2008
per 100,000 (European standard)
68
Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 530) 0.7 % (1 in 140) <0.1 % (1 in 2,500) 0.3 % (1 in 350)
50 years 0.2 % (1 in 590) 0.5 % (1 in 190) <0.1 % (1 in 1,900) 0.3 % (1 in 400)
60 years 0.1 % (1 in 730) 0.4 % (1 in 260) 0.1 % (1 in 1,700) 0.2 % (1 in 490)
70 years 0.1 % (1 in 750) 0.3 % (1 in 380) 0.1 % (1 in 1,400) 0.2 % (1 in 630)
Lifetime risk 0.9 % (1 in 120) 0.3 % (1 in 340)
Table 3 13 3
Incidence and mortality risks in Germany by age, ICD-10 C53, Database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Woman 0.0 0.0 0.0 0.2 1.1 5.3 10.2 16.3 18.4 19.3 17.0 16.9 13.2 13.6 14.6 15.4 15.2 18.7
Table 3 13 2
















Figure 3 13 4 
Age-specific incidence rates, ICD-10 C53, Germany, 2007 – 2008
per 100,000
 Cancer in Germany | Cervix
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Figure 3 13 6
International comparison of age-standardised incidence and mortality rates 
ICD-10 C53, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)






















Figure 3 13 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C53, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
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 2007 2008 Prediction for 2012
 Woman Woman Woman
Incident cases 11,340 11,280 11,200
Crude incidence rate1 27.0 26.9 26.9
Standardised incidence rate1.² 17.6 17.2 16.4
Median age at diagnosis 69 69
Deaths 2,443 2,420
Crude mortality rate1 5.8 5.8
Standardised mortality rate1.² 3.1 3.0
5-year prevalence 42,300 42,700 42,600
Absolute 5-year survival rate (2007–2008)3 70 (63-76)
Relative 5-year survival rate (2007–2008)3 79 (72-85)
Table 3 14 1
Overview of the key epidemiological parameters for Germany, ICD-10 C54 – 55 
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 14  Uterus
Epidemiology
With an annual incidence of some 11,280 newly dia-
gnosed cases, and accounting for 5.1 % of all malig-
nant neoplasms, uterine cancer is the fourth most 
common form of cancer for women and the most 
common cancer of the female genital organs. How-
ever, due to the good prognosis, it only leads to 2.4 
% of all cancer related deaths.
One in 47 women (2.1 %) develops cancer of the 
uterus in the course of her life, one in 200 dies as a 
result. Nevertheless, the age-standardised incidence 
rate in Germany continues to decrease. Like the 
mortality rate for cervical cancer, the mortality rate 
for uterine cancer is also steadily declining. The 
incidence and mortality risks are highest at 70 years 
of age. The median age at diagnosis is 69 years. His-
tologically, cancers of the uterus are mostly endome-
trial, i.e. adenocarcinomas originating from the 
lining of the uterus.(approx. 68 %). Some 78 % of 
carcinomas are diagnosed while still in Stage T1. 
Uterus carcinomas have a good prognosis. The 
relative 5-year survival rate in Germany is approx. 
79 %. 
Risk factors
In addition to age, the long-term influence of oestro-
gen is a key risk factor. Therefore, the risk is increa-
sed by factors such as early first menses (menarche) 
and late onset of menopause, as well as childlessness 
or diseases of the ovaries, e.g. polycystic ovary syn-
drome (PCOS). Oestrogen as monotherapy during 
menopause also increases the risk, although the 
combination with progesterone does not. Oral con-
traceptives, in particular oestrogen-progesterone 
combinations, lower the risk. Women with breast 
cancer who have been treated with tamoxifen fre-
quently develop a hyperplasia of the endometrial 
lining of the uterus and as a result have a higher car-
cinoma risk. 
For hormone-dependent tumours, life-style rela-
ted risk factors play a role, above all overweight and 
lack of exercise. Women with diabetes mellitus 2 
develop uterine cancer more frequently. Gene muta-
tions which can lead to hereditary nonpolyposis colo-
rectal carcinoma (HNPCC), also contribute to a hig-
her risk of uterine cancer.
For the rarer oestrogen-independent forms of this 
tumour, advanced age is a risk. Exposure of the ute-
rus to radiation can also increase the risk. It is not 
possible to specify the role played by lifestyle factors 
or genetic factors for this form of uterus tumour.
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Figure 3 14 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C54 – 55, Germany, 2007 – 2008 
Figure 3 14 3a
Absolute survival rates up to 5 years after diagnosis, 
ICD-10 C54 – 55, Germany, 2007 – 2008








T1       T2        T3       T4       no information        DCO Women
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
Figure 3 14 2
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports)  
ICD-10 C54 – 55, Germany, 2007 – 2008






























Figure 3 14 1b
Absolute numbers of new cases and deaths,  
ICD-10 C54 – 55, Germany, 1999 – 2008
Figure 3 14 1a
Age-standardised incidence and mortality rates,  
ICD-10 C54 – 55, Germany, 1999 – 2008
per 100,000 (European standard)
72 Cancer in Germany | Uterus
Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 980) 2.1 % (1 in 47) <0.1 % (1 in 12,000) 0.5 % (1 in 200)
50 years 0.3 % (1 in 290) 2.1 % (1 in 48) <0.1 % (1 in 3,200) 0.5 % (1 in 200)
60 years 0.6 % (1 in 170) 1.8 % (1 in 55) 0.1 % (1 in 1,000) 0.5 % (1 in 210)
70 years 0.8 % (1 in 130) 1.3 % (1 in 76) 0.2 % (1 in 550) 0.4 % (1 in 240)
Lifetime risk 2.1 % (1 in 47) 0.5 % (1 in 200)
Table 3 14 3
Incidence and mortality rates in Germany by age, ICD-10 C54 – 55, Database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Frauen 0.0 0.0 0.0 0.1 0.1 0.5 1.4 2.3 5.5 13.6 26.4 43.1 56.5 70.8 84.1 81.5 81.1 71.5
Table 3 14 2















Figure 3 14 4 
Age-specific incidence rates, ICD-10 C54 – 55, Germany, 2007 – 2008
per 100,000 
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Figure 3 14 6
International comparison of age-standardised incidence and mortality rates 
ICD-10 C54 – 55, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)






















Figure 3 14 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C54 – 55, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
1 with C58  2 only C54
74 Cancer in Germany | Ovaries
 2007 2008 Prediction for 2012
 Woman Woman Woman
Incident cases 8,010 7,790 7,200
Crude incidence rate1 19.1 18.6 17.5
Standardised incidence rate1.² 12.7 12.2 11.0
Median age at diagnosis 69 69
Deaths 5,564 5,529
Crude mortality rate1 13.3 13.2
Standardised mortality rate1.² 7.7 7.6
5-year prevalence 20,300 20,300 18,800
Absolute 5-year survival rate (2007–2008)3 37 (28-42)
Relative 5-year survival rate (2007–2008)3 40 (31-45)
Table 3 15 1
Overview of the key epidemiological parameters for Germany, ICD-10 C56
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 15  Ovaries
Epidemiology
Histologically, more than 90 % of malignant 
tumours of the ovaries are adenocarcinomas. For 
women, cancer of the ovaries account for 3.5 % of all 
malignant neoplasms and 5.6 % of all deaths due to 
cancer. The incidence rates increase continually up 
to the age of 75 years and then remain fairly cons-
tant. Between 5 and 10 % of all cases of ovarian can-
cer (mostly germ cell tumours) affect women under 
the age of 45 years. The median age at diagnosis is 
69 years. The risk of developing a malignant ovarian 
tumour is 1.5 % (1 in 68 women).
There has been a marked decrease in the inci-
dence of ovarian cancer in Germany since the 1990s, 
but the decline in the numbers of deaths is less pro-
nounced. At diagnosis, 59 % of cases are already at 
the T3 stage, and 29 % are T1 stage. 
The survival prospects of patients with ovarian 
cancer are poor in comparison with women with 
other cancers of the genital organs. The relative 
5-year survival rate is currently about 40 %.
Risk factors
The risk of developing ovarian cancer increases with 
age. Among the lifestyle-related risk factors, obesity 
plays a role. There are important relationships with 
hormonal influences: childlessness, an early first 
menstruation, and a late onset of menopause lead to 
a comparatively large number of ovulatory cycles and 
thus to a higher risk of ovarian carcinomas compa-
red to women with numerous births, longer periods 
of breast-feeding, and an early onset of menopause. 
During menopause, hormone replacement therapy 
(in particular with oestrogen monotherapy) repre-
sents a risk factor. In contrast, hormonal ovulation 
inhibitors (the “Pill”) protects against ovarian cancer. 
The risk is also higher for women with polycystic 
ovaries, presumably also due to hormonal factors. 
Women have an increased risk of ovarian cancer 
if first degree relatives have been diagnosed with 
breast or ovarian cancer, or if they themselves have 
already had cancer of the breast, uterus or bowel. 
Underlying genetic mutations, above all of BRCA1 
and BRCA2, considerably increase the incidence 
risk, but they only play a role in a small proportion of 
cases. Other genetic factors are currently still a topic 
of research.
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Figure 3 15 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C56, Germany, 2007 – 2008
Figure 3 15 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C56, Germany, 2007 – 2008
T1       T2        T3       T4       no information        DCO Women
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
Figure 3 15 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C56, Germany, 2007 – 2008






























Figure 3 15 1b
Absolute numbers of new cases and deaths,  
ICD-10 C56, Germany 1999 – 2008
Figure 3 15 1a
Age-standardised incidence and mortality rates,  
ICD-10 C56, Germany 1999 – 2008
per 100,000 (European standard)
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Männer Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 880) 1.4 % (1 in 70) <0.1 % (1 in 2,900) 1.1 % (1 in 91)
50 years 0.2 % (1 in 440) 1.3 % (1 in 74) 0.1 % (1 in 840) 1.1 % (1 in 93)
60 years 0.3 % (1 in 290) 1.2 % (1 in 87) 0.2 % (1 in 410) 1.0 % (1 in 100)
70 years 0.5 % (1 in 210) 0.9 % (1 in 110) 0.4 % (1 in 260) 0.8 % (1 in 120)
Lifetime risk 1.5 % (1 in 68) 1.1 % (1 in 92)
Table 3 15 3
Incidence and mortality rates in Germany by age, ICD-10 C56, Database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Woman 0.0 0.1 0.2 1.4 1.4 1.8 2.0 4.5 8.0 15.3 19.4 27.0 33.1 41.2 50.1 56.1 57.1 55.7
Table 3 15 2















Figure 3 15 4 
Age-specific incidence rates, ICD-10 C56, Germany, 2007 – 2008
per 100,000
 Cancer in Germany | Ovaries
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Figure 3 15 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C56, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)






















Figure 3 15 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C56, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C56 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
78 Cancer in Germany | Prostate
 2007 2008 Prediction for 2012
 Men Men Men
Incident cases 64,500 63,440 67,600
Crude incidence rate1 160.1 157.7 169.6
Standardised incidence rate1.² 114.8 110.9 110.9
Median age at diagnosis 70 70
Deaths 11,448 12,134
Crude mortality rate1 28.4 30.2
Standardised mortality rate1.² 20.2 20.6
5-year prevalence 243,100 251,700
Absolute 5-year survival rate (2007–2008)3 77 (73-80)
Relative 5-year survival rate (2007–2008)3 92 (87-94)
Table 3 16 1
Overview of the key epidemiological parameters for Germany, ICD-10 C61
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 16  Prostate
Epidemiology
Prostate cancer remains the most common form of 
cancer among men and the third most common 
cause of cancer-related deaths among men in Ger-
many. In 2008 there were some 63,400 newly diag-
nosed cases. The annual number of newly diag-
nosed prostate tumours has therefore risen by some 
50 % since 1999, and the age-standardised inci-
dence rate has increased by 25 %. On the other 
hand, the mortality rate shows a slight decline since 
2003. The upward trend in incidence rates which 
already began in the early 1980s is largely attributa-
ble to the increased discovery of early-stage tumours 
by the prostate specific antigen (PSA) test. This has 
led to appreciably higher incidence rates among 
men between 50 and 69 years of age and to a reduc-
tion in the median age at diagnosis to 70 years in 
2008.
Hardly any cases of prostate cancer are diagnosed 
before the age of 50 years. This risk of a 40-year-old 
man of developing prostate cancer in the next ten 
years is only 0.1 %, compared with 6.6 % for a 
70-year-old.
The relative 5-year survival rate for prostate can-
cer in Germany has improved considerably in recent 
years, in part due to diagnosis at an earlier stage. It 
is now 92 %, which is the second highest survival 
rate in Germany after testicular cancer (96 %). 
Diagnosis at T1 and T2 stages accounts together 
for 76 % of cases, compared with only 3 % for the T4 
stage.
Risk factors and early detection
Little is known about the causes of prostate carcino-
ma development and the factors influencing its pro-
gression. A major risk factor, however, is age. Testos-
terone also clearly plays a role, and without it prosta-
te cancer would not develop. There is also evidence 
of clusters of cases among close relatives, although it 
is not clear whether inheritable gene mutations are 
involved.
Despite extensive research, there are few reliable 
findings about risk factors relating to lifestyle, diet, 
or the environment. However, there does appear to 
be a link between regular, high levels of alcohol con-
sumption and the risk of developing prostate cancer. 
A large-scale cancer prevention study has shown that 
taking vitamin E as a dietary supplement increases 
the risk of having prostate cancer.
The statutory early detection programme in Ger-
many provides for an annual prostate examination 
for all men above the age of 45 years. This includes 
questions about symptoms and other health chan-
ges, the investigation of the external sexual organs, 
and palpation examination of the prostate and the 
lymph nodes. A test for levels of prostate-specific 
antigen (PSA) in blood is not part of the screening 
programme, because so far its benefits have not been 
established.
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Figure 3 16 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C61, Germany, 2007 – 2008
Figure 3 16 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C61, Germany, 2007 – 2008
Figure 3 16 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C61, Germany, 2007 – 2008
T1       T2        T3       T4       no information        DCO Men
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %






























Figure 3 16 1b
Absolute numbers of new cases and deaths,  
ICD-10 C61, Germany, 1999 – 2008
Figure 3 16 1a
Age-standardised incidence and mortality rates,  
ICD-10 C61, Germany, 1999 – 2008
per 100,000 (European standard)
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 900) 13.3 % (1 in 7) <0.1 % (1 in 20,000) 3.3 % (1 in 30)
50 years 1.2 % (1 in 83) 13.6 % (1 in 7) 0.1 % (1 in 1,400) 3.4 % (1 in 29)
60 years 4.6 % (1 in 22) 13.4 % (1 in 7) 0.4 % (1 in 250) 3.6 % (1 in 28)
70 years 6.6 % (1 in 15) 10.8 % (1 in 9) 1.3 % (1 in 79) 3.8 % (1 in 27)
Lifetime risk 13.0 % (1 in 8) 3.3 % (1 in 31)
Table 3 16 3
Incidence and mortality rates in Germany by age, ICD-10 C61, Database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.3 2.3 15.3 58.2 169.4 395.5 626.3 753.1 771.4 718.9 732.7
Table 3 16 2















Figure 3 16 4 
Age-specific incidence rates, ICD-10 C61, Germany, 2007 – 2008
per 100,000
 Cancer in Germany | Prostate
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Figure 3 16 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C61, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)






















Figure 3 16 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C61, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C61 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
82 Cancer in Germany | Testicle
 2007 2008 Prediction for 2012
 Men Men Men
Incident cases 4,030 3,970 3,900
Crude incidence rate1 10.0 9.9 9.8
Standardised incidence rate1.² 9.6 9.5 9.5
Median age at diagnosis 38 38
Deaths 152 153
Crude mortality rate1 0.4 0.4
Standardised mortality rate1.² 0.3 0.3
5-year prevalence 19,000 18,900 18,500
Absolute 5-year survival rate (2007–2008)3 94 (91-97)
Relative 5-year survival rate (2007–2008)3 96 (92-98)
Table 3 17 1
Overview of the key epidemiological parameters for Germany, ICD-10 C62
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 17  Testicle
Epidemiology
In 2008 some 3,970 men in Germany were diag-
nosed with testicular cancer. It accounts for 1.6 % of 
all cases of cancer, making it a relatively rare form. 
Due to the low number of deaths from testicular 
cancer (153 in 2008) registration completeness can-
not be estimated with certainty, and the projection of 
the national incidence rate for Germany is also 
uncertain. In contrast to almost all other types of 
cancer, most cases are diagnosed at a relatively 
young age, namely between 25 and 45 years. In this 
age group, testicular cancer is the most common 
malignant tumour for men. The median age at dia-
gnosis is 38 years. The highest lifetime risk of ever 
being diagnosed with testicular cancer is at the age 
of 20 years (1 in 150 men). 
In Germany, as in other European countries, the 
age-standardised incidence of testicular cancer has 
been increasing for decades, while the mortality has 
decreased. The decline in mortality is explained by 
the successful use of cis-platinum in the cytostatic 
therapy of testicular cancer. Some 92 % of testicular 
tumours are diagnosed either in stage T1 (58 %) or 
T2 (34 %). Histologically, approx. 62 % of cases of 
testicular cancers are seminomas and approx. 18 % 
of cases are malignant teratomas.
With a relative 5-year survival rate of approx. 96 
%, testicular cancer has one of the more favourable 
prognoses among malignant neoplasms. 
 
Risk factors
A confirmed risk factor for testicular cancer is crypt-
orchism (undescended testis), even after this has 
been properly treated. Men who have already had 
cancer in one testicle have an increased risk of deve-
loping a tumour in the other one. Infertility and rare, 
genetically caused disturbances in sexual develop-
ment such as Klinefelter’s syndrome also increase 
the likelihood of developing testicular cancer. In a 
small proportion of cases there may be a genetic pre-
disposition. Sons and brothers (particularly twin 
brothers) of patients with testicular cancer have a 
markedly higher incidence risk. A hypothesis is that 
the predisposition for seminoma tumours, the most 
common type, may have its origins in cells which are 
scattered during the embryonic stage, and which 
then undergo a malignant development in puberty. 
A birth weight below 2500g or above 4500g and tall 
stature are discussed as possible risk factors. The 
causes of the increase in incidence observed in 
recent decades are not clear. It has been proven that 
an early diagnosis is correlated with the stage of the 
cancer and with a better prognosis. Men between 20 
and 40 years of age are advised to carry out regular 
self-examinations by palpation of the testes.
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Figure 3 17 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C62, Germany, 2007 – 2008
Figure 3 17 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C62, Germany, 2007 – 2008
T1       T2        T3       T4       no information        DCO Men
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
Figure 3 17 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C62, Germany, 2007 – 2008






























Figure 3 17 1b
Absolute numbers of new cases and deaths,  
ICD-10 C62, Germany, 1999 – 2008
Figure 3 17 1a
Age-standardised incidence and mortality rates,  
ICD-10 C62, Germany, 1999 – 2008
per 100,000 (European standard)
84 Cancer in Germany | Testicle
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.2 % (1 in 610) 0.7 % (1 in 150) <0.1 % (1 in 40,000) <0.1 % (1 in 3,600)
50 years 0.2 % (1 in 460) 0.5 % (1 in 200) <0.1 % (1 in 21,000) <0.1 % (1 in 3,900)
60 years 0.2 % (1 in 610) 0.3 % (1 in 350) <0.1 % (1 in 17,000) <0.1 % (1 in 4,800)
70 years 0.1 % (1 in 1,500) 0.1 % (1 in 790) <0.1 % (1 in 21,000) <0.1 % (1 in 6,400)
Lifetime risk 0.7 % (1 in 150) <0.1 % (1 in 3,600)
Table 3 17 3
Incidence and mortality rates in Germany by age, ICD-10 C62, Database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.3 0.1 0.1 4.7 14.1 20.7 21.8 21.7 20.1 13.9 7.9 5.5 3.7 2.2 2.0 1.8 3.3 4.5
Table 3 17 2















Figure 3 17 4 
Age-specific incidence rates, ICD-10 C62, Germany, 2007 – 2008
per 100,000
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Figure 3 17 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C62, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)






















Figure 3 17 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C62, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
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 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 8,830 5,490 8,960 5,540 9,300 5,800
Crude incidence rate1 21.9 13.1 22.3 13.3 23.3 13.9
Standardised incidence rate1.² 16.7 8.2 16.5 8.2 16.1 8.3
Median age at diagnosis 68 71 68 71
Deaths 2,888 2,031 3,060 2,041
Crude mortality rate1 7.2 4.8 7.6 4.9
Standardised mortality rate1.² 5.2 2.4 5.4 2.5
5-year prevalence 30,000 18,600 30,800 19,100 31,700 20,000
Absolute 5-year survival rate (2007–2008)3 65 (58-67) 67 (58-72)
Relative 5-year survival rate (2007–2008)3 74 (67-77) 75 (66-79)
Table 3 18 1
Overview of the key epidemiological parameters for Germany, ICD-10 C64
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 18  Kidney 
 Cancer in Germany | Kidney 
Epidemiology
Malignant neoplasms of the kidney can develop 
from various tissues. Renal cell carcinomas (hyper-
nephromas) account for 90 % of all kidney tumours 
in adults. In contrast, nephroblastomas (Wilms’ 
tumours), lymphomas, and sarcomas of the kidney 
are more frequent in children.
The age-standardised incidence rates since the 
end of the 1990s have been fairly constant for men 
and women, although the incidence rate for men is 
markedly higher than that for women. The raw inci-
dence rates have increased slightly in recent years, 
whereas the age-standardised mortality rates have 
shown a downward trend for both sexes.
The lifetime risk of developing kidney cancer is 
1.8 % for men, compared with 1.1 % for women. The 
median age at diagnosis is 68 years for men and 71 
years for women.
The relative 5-year survival rate for kidney 
tumours is approx. 75 %, and the prognosis for 
tumours which are diagnosed at an early stage is 
good. However, at an advanced stage the prognosis 
is rather unfavourable. As the figure shows, kidney 
cancer in Germany is mostly diagnosed in the early 
stages (T1 and T2) – these account for 74 % of cases 
for men and women. 
Risk factors and early detection
Smoking and passive exposure to tobacco smoke, as 
well as hypertension and obesity are the most impor-
tant risk factors. There seems to be a relationship 
between overweight and the development of kidney 
cancer in women, in particular. In men, the nature of 
the fat distribution may possibly be decisive. Studies 
have also found that alcohol consumption is a possi-
ble risk factor.
Occupational exposure to substances which may 
damage the kidneys, e.g. halogenated hydrocarbons 
or cadmium, can also increase the risk of cancer. Car-
cinogenesis in the kidney can be promoted by chro-
nic renal insufficiency, regardless of the cause of the 
latter. After a kidney transplant the immunosup-
pressed patient still has a risk of developing a renal 
cell carcinoma.
Familial predisposition probably plays a role in 
relatively few cases. About four per cent of renal cell 
carcinomas occur in patients with complex heredi-
tary diseases such as Hippel-Lindau syndrome. Such 
genetically associated renal cell carcinomas are often 
multifocal and occur more often at a younger age 
than kidney cancers not associated with a genetic 
disposition.
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Figure 3 18 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C64, Germany, 2007 – 2008
Figure 3 18 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C64, Germany, 2007 – 2008
Figure 3 18 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports) ICD-10 C64, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information        DCO
Women
Men


































Figure 3 18 1b
Absolute numbers of new cases and deaths,  
ICD-10 C64, Germany, 1999 – 2008
Figure 3 18 1a
Age-standardised incidence and mortality rates,  
ICD-10 C64, Germany, 1999 – 2008
per 100,000 (European standard)
 ICD-10 C64 | Cancer in Germany 
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 970) 1.8 % (1 in 57) <0.1 % (1 in 6,300) 0.7 % (1 in 150)
50 years 0.3 % (1 in 360) 1.7 % (1 in 59) 0.1 % (1 in 1,400) 0.7 % (1 in 150)
60 years 0.5 % (1 in 190) 1.5 % (1 in 66) 0.2 % (1 in 620) 0.6 % (1 in 150)
70 years 0.7 % (1 in 130) 1.2 % (1 in 85) 0.3 % (1 in 340) 0.6 % (1 in 180)
Lifetime risk 1.8 % (1 in 57) 0.7 % (1 in 150)
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 2,000) 1.1 % (1 in 95) <0.1 % (1 in 17,000) 0.4 % (1 in 240)
50 years 0.1 % (1 in 800) 1.0 % (1 in 98) <0.1 % (1 in 3,700) 0.4 % (1 in 240)
60 years 0.3 % (1 in 380) 0.9 % (1 in 110) 0.1 % (1 in 1,600) 0.4 % (1 in 250)
70 years 0.4 % (1 in 240) 0.7 % (1 in 140) 0.2 % (1 in 640) 0.4 % (1 in 270)
Lifetime risk 1.1 % (1 in 93) 0.4 % (1 in 240)
Table 3 18 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C64, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 2.0 0.4 0.1 0.2 0.2 0.5 1.6 3.6 7.0 12.9 22.1 35.8 47.8 65.2 81.5 94.6 92.0 63.3
Woman 1.9 0.9 0.2 0.2 0.2 0.6 0.6 1.7 4.0 5.4 9.7 15.7 22.7 32.2 42.5 50.2 47.7 34.5
Table 3 18 2
Age-specific incidence rates in Germany by gender, ICD-10 C64, 2007 – 2008
per 100,000













Figure 3 18 4 
Age-specific incidence rates in Germany by gender  ICD-10 C64, 2007 – 2008
per 100,000
 Cancer in Germany | Kidney
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Figure 3 18 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C64, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 18 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C64, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C64 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
1 with C65   2 with C65-66, C68
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Epidemiology
Some 16,000 people were diagnosed with an invasi-
ve bladder carcinoma in 2008 in Germany, only just 
over a quarter of them women. In addition, there 
were more than 12,000 cases of in situ tumours or 
indeterminate neoplasms. The latter are counted 
with bladder cancer cases in many registries in order 
to present long-term trends, because the criteria for 
determining malignancy of neoplasms of the blad-
der have been changed several times in recent deca-
des. Some 95 % of invasive tumours of the bladder 
are carcinomas of the urothelium, which are fre-
quently multifocal (occurring simultaneously at 
various places in the same organ).
The incidence rates increase steadily with age, 
with only about one in five being diagnosed before 
65 years of age. The age-standardised incidence and 
mortality rates for men show a clear downward 
trend, probably due to a decline in tobacco con-
sumption, but possibly also because of a decrease in 
occupational exposure to carcinogens. However, 
with the increasing proportion of older people in the 
population, the number of newly diagnosed cases in 
men increased slightly. For women, the age-standar-
dised incidence rate has been increasing in recent 
years, while the mortality rate went down slightly. 
The mortality rate for bladder cancer continues to be 
higher in the eastern federal states than in the rest 
of Germany. This corresponds to higher mortality 
rates in the eastern neighbouring countries, particu-
larly for men. 
The higher survival rates for men compared with 
women relates to the more favourable distribution of 
tumour stages at diagnosis (48 % vs. 37 % T1 for inva-
sive carcinomas, respectively). The relative propor-
tion of in situ carcinomas for men is 45 %, compared 
with 40 % for women.
Risk factors
Tobacco consumption is a key risk factor for the deve-
lopment of cancer of the bladder. Passive smoking 
also contributes to an increase in risk. The risk is 
further increased by exposure to chemical substances 
such as aromatic amines, especially for certain occu-
pational groups. The known hazardous substances 
have largely been eliminated from industrial proces-
ses and the workplace in Europe. However, there is a 
long latency period between exposure and the deve-
lopment of cancer, so that bladder carcinomas caused 
by occupational exposure will continue to be registe-
red. Cytostatic drugs used in chemotherapy and radi-
ation therapy of this part of the body can increase the 
risk. The risk potential for other medications is under 
discussion. Chronic inflammatory damage to the 
mucosa of the bladder also increases the risk of can-
cer of the bladder. Family clusters have been obser-
ved. There are indications that genetic factors play a 
direct role in the occurrence of bladder cancer, by 
influencing the susceptibility to carcinogens. 
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 11,090 4,310 11,460 4,510 11,500 4,700
(20,470)5 (7,040)5 (20,850)5 (7,490)5
Crude incidence rate1 27.5 (50.7)5 10.3 (16.7)5 28.5 (52.4)5 10.8 (17.8)5 28.9 11.4
Standardised incidence rate1.² 19.8 (36.7)5 5.4 (9.4)5 20.1 (37.1)5 5.6 (9.9)5 18.5 5.7
Median age at diagnosis 73 (72)5 77 (75)5 73 (72)5 77 (74)5
Deaths 3,639 1,965 3,611 1,921
Crude mortality rate1 9.0 4.7 9.0 4.6
Standardised mortality rate1.² 6.5 2.1 6.2 2.0
5-year prevalence 32,300 10,400 32,900 10,700 33,500 11,400
Absolute 5-year survival rate (2007–2008)3 48 (38-57) 40 (31-51)
Relative 5-year survival rate (2007–2008)3 60 (50-69) 49 (39-62)
Table 3 19 1
Overview of the key epidemiological parameters for Germany, ICD-10 C67
1 per 100,000 persons  2 age-standardised (European Standard)  3 in percentages (lowest and highest value of the included German federal states)  4 in parentheses: 
including  in situ tumours (D09.0)  and  neoplasms of uncertain or unknown behavior (D41.4)
3 19  Bladder
 Cancer in Germany | Bladder
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Figure 3 19 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C67, Germany, 2007 – 2008
Figure 3 19 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C67, Germany, 2007 – 2008
Figure 3 19 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C67, Germany, 2007 – 2008 
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
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Women
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Figure 3 19 1b
Absolute numbers of new cases and deaths,  
ICD-10 C67, Germany, 1999 – 2008
Figure 3 19 1a
Age-standardised incidence and mortality rates,  
ICD-10 C67, Germany, 1999 – 2008
per 100,000 (European standard)
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,000) 2.7 % (1 in 38) <0.1 % (1 in 11,600) 1.0 % (1 in 100)
50 years 0.2 % (1 in 460) 2.7 % (1 in 37) <0.1 % (1 in 2,600) 1.0 % (1 in 100)
60 years 0.6 % (1 in 180) 2.6 % (1 in 38) 0.1 % (1 in 840) 1.0 % (1 in 100)
70 years 1.1 % (1 in 88) 2.4 % (1 in 41) 0.4 % (1 in 280) 1.0 % (1 in 100)
Lifetime risk 2.6 % (1 in 38) 0.9 % (1 in 110)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 4,900) 0.9 % (1 in 110) <0.1 % (1 in 22,000) 0.4 % (1 in 240)
50 years 0.1 % (1 in 1,600) 0.9 % (1 in 110) <0.1 % (1 in 6,500) 0.4 % (1 in 240)
60 years 0.2 % (1 in 630) 0.9 % (1 in 110) <0.1 % (1 in 2,600) 0.4 % (1 in 240)
70 years 0.3 % (1 in 310) 0.8 % (1 in 130) 0.1 % (1 in 860) 0.4 % (1 in 240)
Lifetime risk 0.9 % (1 in 110) 0.4 % (1 in 240)
Table 3 19 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C67, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.2 0.0 0.0 0.1 0.1 0.2 0.3 1.1 2.2 6.9 15.2 28.3 46.0 74.1 104.1 167.7 216.2 262.3
Woman 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.5 1.1 2.6 4.7 8.0 12.4 19.6 28.0 40.7 55.9 71.5
Table 3 19 2
Age-specific incidence rates in Germany by gender, ICD-10 C67, 2007 – 2008
per 100,000













Figure 3 19 4 
Age-specific incidence rates in Germany by gender  ICD-10 C67, 2007 – 2008
per 100,000
 Cancer in Germany | Bladder
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Figure 3 19 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C67, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 19 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C67, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
1 no comparable data
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Epidemiology
Cancers of the central nervous system (CNS) affect the 
brain, including the brain stem, in 95 % of cases. The 
remaining 5 % are cancers of the meninges, the crani-
al nerves, and the spinal nerves in the cauda equina. 
Malignant neoplasms of the central nervous system 
originate from glial cells, nerve sheaths and menin-
ges. Histologically, they are mostly glioblastomas, 
other gliomatous tumours and astrocytomas. 
In 2008, some 7,000 people in Germany were 
diagnosed with a CNS tumour, women at a median 
age of 68 years, men already at 64 years. CNS 
tumours can occur at all ages, and they account for 
more than 20 % of all childhood cancers. 
The increase in the mortality rates for malignant 
neoplasms of the central nervous system through 
the 1980s to the mid-1990s in Germany affected 
almost exclusively the over-65-year-olds. Recently, 
mortality rates have been decreasing while the age-
standardised incidence rates in Germany have been 
largely stable since the start of the millennium. Only 
in the case of men over the age of 70 has there been 
a slight increase in incidence.
The relative 5-year survival rates for patients with 
cancer of the central nervous system were calculated 
as 18 % for men and 22 % for women, although 
almost one case in five could not be taken into 
account because of an unknown date of diagnosis 
(DCO cases). Current survival rates in the USA are 
higher, namely 34 % and 38 %, respectively.
Risk factors
The causes of the various brain tumours are current-
ly unclear. The only exception is among patients with 
very rare hereditable tumour syndromes. They have 
a markedly higher risk of developing a brain tumour. 
While there is a slightly increased risk after a thera-
peutic radiation of the head in childhood (after a con-
siderable latency period), currently no data show a 
measureable risk from exposure to ionising radiati-
on as part of diagnostic imaging procedures or from 
other forms of exposure to radiation. At the present 
state of knowledge, neither environmental factors 
nor electromagnetic radiation from sources such as 
mobile phone contribute to increasing the risk. The-
re is also no proof, to date, that viruses or toxic subs-
tances can cause brain tumours in humans. 
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 3,710 2,960 3,810 2,990 4,100 3,000
Crude incidence rate1 9.2 7.1 9.5 7.1 10.3 7.3
Standardised incidence rate1.² 7.6 5.3 7.7 5.3 7.9 5.3
Median age at diagnosis 64 67 64 68
Deaths 2,922 2,500 3,008 2,554
Crude mortality rate1 7.2 5.9 7.4 6.1
Standardised mortality rate1.² 5.7 4.0 5.8 4.0
5-year prevalence 5,700 4,400 5,800 4,500 6,000 4,600
Absolute 5-year survival rate (2007–2008)3 17 (11-24) 21 (9-28)
Relative 5-year survival rate (2007–2008)3 18 (12-26) 22 (10-29)
Table 3 20 1
Overview of the key epidemiological parameters for Germany, ICD-10 C70 – 72
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 20  Central nervous system
 Cancer in Germany | Central nervous system
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Figure 3 20 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C70 – 72, Germany, 2007 – 2008
Figure 3 20 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C70 – 72, Germany, 2007 – 2008
Figure 3 20 2
Distribution of T-stages at first diagnosis 
T-stages are not defined for tumours of the central nervous system.


































Figure 3 20 1b
Absolute numbers of new cases and deaths,  
ICD-10 C70 – 72, Germany, 1999 – 2008
Figure 3 20 1a
Age-standardised incidence and mortality rates, 
ICD-10 C70 – 72, Germany, 1999 – 2008
per 100,000 (European standard)
 ICD-10 C70 – 72 | Cancer in Germany 
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,500) 0.6 % (1 in 160) <0.1 % (1 in 2,100) 0.5 % (1 in 180)
50 years 0.1 % (1 in 840) 0.6 % (1 in 170) 0.1 % (1 in 1,000) 0.5 % (1 in 200)
60 years 0.2 % (1 in 540) 0.5 % (1 in 200) 0.2 % (1 in 610) 0.5 % (1 in 220)
70 years 0.2 % (1 in 410) 0.4 % (1 in 260) 0.2 % (1 in 470) 0.3 % (1 in 300)
Lifetime risk 0.7 % (1 in 140) 0.6 % (1 in 170)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,500) 0.5 % (1 in 200) <0.1 % (1 in 3,600) 0.5 % (1 in 220)
50 years 0.1 % (1 in 1,300) 0.5 % (1 in 220) 0.1 % (1 in 1,800) 0.4 % (1 in 230)
60 years 0.1 % (1 in 780) 0.4 % (1 in 250) 0.1 % (1 in 830) 0.4 % (1 in 250)
70 years 0.2 % (1 in 580) 0.3 % (1 in 340) 0.2 % (1 in 600) 0.3 % (1 in 330)
Lifetime risk 0.6 % (1 in 170) 0.5 % (1 in 200)
Table 3 20 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C70 – 72, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 3.0 2.2 1.8 1.6 1.3 2.4 3.8 5.0 5.7 7.5 10.3 13.4 19.6 19.7 28.6 29.0 26.8 22.6
Woman 2.8 2.1 1.7 1.4 0.9 2.9 2.6 3.5 4.1 4.6 5.6 10.0 10.9 16.3 17.4 19.3 16.6 14.5
Table 3 20 2
Age-specific incidence rates in Germany by gender, ICD-10 C70 – 72, 2007 – 2008
per 100,000













Figure 3 20 4 
Age-specific incidence rates in Germany by gender  ICD-10 C70 – 72, 2007 – 2008
per 100,000
 Cancer in Germany | Central nervous system
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Figure 3 20 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C70 – 72, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 20 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C70 – 72, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C70 – 72 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
1 no comparable data
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Epidemiology
Thyroid cancer accounts for about 1.9 % of malig-
nant neoplasms for women and 0.7 % for men and 
causes 0.4 % and 0.2 % of all cancer-related deaths, 
respectively. The lifetime risk of developing thyroid 
cancer is more than twice as high for women than for 
men (0.7 % and 0.3 %, respectively).
In the period from 1999 to 2008, the mortality 
rates in Germany have decreased slightly for both 
men and women, while the numbers of newly diag-
nosed cases and the age-standardised incidence 
rates have increased markedly for both sexes. This 
trend is more marked for women than for men, and 
is observed to a similar extent in other countries, 
such as England, Austria, and the USA. 
In 2008, the highest incidence rates for women 
were between ages 55 and 60 years, and for men bet-
ween 60 and 65 years. The median age at diagnosis 
for women was 52 years and for men 56 years. Can-
cers of the thyroid gland are diagnosed earlier for 
women and at a better stage for treatment (approx. 
62 % in Stage T1, 18 % in Stage T3). For men, appro-
ximately 52 % of cases were diagnosed in Stage T1 
and 23 % in Stage T3. Histologically, cases most fre-
quently involve papillary adenocarcinomas (72 %) 
and follicular adenocarcinomas (14 %). 
In Germany, the relative 5-year survival rate is 
currently approximately 92 % for women and 86 % 
for men. In both Finland and the USA, survival rates 
for women (93 % and 98 %, respectively) were also 
more favourable than for men (85 % and 94 %, res-
pectively).
Risk factors
The only certain, although comparatively rare envi-
ronmental risk factor is exposure to ionising radiati-
on, particularly in childhood. This includes radiothe-
rapy which extends to the thyroid gland. There is no 
clear proof of other diet- or lifestyle-related risk fac-
tors or environmental risks. It is also unclear why 
more women are affected than men. Many patients 
have a history of iodine deficiency or benign thyroid 
complaints such as struma (goitre) and adenoma, 
which increase the risk for thyroid carcinomas. 
About a fifth of patients with a rare medullary thyroid 
carcinoma have inheritable genetic changes with 
autosomal dominant inheritance. Medullary thyroid 
carcinomas can also occur together with other endo-
crine tumours as a type 2 multiple endocrine neopla-
sia (MEN 2). A genetic component is also suspected 
for the papillary thyroid carcinomas.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 1,560 3,690 1,710 4,160 1,800 4,300
Crude incidence rate1 3.9 8.8 4.3 9.9 4.5 10.3
Standardised incidence rate1.² 3.2 7.5 3.5 8.6 3.6 9.0
Median age at diagnosis 57 53 56 52
Deaths 274 420 279 429
Crude mortality rate1 0.7 1.0 0.7 1.0
Standardised mortality rate1.² 0.5 0.5 0.5 0.5
5-year prevalence 5,500 14,400 5,900 15,600 6,800 18,300
Absolute 5-year survival rate (2007–2008)3 80 (70-90) 88 (80-91)
Relative 5-year survival rate (2007–2008)3 86 (76-96) 92 (84-95)
Table 3 21 1
Overview of the key epidemiological parameters for Germany, ICD-10 C73
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 21  Thyroid gland
 Cancer in Germany | Thyroid gland
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Figure 3 21 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C73, Germany, 2007 – 2008
Figure 3 21 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C73, Germany, 2007 – 2008
T1       T2        T3       T4       
10 %0 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
no information        DCO
Women
Men
Figure 3 21 2
Distribution of T-stages at first diagnosis  (top: all cases; bottom: only valid reports)  
ICD-10 C73, Germany, 2007 – 2008 

















Figure 3 21 1b
Absolute numbers of new cases and deaths,  
ICD-10 C73, Germany, 1999 – 2008

















Figure 3 21 1a
Age-standardised incidence and mortality rates,  
ICD-10 C73, Germany, 1999 – 2008
per 100,000 (European standard)
 ICD-10 C73 | Cancer in Germany 
100
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,300) 0.3 % (1 in 380) <0.1 % (1 in 58,000) 0.1 % (1 in 1,600)
50 years 0.1 % (1 in 1,400) 0.2 % (1 in 440) <0.1 % (1 in 16,000) 0.1 % (1 in 1,600)
60 years 0.1 % (1 in 1,300) 0.2 % (1 in 590) <0.1 % (1 in 7,400) 0.1 % (1 in 1,800)
70 years 0.1 % (1 in 1,500) 0.1 % (1 in 950) <0.1 % (1 in 3,800) 0.1 % (1 in 1,800)
Lifetime risk 0.3 % (1 in 320) 0.1 % (1 in 1,600)
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 730) 0.6 % (1 in 180) <0.1 % (1 in 77,000) 0.1 % (1 in 1,100)
50 years 0.1 % (1 in 690) 0.4 % (1 in 230) <0.1 % (1 in 23,000) 0.1 % (1 in 1,100)
60 years 0.1 % (1 in 690) 0.3 % (1 in 330) <0.1 % (1 in 7,800) 0.1 % (1 in 1,100)
70 years 0.1 % (1 in 880) 0.2 % (1 in 580) <0.1 % (1 in 3,000) 0.1 % (1 in 1,200)
Lifetime risk 0.7 % (1 in 140) 0.1 % (1 in 1,100)
Table 3 21 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C73, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.2 0.6 0.9 1.4 2.6 3.4 3.9 4.6 6.5 7.4 8.5 7.8 8.0 7.4 8.0 5.5
Woman 0.0 0.1 0.2 2.4 3.4 6.0 9.0 11.9 12.9 12.8 14.3 15.2 13.8 13.9 13.1 11.2 8.1 7.0
Table 3 21 2
Age-specific incidence rates in Germany by gender, ICD-10 C73, 2007 – 2008
per 100,000













Figure 3 21 4 
Age-specific incidence rates in Germany by gender  ICD-10 C73, 2007 – 2008
per 100,000
 Cancer in Germany | Thyroid gland
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Figure 3 21 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C73, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 21 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C73, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C73 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
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Epidemiology
Hodgkin‘s lymphoma is distinguished from non-
Hodgkin lymphomas histologically by the presence 
of Reed-Sternberg giant cells in the bone marrow.
Hodgkin’s lymphoma is a rare disease, and in Ger-
many 1,160 men and 920 women were newly diag-
nosed in 2008. It can occur at any age, and about 
one patient in ten was under the age of 20 years at 
diagnosis. In contrast to almost all other types of 
cancer, the incidence risk does not increase after the 
age of 15 years.
There have been no clear trends in recent years 
for incidence rates or the absolute numbers of newly 
diagnosed cases, but there has been a decline in the 
number of people dying of Hodgkin‘s lymphoma in 
Germany to just above 300 in 2008, nearly 200 
fewer than ten years previously. The prognosis is 
correspondingly favourable, and five years after dia-
gnosis some 80 % of adult patients are still alive. 
Risk factors
Risk factors for Hodgkin’s lymphoma have not been 
clarified. Specific lifestyle-related risk factors or envi-
ronmental risks cannot yet be made responsible for 
the development of Hodgkin’s lymphoma. As with 
non-Hodgkin lymphomas, congenital and acquired 
characteristics of the immune system and viral infec-
tions are topics of debate, although their influence 
has not yet been quantified, and it has not been pos-
sible to identify a definite cause for an individual 
patient.
An involvement of the Epstein-Barr virus (which 
causes glandular fever), and of retroviruses (e.g. 
HTLV or HIV) has long been suspected, and recent 
studies have confirmed the role of the Epstein-Barr 
virus. Among participants in a study who had had 
glandular fever before they were six years old, the 
proportion of Hodgkin’s patients was nine times hig-
her than in the control group. Recent studies also 
show that the hepatitis B virus plays a role. 
The children and siblings of patients with 
Hodgkin’s lymphoma have a much higher risk of 
developing the disease themselves. Researchers are 
therefore paying increasing attention to hereditary 
factors, although as yet no risk-enhancing inherita-
ble genetic mutations could be clearly identified.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 1,150 880 1,160 920 1,100 900
Crude incidence rate1 2.9 2.1 2.9 2.2 2.8 2.1
Standardised incidence rate1.² 2.6 2.0 2.7 2.0 2.6 2.0
Median age at diagnosis 44 39 47 49
Deaths 158 149 193 148
Crude mortality rate1 0.4 0.4 0.5 0.4
Standardised mortality rate1.² 0.3 0.2 0.4 0.2
5-year prevalence 4,700 3,600 4,700 3,700 4,700 3,500
Absolute 5-year survival rate (2007–2008)3 79 (64-94) 79 (67-93)
Relative 5-year survival rate (2007–2008)3 83 (68-98) 82 (69-95)
Table 3 22 1
Overview of the key epidemiological parameters for Germany, ICD-10 C81
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 22  Hodgkin’s lymphoma
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Figure 3 22 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C81, Germany, 2007 – 2008
Figure 3 22 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C81, Germany, 2007 – 2008
Figure 3 22 2
Distribution of T-stages at first diagnosis 
 T-Stages are not defined for Hodgkin’s lymphoma.


































Figure 3 22 1b
Absolute numbers of new cases and deaths,  
ICD-10 C81, Germany, 1999 – 2008
Figure 3 22 1a
Age-standardised incidence and mortality rates,  
ICD-10 C81, Germany, 1999 – 2008
per 100,000 (European standard)
 ICD-10 C81 | Cancer in Germany 
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,800) 0.2 % (1 in 520) <0.1 % (1 in 141,000) <0.1 % (1 in 2,500)
50 years <0.1 % (1 in 3,300) 0.2 % (1 in 640) <0.1 % (1 in 37,000) <0.1 % (1 in 2,500)
60 years <0.1 % (1 in 3,900) 0.1 % (1 in 790) <0.1 % (1 in 31,000) <0.1 % (1 in 2,700)
70 years <0.1 % (1 in 3,400) 0.1 % (1 in 960) <0.1 % (1 in 24,000) <0.1 % (1 in 2,900)
Lifetime risk 0.2 % (1 in 460) <0.1 % (1 in 2,500)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 2,900) 0.2 % (1 in 630) <0.1 % (1 in 78,000) <0.1 % (1 in 3,400)
50 years <0.1 % (1 in 3,900) 0.1 % (1 in 800) <0.1 % (1 in 146,000) <0.1 % (1 in 3,500)
60 years <0.1 % (1 in 3,700) 0.1 % (1 in 1,000) <0.1 % (1 in 69,000) <0.1 % (1 in 3,600)
70 years <0.1 % (1 in 3,500) 0.1 % (1 in 1,200) <0.1 % (1 in 49,000) <0.1 % (1 in 3,700)
Lifetime risk 0.2 % (1 in 560) <0.1 % (1 in 3,400)
Table 3 22 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C81, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.2 0.8 1.4 3.2 3.8 3.3 3.3 2.9 3.2 2.3 2.9 3.2 2.9 3.5 4.7 2.9 4.6 2.7
Woman 0.0 0.3 1.3 3.9 2.9 3.9 3.0 2.1 1.4 1.5 1.3 1.4 1.9 2.2 2.3 3.1 3.9 3.2
Table 3 22 2
Age-specific incidence rates in Germany by gender, ICD-10 C81, 2007 – 2008
per 100,000













Figure 3 22 4 
Age-specific incidence rates in Germany by gender  ICD-10 C81, 2007 – 2008
per 100,000
 Cancer in Germany | Hodgkin’s lymphoma
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Figure 3 22 6
International comparison of age-standardised incidence and mortality rates
ICD-10 C81, 2007 – 2008 or latest available year (details and data sources see appendix)
per 100,000 (European standard)










































Figure 3 22 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C81, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C81 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
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Epidemiology
Non-Hodgkin lymphomas originate from cells of 
the lymphatic system, mostly from B-lymphocytes. 
A distinction is made between high-grade and low-
grade malignancy forms. In 2008 13,700 people 
were diagnosed in Germany with a non-Hodgkin 
lymphoma. The disease already occurs in childhood, 
but the incidence risk increases almost linearly with 
age. The median age at diagnosis for men was 68 
years and for women 71 years. 
The recent increases in age-standardised inci-
dence rates should be seen against the background 
of falling rates for leukaemias, because chronic lym-
phatic leukaemias are meanwhile classified clini-
cally under the low-grade malignancy non-Hodgkin 
lymphomas. The age-standardised mortality rates 
increased into the late 1990s, but then sank over the 
following ten years. Some 5,600 people die of the 
disease in Germany every year. 
The prognosis for patients with a non-Hodgkin 
lymphoma is generally rather good, with relative 
5-year survival rates of 65 % for men and 68 % for 
women, although the prognosis depends on the age 
at diagnosis and the type and distribution of the 
disease. Some cases, in particular highly malignant 
forms, can meanwhile be treated with the prospect 
of a permanent cure.
Risk factors
The known risk factors for non-Hodgkin lymphomas 
are not present in all patients. Since this is a group of 
differing lymphomas, it is only possible to make 
limited statements about risk factors that are valid 
for all forms.
An immune system deficiency (due to HIV infec-
tion or immunosuppressive treatment) is associated 
with an increased risk. Rare autoimmune diseases 
also increase the risk for some lymphomas. Viruses 
contribute to the development of these diseases, but 
it is difficult to assess their influence. There is a con-
firmed relationship between an Epstein-Barr virus 
infection and Burkitt’s lymphoma, which mainly 
occurs in Africa. T-cell lymphomas are more fre-
quently observed in carriers of the human T-cell leu-
kaemia virus (HTLV-1). Studies suggest that certain 
types of lymphoma are more likely to develop in peo-
ple chronically infected with Hepatitis viruses (Type 
B or C). Chronic infection of the stomach with the 
bacterium Helicobacter pylori can lead to a lym-
phoma of the gastric mucosa (MALT lymphoma). 
Heavy metals, organic solvents, some herbicides, 
insecticides and fungicides are discussed as possible 
initiating factors. Exposure to nuclear radiation can 
also cause malignant lymphomas. It would also 
seem that smoking and obesity play a role in the 
highly aggressive forms. However, in general there is 
as yet no clear proof of the influence of lifestyle. New 
investigations indicate that inheritable genetic vari-
ants could influence the risk of developing the 
disease without being a direct cause of lymphomas.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 7,250 6,430 7,270 6,430 7,800 6,500
Crude incidence rate1 18.0 15.3 18.1 15.4 19.6 15.8
Standardised incidence rate1.² 13.9 9.9 13.7 9.8 14.1 10.0
Median age at diagnosis 68 71 68 71
Deaths 2,876 2,598 2,926 2,658
Crude mortality rate1 7.1 6.2 7.3 6.3
Standardised mortality rate1.² 5.3 3.2 5.2 3.2
5-year prevalence 21,700 19,800 22,400 20,200 23,900 20,800
Absolute 5-year survival rate (2007–2008)3 57 (49-61) 60 (55-64)
Relative 5-year survival rate (2007–2008)3 65 (56-70) 68 (64-71)
Table 3 23 1
Overview of the key epidemiological parameters for Germany, ICD-10 C82 – 85
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 23  Non-Hodgkin lymphomas
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Figure 3 23 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C82 – 85, Germany, 2007 – 2008
Figure 3 23 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C82 – 85, Germany, 2007 – 2008


































Figure 3 23 1b
Absolute numbers of new cases and deaths,  
ICD-10 C82 – 85, Germany 1999 – 2008
Figure 3 23 1a
Age-standardised incidence and mortality rates,  
ICD-10 C82 – 85, Germany 1999 – 2008
per 100,000 (European standard)
 ICD-10 C82 – 85 | Cancer in Germany 
C82¹ C832 C843 C854
Men 18 % 43 % 9 % 29 %
Woman 23 % 40 % 7 % 30 %
Table 3 23 2
Proportion of the various non-Hodgkin lymphomas for all new diagnoses C82-C85, Germany, 2007 – 2008
1 Follicular/nodular non-Hodgkin lymphoma
2 Diffuse non-Hodgkin lymphoma
3 Peripheral and cutaneous T-cell lymphomas
4 Other and unspecified types of non-Hodgkin lymphomas
Figure 3 23 2
Distribution of T-stages at first diagnosis
T stages are not defined for non-Hodgkin lymphoma.
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,100) 1.4 % (1 in 71) <0.1 % (1 in 6,500) 0.7 % (1 in 150)
50 years 0.2 % (1 in 510) 1.3 % (1 in 74) 0.1 % (1 in 2,000) 0.7 % (1 in 150)
60 years 0.4 % (1 in 260) 1.2 % (1 in 81) 0.1 % (1 in 750) 0.7 % (1 in 150)
70 years 0.6 % (1 in 180) 1.0 % (1 in 100) 0.3 % (1 in 350) 0.6 % (1 in 160)
Lifetime risk 1.5 % (1 in 68) 0.7 % (1 in 150)
Women aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,500) 1.2 % (1 in 84) <0.1 % (1 in 8,200) 0.5 % (1 in 180)
50 years 0.2 % (1 in 590) 1.1 % (1 in 87) <0.1 % (1 in 3,600) 0.5 % (1 in 180)
60 years 0.3 % (1 in 350) 1.0 % (1 in 99) 0.1 % (1 in 1,300) 0.5 % (1 in 190)
70 years 0.4 % (1 in 250) 0.8 % (1 in 130) 0.2 % (1 in 510) 0.5 % (1 in 200)
Lifetime risk 1.2 % (1 in 81) 0.5 % (1 in 180)
Table 3 23 4
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C82 – 85, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.8 1.8 1.3 1.0 2.4 3.0 3.8 6.0 6.7 11.3 15.3 24.6 34.0 47.7 58.8 78.3 79.6 84.9
Woman 0.2 0.8 0.8 1.1 1.6 2.4 1.9 3.3 5.5 7.2 13.7 21.2 24.6 34.8 39.7 48.8 55.4 52.2
Table 3 23 3
Age-specific incidence rates in Germany by gender, ICD-10 C82 – 85, 2007 – 2008
per 100,000













Figure 3 23 4 
Age-specific incidence rates in Germany by gender  ICD-10 C82 – 85, 2007 – 2008
per 100,000
 Cancer in Germany | Non-Hodgkin lymphomas
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Figure 3 23 6
International comparison of age-standardised incidence and mortality rates 
ICD-10 C82 – 85, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 23 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C82 – 85, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C82 – 85 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
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Epidemiology 
Multiple myeloma is a malignant accumulation of 
antibody-producing plasma cells. It usually begins 
in the bone marrow and frequently forms at various 
locations in the bone marrow (multiple myeloma) 
with associated complications such as fractures and 
bone pains, or changes in blood counts. In some 5 % 
of cases, diagnosis is the result of other organs being 
affected in addition to the bone marrow. 
In 2008, new cases were diagnosed in Germany 
for some 3,000 men and 2,600 women. The inci-
dence risk increases markedly in advanced age, but 
diagnosis before the age of 45 years is extremely rare 
(about 2 % of all cases). After age-standardisation, 
both incidence rates and mortality rates have 
recently shown a slight downward trend. However, 
the absolute numbers have nevertheless risen due to 
demographic effects. 
The prognosis is rather unfavourable, with a rela-
tive 5-year survival rate of about 40 %. Even after 
maximum therapy, e.g. autologous stem cell trans-
plantation, a cure is not to be expected. However, 
some patients may experience few symptoms for a 
relatively long period, and under therapy temporary 
remission is possible.
Risk factors
The causes of multiple myeloma are mostly unk-
nown. Recognised risk factors are advanced age, 
male gender, and a case of multiple myeloma among 
first-degree relatives. Chronic infections such as 
with HIV or hepatitis C virus are associated with an 
increased risk for the development of multiple mye-
loma. Whether certain lifestyle factors, exposure to 
environmental pollutants or to nuclear radiation sig-
nificantly increase the risk of developing multiple 
myeloma is currently a topic of debate. Familial clus-
ters have been observed, but so far there is no proof 
of heritable factors. Genetic factors are suggested by 
differences in incidence between ethnic groups. The 
rates are highest among African Americans in the 
USA, and lowest in China. A monoclonal gammopa-
thy of undetermined significance (MGUS) is regar-
ded as a preliminary stage of multiple myeloma.
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 3,000 2,620 2,980 2,650 3,200 2,800
Crude incidence rate1 7.5 6.2 7.4 6.3 8.1 6.7
Standardised incidence rate1.² 5.4 3.6 5.3 3.6 5.2 3.7
Median age at diagnosis 70 72 71 74
Deaths 1,856 1,800 1,882 1,786
Crude mortality rate1 4.6 4.3 4.7 4.3
Standardised mortality rate1.² 3.3 2.2 3.3 2.2
5-year prevalence 7,100 6,400 7,200 6,500 7,500 6,700
Absolute 5-year survival rate (2007–2008)3 35 (26-40) 36 (22-48)
Relative 5-year survival rate (2007–2008)3 41 (30-46) 41 (25-53)
Table 3 24 1
Overview of the key epidemiological parameters for Germany, ICD-10 C90
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 24  Multiple myeloma
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Figure 3 24 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C90, Germany, 2007 – 2008
Figure 3 24 3a
Absolute survival rates up to 5 years after diagnosis,  
ICD-10 C90, Germany, 2007 – 2008
Figure 3 24 2
Distribution of T-stages at first diagnosis 
T stages are not defined for Muliple myeloma.


































Figure 3 24 1b
Absolute numbers of new cases and deaths,  
ICD-10 C90, Germany, 1999 – 2008
Figure 3 24 1a
Age-standardised incidence and mortality rates,  
ICD-10 C90, Germany, 1999 – 2008
per 100,000 (European standard)
 ICD-10 C90 | Cancer in Germany 
112
Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 4,300) 0.7 % (1 in 150) <0.1 % (1 in 19,000) 0.4 % (1 in 230)
50 years 0.1 % (1 in 1,600) 0.7 % (1 in 150) <0.1 % (1 in 3,100) 0.4 % (1 in 220)
60 years 0.2 % (1 in 620) 0.6 % (1 in 160) 0.1 % (1 in 1,100) 0.4 % (1 in 230)
70 years 0.3 % (1 in 350) 0.6 % (1 in 180) 0.2 % (1 in 530) 0.4 % (1 in 240)
Lifetime risk 0.6 % (1 in 150) 0.4 % (1 in 230)
Women aged in the next ten years ever in the next ten years ever
40 years <0.1 % (1 in 6,200) 0.5 % (1 in 190) <0.1 % (1 in 18,000) 0.4 % (1 in 270)
50 years 0.1 % (1 in 1,800) 0.5 % (1 in 190) <0.1 % (1 in 5,200) 0.4 % (1 in 270)
60 years 0.1 % (1 in 840) 0.5 % (1 in 210) 0.1 % (1 in 1,500) 0.4 % (1 in 280)
70 years 0.2 % (1 in 500) 0.4 % (1 in 260) 0.1 % (1 in 710) 0.3 % (1 in 320)
Lifetime risk 0.5 % (1 in 190) 0.4 % (1 in 280)
Table 3 24 3
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C90, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.5 1.3 3.4 3.1 8.6 14.7 19.8 27.1 42.7 47.3 56.9
Woman 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.5 2.6 4.2 6.8 10.0 14.3 19.0 25.5 28.4 22.9
Table 3 24 2
Age-specific incidence rates in Germany by gender, ICD-10 C90, 2007 – 2008
per 100,000 
Figure 3 24 4 
Age-specific incidence rates in Germany by gender  ICD-10 C90, 2007 – 2008
per 100,000
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Figure 3 24 6
International comparison of age-standardised incidence and mortality rates 
ICD-10 C90 , 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
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Figure 3 24 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C90, 2007 – 2008
per 100,000 (European standard)
1 without DCO cases  2 no incidence data yet
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Epidemiology
In 2008, some 11,400 people were diagnosed with 
leukaemia in Germany, of which some 5 % were 
below 15 years of age. In more than a third of cases 
the chronic lymphatic form (CLL) was diagnosed, 
and in over a quarter of cases an acute myeloid leu-
kaemia (AML).
The incidence risk for leukaemias falls with age 
during childhood, and then increases again conti-
nuously above 20 years of age.
The age-standardised incidence rates have 
recently shown a downward trend for both sexes. 
However, in view of the vague distinction between 
CLL and non-Hodgkin lymphomas (C82-C85) this 
trend should be interpreted carefully, especially 
since the incidence rates of the latter have increased 
to a similar extent. After years of stagnation, the age-
standardised mortality rates have declined conti-
nuously since the end of the 1990s for both sexes.
The prognosis for leukaemia depends on its form 
and the age of the subject at diagnosis. It is most 
favourable for the leukaemia forms in childhood, 
whereas in adults in particular the acute forms con-
tinue to have a very poor prognosis. The prognosis 
for chronic forms in old age is moderately good: 5 
years after diagnosis, about half of the patients are 
still alive. However, a permanent cure is rarely achie-
ved, e.g. after a risky stem cell transplantation.
Risk factors
Some risk factors are known to cause acute leuka-
emias, e.g. ionising radiation in radiotherapy, cytos-
tatic drugs in chemotherapy for cancer, and probably 
also various chemicals (as a result of occupational 
exposure, etc.). However these factors are not in the 
medical history of most patients. In particular the 
causes of chronic leukaemias – the most frequent 
form of leukaemia among adults – are still unclear. 
An influence of dietary habits or lifestyle factors 
is under discussion, particularly for chronic lympha-
tic leukaemias. So far, however, there is no proof of 
such influence for this or for other chronic and acute 
forms of leukaemia. 
Some relatively rare genetic changes can increase 
the incidence risk, including trisomy 21. Research is 
being carried out on other genetic changes which 
may contribute to an increased risk.
The influence of viruses is still unclear and is a 
topic of on-going research. There is a debate about 
whether insufficient training of the immune system 
in childhood contributes towards increased risk, alt-
hough no conclusion has been reached. No associa-
tion with exposure to electromagnetic fields of any 
origin could yet be proven. 
 2007 2008 Prediction for 2012
 Men Women Men Woman Men Women
Incident cases 6,180 5,220 6,340 5,080 6,500 4,900
Crude incidence rate1 15.3 12.4 15.8 12.1 16.2 11.9
Standardised incidence rate1.² 12.3 8.2 12.4 7.9 11.9 7.6
Median age at diagnosis 70 73 70 73
Deaths 3,699 3,263 3,908 3,400
Crude mortality rate1 9.2 7.8 9.7 8.1
Standardised mortality rate1.² 6.8 4.2 6.9 4.2
5-year prevalence 17,100 13,200 17,400 13,300 17,600 12,800
Absolute 5-year survival rate (2007–2008)3 47 (33-55) 43 (29-49)
Relative 5-year survival rate (2007–2008)3 54 (39-63) 49 (34-56)
Table 3 25 1
Overview of the key epidemiological parameters for Germany, ICD-10 C91 – 95
1 per 100,000 persons   2 age-standardised(European Standard)   3 in percentages (lowest and highest value of the included German federal states)
3 25  Leukaemias 
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Figure 3 25 3b
Relative survival rates up to 5 years after diagnosis,  
ICD-10 C91 – 95, Germany, 2007 – 2008
Figure 3 25 3a
Absolute survival rates up to 5 years after diagnosis, 
ICD-10 C91 – 95, Germany, 2007 – 2008
Figure 3 25 2
Distribution of T-stages at first diagnosis 
T stages are not defined for leukaemias.


































Figure 3 25 1b
Absolute numbers of new cases and deaths,  
ICD-10 C91 – 95, Germany, 1999 – 2008
Figure 3 25 1a
Age-standardised incidence and mortality rates,  
ICD-10 C91 – 95, Germany, 1999 – 2008
per 100,000 (European standard)
 ICD-10 C91 – 95 | Cancer in Germany 
AML¹ ALL2 CML3 CLL4 Others Indeterminate
Men 25 % 7 % 10 % 40 % 10 % 8 %
Woman 29 % 8 % 10 % 34 % 9 % 10 %
Table 3 25 2
Proportion of forms of leukaemia among all new cases C91 – 95, Germany, 2007 – 2008
1 Acute myeloid leukaemia  2 Acute lymphatic leukaemia   3 Chronic myeloid leukaemia   4 Chronic lymphatic leukaemia
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Männer Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
40 years 0.1 % (1 in 1,500) 1.2 % (1 in 83) <0.1 % (1 in 4,600) 0.9 % (1 in 110)
50 years 0.1 % (1 in 710) 1.2 % (1 in 85) 0.1 % (1 in 1,800) 0.9 % (1 in 110)
60 years 0.3 % (1 in 360) 1.1 % (1 in 90) 0.2 % (1 in 600) 0.9 % (1 in 110)
70 years 0.5 % (1 in 200) 1.0 % (1 in 100) 0.4 % (1 in 250) 0.8 % (1 in 120)
Lifetime risk 1.3 % (1 in 74) 0.9 % (1 in 110)
Women aged in den nächsten 10 Jahren jemals in den nächsten 10 Jahren jemals
40 years <0.1 % (1 in 2,100) 0.9 % (1 in 110) <0.1 % (1 in 6,700) 0.7 % (1 in 150)
50 years 0.1 % (1 in 1,100) 0.9 % (1 in 120) <0.1 % (1 in 2,600) 0.7 % (1 in 150)
60 years 0.2 % (1 in 570) 0.8 % (1 in 120) 0.1 % (1 in 980) 0.7 % (1 in 150)
70 years 0.3 % (1 in 320) 0.7 % (1 in 150) 0.2 % (1 in 430) 0.6 % (1 in 160)
Lifetime risk 1.0 % (1 in 100) 0.7 % (1 in 140)
Table 3 25 4
Cancer incidence and mortality risks in Germany by age and gender, ICD-10 C91 – 95, database 2008
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Men 8.6 4.2 3.4 2.5 2.1 3.8 3.1 3.8 4.6 8.2 11.2 17.4 23.5 35.9 51.9 66.6 91.8 87.1
Woman 8.6 3.9 2.3 1.4 2.0 0.8 2.7 3.5 3.2 6.3 7.3 11.3 14.2 23.7 26.3 42.3 55.2 52.5
Table 3 25 3
Age-specific incidence rates in Germany by gender, ICD-10 C91 – 95, 2007 – 2008
per 100,000
Figure 3 25 4 
Age-specific incidence rates in Germany by gender  ICD-10 C91 – 95, 2007 – 2008
per 100,000
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Figure 3 25 6
International comparison of age-standardised incidence and mortality rates 
ICD-10 C91 – 95, 2007 – 2008 or latest available year (details and sources, see appendix)
per 100,000 (European standard)










































Figure 3 25 5 
Registered age-standardised incidence rates in German federal states, ICD-10 C91 – 95, 2007 – 2008
per 100,000 (European standard)
 ICD-10 C91 – 95 | Cancer in Germany 
1 without DCO cases  2 no incidence data yet
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4  Cancer in children
The German Childhood Cancer Registry (GCCR) 
has been based at the Institute of Medical Biostatis-
tics, Epidemiology and Informatics at the University 
Medical Centre of the Johannes Gutenberg Univer-
sity, Mainz, since beginning its work in 1980. Close 
cooperation with the Society for Paediatric Oncology 
and Haematology (GPOH) and its associated hospi-
tals was part of the GCCR‘s original conception. 
This is a characteristic feature of the registry which 
cannot be easily applied to adult oncology. This nati-
onwide, population based childhood cancer registry 
with a high level of data quality and a degree of com-
pleteness of over 95 % (since about 1987) has been 
built up covering the whole of Germany. The GCCR 
thus meets international standards for population 
based cancer registries. A further characteristic of 
the GCCR is that it has implemented an active, 
open-end, long-term follow-up which continues 
long into adulthood. In this way, the registry also 
provides the basis for research into long-term effects 
and second tumours, and for studies with long-term 
survivors in general. The registry population com-
prises children who are diagnosed with a malignant 
disease or a histologically benign brain tumour 
before their 15th birthday and are part of the resident 
population of the Federal Republic of Germany 
when diagnosed. Cancer cases in eastern Germany 
have also been registered since 1991. The current 
data pool consists of over 48,000 cancer cases. 
Since 1 January 2009, the GCCR has been registe-
ring all children and adolescents up to the age of 18 
years (i.e. who are diagnosed before their 18th birth-
day) on the basis of the „Agreement of the Joint 
Federal Committee on Quality-Assurance Measures 
for the In-Patient Care of Children and Adolescents 
with Haemato-Oncological Diseases (GBA)“. This 
will make it possible to better consider the needs of 
the collaborating hospitals which have been com-
bining paediatric and adolescent medicine for seve-
ral years now and thus also treat cancer patients 
aged 15 years and over. 
Incidence of childhood cancers
About 1,800 cases of childhood cancer are newly dia-
gnosed every year in Germany. With an overall 
population of approx. 11 million children under the 
age of 15 years, this means an annual incidence of 
about 15.9 per 100,000 children in this age group. 
The likelihood that a newborn child will develop a 
malignant disease within the first 15 years of his/her 
life is 0.2 %. In other words, a malignant cancer is 
diagnosed in approx. one in 500 children up to their 
15th birthday.
Range of diagnoses
The pattern of cancer diagnoses in children is com-
pletely different from that of adults. For example, 
children are mostly affected by hematologic diseases 
and embryonic tumours (neuroblastomas, retino-
blastomas, nephroblastomas, medulloblastomas, 
embryonic rhabdomyosarcomas or germ-cell 
tumours); carcinomas, by contrast, are very rare in 
childhood (making up about 2 % of all malignant 
diseases). The largest diagnostic groups are leuka-
emias (34.1 %), CNS tumours (23.2 %) and lympho-
mas (11.4 %). Overall cancer incidence among child-
ren under the age of five is about twice as high as in 
the 5- to 14-year-old age group. The median age at 
onset among the under-15-year-olds is five years, ele-
ven months. Boys are diagnosed with cancer 1.2 
times more frequently than girls.
Leukaemias
Leukaemias make up more than a third of all can-
cers among the under-15-year-olds. The most com-
mon single diagnosis overall (26.7 %) is lymphatic 
Lymphomas  11.4 %  
Leukaemias  34.1 %  
CNS tumours  23.2 %  
Peripheral nervous cell tumours  7.0 %  
Soft-tissue sarcomas  6.0 %
Kidney tumours  5.6 %  
Bone tumours  4.5 %  
Other diagnoses  5.3 %   
Germ-cell tumours  3.0 % 
Figure 4 1
Cancer in children (determined for the period 2001-2010)
 Cancer in children | Cancer in Germany 119
leukaemia (LL). It occurs more than twice as fre-
quently among children under the age of five as in 
the other age groups. 4.5 % of all childhood malig-
nancies are acute myeloid leukaemias (AML). AML 
is most common among children under the age of 
two. The survival prospects for AML are markedly 
lower than for LL. The causes of leukaemias in child-
hood remain largely uncertain, even today. For a 
long time, environmental influences were suspec-
ted of causing childhood leukaemias. Since then it 
has been shown that the number of cases caused by 
most environmental factors (low-dose ionizing radi-
ation, non-ionizing radiation and pesticides) is quite 
small after all, even if a weak association with leuka-
emias in childhood cannot be ruled out. A number 
of clues have meanwhile strengthened hypotheses 
that assign a key role to infectious pathogens in the 
development of childhood leukaemias. Especially 
children with an insufficiently modulated immune 
system in infancy can have a higher risk of develo-
ping leukaemia.
CNS tumours
The most common single diagnoses among CNS 
tumours are astrocytomas (total: 11.0 %), intracranial 
and intraspinal embryonal tumours (4.6 %) and 
ependymomas (2.3 %). The increase in the inci-
dence of CNS tumours observed in a number of 
western countries over the past decades may be con-
nected with general changes in environmental fac-
tors and related exposures. For example, a number 
of epidemiological studies are looking into the pos-
sible influence of ionizing radiation, electromagne-












New cases by age and sex, all childhood malignancies
Number of cases per 100,000 by age group, determined for the period 2001-2010
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New cases by age and sex, childhood lymphatic leukaemia (LL)
Number of cases per 100,000 by age group, determined for the period 2001-2010
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Figure 4 4
Trends in the incidence of selected diagnostic groups and for all childhood malignancies
Number of cases per 100,000 (age standardized), including eastern Germany since 1991
 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 












Trends in the incidence of childhood leukaemias, myeloproliferative and myelodysplastic disorders
Number of cases per 100,000 (age standardized), including eastern Germany since 1991
 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 











 Cancer in children | Cancer in Germany 121
ween 2000 and 2009 and followed up, the overall 
chance of survival is 84 % after five years, 81 % after 
ten years, and 80 % after 15 years. The encouraging 
increase in the number of long-term survivors is 
increasingly focusing attention on the long-term 
observation of former paediatric cancer patients. The 
GCCR provides an ideal data basis for carrying out 
studies with long-term survivors. As the above figu-
res show, it is already possible to provide information 
on long-term survival (for example after 15 years) and 
to estimate the risk of developing a second malig-
nancy after cancer in childhood. Examples of further 
research possibilities include the incidence of other 
long-term effects, such as the possible effects of the-
rapy on fertility, and studies examining the health 
risks of the descendants of fathers and mothers who 
had childhood cancer. About 19,000 of the more 
than 33,000 patients currently known to be alive 
have been under observation by the registry for at 
least ten years. About three quarters of these patients 
are at least 18 years old in the meantime and are thus, 




Incidence and survival rates for the most common diagnoses, determined for the period 2000-2009
Cancer sites Incidence* Survival rate in percent %**
after 5 years after 10 years after 15 years
Retinoblastomas 0.4 98 98 98
Hodgkin’s lymphomas 0.6 98 97 96
Germ cell tumours 0.5 95 94 93
Nephroblastomas 1.0 93 93 92
Lymphoid leukaemias 4.4 90 88 87
Non-Hodgkin lymphomas 0.6 88 87 85
Astrocytomas 1.7 80 77 75
Neuroblastomas and ganglioneuroblastomas 1.4 78 75 74
Osteosarcomas 0.3 75 71 70
Rhabdomyosarcomas 0.5 74 72 71
Ewing's tumours and related bone sarkomas 0.3 70 67 65
Acute myeloid leukaemias 0.7 70 68 67
Intracranial & intraspinal embryonal tumours 0.8 65 58 55
All malignancies 16.0 84 81 80
*  Related to 100,000 children under the age of 15, age standardized (standard: SEGI world population), children diagnosed 2000-2009
** Brenner H, Spix C. Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates. Br J Cancer 89, 
1260-1265, 2003.
Lymphomas
The most common lymphomas are Non-Hodgkin 
lymphomas (NHL), including Burkitt‘s lymphoma 
(total: 6.5 %), and Hodgkin’s lymphoma (4.8 %). The 
chances of survival with Hodgkin’s lymphoma are 
among the best in paediatric oncology. Children with 
congenital or acquired immunodeficiency and those 
who have had immunosuppressive therapy are at 
increased risk of developing NHL. An association is 
suspected between lymphomas and ionizing radiati-
on; this has not, however, been substantiated.
 
Other common malignant diseases
Other common malignant diseases in childhood 
include neuroblastomas (nerve-cell tumours), neph-
roblastomas (kidney tumours), germ-cell tumours, 
bone tumours and rhabdomyosarcomas (tumours of 
the skeletal musculature). Among these malignan-
cies, the prognosis for children with nephroblastoma 
or a germ-cell tumour is much more favourable than 
for the others.
Survival
Children with cancer make up fewer than 1 % of all 
cancer patients. However, malignant neoplasms are 
the second most common cause of death among 
children. Fortunately, the survival probability has 
improved dramatically over the last 30 years thanks 
to significantly more differentiated diagnostics and 
the use of multimodal therapy concepts. In the early 
1980s the chances of children with cancer being still 
alive five years after diagnosis were 67 %; this figure 
has risen to 84 % since then. Looking at all patients 
of the registry population who were diagnosed bet-
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After the Federal Cancer Registry Data Act (Bundes-
krebsregisterdatengesetz – BKRG) came into force 
in August 2009, the German Centre for Cancer 
Registry Data was set up as an independent division 
within the Robert Koch Institute’s Department of 
Epidemiology and Health Reporting to perform the 
tasks laid down in the Act:
 ▶ to check the completeness of case finding and of 
the variables included in the anonymized data 
submitted by the epidemiological (population-
based) state cancer registries;
 ▶ to analyse these data
 ▶ to publish the findings on cancer incidence in 
Germany and its development over time together 
with the Association of Population based Cancer 
Registries in Germany (GEKID)
 ▶ to conduct a nationwide record linkage with the 
data from the different state cancer registries to 
discover any duplicate notifications and to 
inform the cancer registries accordingly
 ▶ to compile, update and extrapolate a dataset 
from the reviewed data from the state cancer 
registries
 ▶ to regularly estimate and analyse survival rates, 
stage distribution at diagnosis of the respective 
cancer, and other indicators, particularly on pre-
valence, the risk of developing and dying of the 
disease, and how these indicators develop over 
time
 ▶ to examine data from various states to determine 
any regional differences in selected cancer sites
 ▶ to provide a dataset for evaluating health-policy 
measures of cancer prevention, cancer scree-
ning, cancer treatment and healthcare
 ▶ to conduct analyses and studies on all aspects of 
cancer
 ▶ to write a comprehensive report on cancer in 
Germany every five years
 ▶ to further enhance methods and standardization 
rules on data collection and data transfer, and to 
analyse the data together with the state cancer 
registries
 ▶ to collaborate in scientific bodies as well as Euro-
pean and international organizations on cancer 
registration and cancer epidemiology (inter alia 
active participation in the working groups of the 
National Cancer Plan)
 ▶ To complement the classical printed products 
through interactive analysis tools and an expan-
ded presence on the Web
The work of the German Centre for Cancer Registry 
Data is supported by a scientific advisory board with 
an office at the RKI. This advisory board can also 
give permission for the dataset at the Centre for 
Cancer Registry Data to be made available to third 
parties on application – i.e. in addition to the state 
cancer registries – if a justified and, in particular, 
scientific interest can be substantiated. Further 
information on the German Centre for Cancer 
Registry Data is available on the Internet at 
www.krebsdaten.de. 
Staff of the German Centre for Cancer Registry 
Data:
Dr Klaus Kraywinkel (section head) 
Nadia Baras 
Dr Benjamin Barnes 
Dr Joachim Bertz 
Dr Stefan Dahm 








The German Centre for Cancer Registry Data at the Robert Koch Institute
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The Association of Population-based Cancer Regist-
ries in Germany (GEKID) was formed in 2004 as a 
registered, non-profit-making association. GEKID’s 
members include not only all Germany’s populati-
on-based cancer registries, but also a tumour centre 
and interested scientists working in the field of can-
cer epidemiology. In the field of cancer control, 
GEKID cooperates closely with the Federal Ministry 
of Health, particularly in the context of the National 
Cancer Plan, and the German Centre for Cancer 
Registry Data based at the Robert Koch Institute 
(RKI). GEKID also participates actively in a wide 
range of scientific committees. The association’s 
primary task is to standardize as far as possible the 
content and methodology of cancer registration, 
despite the differences in legislation between the 
federal states. The comparability of results from the 
cancer registries can only be assured by nationwide 
cooperation. To promote such cooperation, GEKID 
published “The Manual of Population-based Cancer 
Registration in 2008. Furthermore, GEKID is a 
joint point of contact for the population-based can-
cer registries on all issues of common interest and 
represents the registries at the European level, e.g. 
in the European Network of Cancer Registries 
(ENCR). In its charter, GEKID has set itself the fol-
lowing  tasks:
 ▶ to be the point of contact both for national and 
international cooperation partners and for the 
interested public
 ▶ to provide information on the status of cancer 
registration in Germany and explain the aims of 
population-based cancer registration
 ▶ to engage in joint information activities and thus 
help the individual cancer registries achieve and 
maintain complete registration
 ▶ to define standards on content as a basis for the 
comparability of population-based cancer regist-
ries
 ▶ to coordinate tasks involving all the registries 
and foster contacts with clinical tumour docu-
mentation
 ▶ to initiate joint research activities 
 ▶ to promote the scientific use of the population 
based cancer registries
 ▶ to use the data to advance quality assurance in 
oncological care 
Important results of GEKID activities in the past two 
years include: 
 ▶ Continuing development of the GEKID’s inter-
active Cancer Atlas with current cancer inci-
dence and mortality from the Federal States. The 
Atlas may be accessed via the GEKID homepage 
and contributes to the scientific use of cancer 
registry data.
 ▶ Agreement of the population-based cancer regis-
tries on a uniform minimal data format for 
registration as well as an exchange format for 
the forwarding of data according to place of resi-
dence and for the delivery of data to the Centre 
for Cancer Registry Data at the RKI.
 ▶ Development and publication of recommenda-
tions by the GEKID Survival Working Group to 
enhance the comparability of results from survi-
val analyses from different population-based 
cancer registries.
Information on GEKID can be obtained on the 
Internet at www.gekid.de or from the respective 
regional member registries (see address section):
Contacts for the Association of Population-based 
Cancer Registries in Germany (Gesellschaft der
epidemiologischen Krebsregister in Deutschland 
e.V., GEKID) (see address section):
Prof Dr Alexander Katalinic
(Chair of GEKID, Schleswig-Holstein Cancer
Registry)
Dr Stefan Hentschel 
(1st Vice-chair, Hamburg Cancer Registry)
Dr Bettina Eisinger 
(2nd Vice-chair, Joint Cancer Registry)
Association of Population-based Cancer Registries in Germany 
(Gesellschaft der epidemiologischen Krebsregister in Deutschland e V , GEKID) 
 Cancer in Germany 125
Addresses
Krebsregister Baden-Württemberg (Baden-Wurttemberg Cancer Registry)
Epidemiologisches Krebsregister (Population-based Cancer Registry)
Deutsches Krebsforschungszentrum (German Cancer Research Centre)
Im Neuenheimer Feld 581
69120 Heidelberg  Telephone: 06221/42 42 20 Telefax: 06221/42 22 03 
 Email: ekr-bw@dkfz.de 
 Internet: www.krebsregister-bw.de
Vertrauensstelle* Baden-Wurttemberg (Baden-Wurttemberg Confidentiality Unit) 
Deutsche Rentenversicherung (German Pension Insurance) Baden-Wurttemberg 
Gartenstr. 105 
76135 Karlsruhe Telephone: 0721/82 57 90 00 Telefax: 0721/82 59 97 90 99
 Email: vs@drv-bw.de
Klinische Landesregisterstelle* (Clinical State Registration Unit)
Baden-Wurttembergische Krankenhausgesellschaft e.V. (Baden-Wurttemberg Hospital Association)
Birkenwaldstr. 145
70191 Stuttgart  Telephone: 0711/257 77 70 Telefax: 0711/257 77 79 
 Email: info@klr-krbw.de 
Bevölkerungsbezogenes Krebsregister Bayern (Bavaria Population-based Cancer Registry) 
Registerstelle* (Registry Unit): 
Östliche Stadtmauerstr. 30 
91054 Erlangen Telephone: 09131/853 60 35 (R) Telefax: 09131/853 60 40 (R) 
 Email: krebsregister@ekr.med.uni-erlangen.de 
 Internet: www.krebsregister-bayern.de
Vertrauensstelle* (Confidentiality Unit) 
Kleinikum Nürnberg-Nord 
Professor-Ernst-Nathan-Str.1 
90419 Nürnberg Telephone: 0911/378 67 38 Telefax: 0911/378 76 19 
 Email: vertrauensstelle@klinikum-nuernberg.de 
 Internet: www.krebsregister-bayern.de
Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern,  
Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen (Joint Cancer Registry of Berlin, Brandenburg,
Mecklenburg-Western Pomerania, Saxony-Anhalt, Saxony and Thuringia), GKR
Brodauer Str. 16 – 22
12621 Berlin Telephone: 030/56 58 14 01 (R) Telefax: 030/56 58 14 44 (R) 
  030/56 58 13 15 (V)  030/56 58 13 33 (V) 
 Email: registerstelle@gkr.berlin.de 
  vertrauensstelle@gkr.berlin.de 
 Internet: www.berlin.de/gkr/
Krebsregister des Landes Bremen (Bremen Cancer Registry) 
Bremer Institut fur Präventionsforschung und Sozialmedizin  
(Bremen Institute for Prevention Research and Social Medicine), BIPS 
Achterstr. 30 
28359 Bremen  Telephone: 0421/218 569 61 (R) Telefax: 0421/218 569 41 (R) 
  0421/218 569 99(V) 
 Email: krebsregister@bips.uni-bremen.de (R) 
  vbkr.kvhb@t-online.de (V) 
 Internet: www.krebsregister.bremen.de
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Hamburgisches Krebsregister (Hamburg Cancer Registry) 
Behörde für Soziales, Familie, Gesundheit und Verbraucherschutz  
(State Ministry of Social Affairs, Family, Health and Consumer Protection) 
Billstr. 80 
20539 Hamburg  Telephone: 040/428 37 22 11 Telefax: 040/428 37 26 55 
 Email: HamburgischesKrebsregister@bgv.hamburg.de 
 Internet: www.hamburg.de/krebsregister
Krebsregister Hessen (Hesse Cancer Registry) Registerstelle* (Registry Unit):  
Hessischen Landesprüfungs- und Untersuchungsamt im Gesundheitswesen  
(Hesse State Health Office, HLPUG) 
Wolframstr. 33 
35683 Dillenburg  Telephone: 02771/32 06 39 Telefax: 02771/366 71  
 Email: stefan.gawrich@hlpug.hessen.de  
 Internet: www.hlpug.de
Vertrauensstelle (Confidentiality Unit): 
Landesärztekammer Hessen (Hesse State Medical Council)
Im Vogelsgesang 3
60488 Frankfurt/Main Telephone: 069/789 04 50 Telefax: 069/78 90 45 29
 Email: vertrauensstelle@laekh.de 
 Internet: www.laekh.de
Epidemiologisches Krebsregister Niedersachsen (Lower Saxony Population-based Cancer Registry)
OFFIS CARE GmbH 
Industriestr. 9
26121 Oldenburg Telephone: 0441/361 05 60 (R) Telefax: 0441/36 10 56 10 (R) 
  0511/450 53 56 (V)  0511/450 51 32 (V) 
 Email: registerstelle@krebsregister-niedersachsen.de 
  vertrauensstelle.ekn@nlga.niedersachsen.de 
  Internet: www.krebsregister-niedersachsen.de
Epidemiologisches Krebsregister NRW gGmbH  
(North Rhine-Westphalia Population-based Cancer Registry) 
Robert-Koch-Str. 40
48149 Münster Telephone: 0251/835 85 71 Telefax: 0251/835 85 77 
 Email: info@krebsregister.nrw.de 
 Internet: www.krebsregister.nrw.de
 
Krebsregister Rheinland-Pfalz (Rhineland-Palatinate Cancer Registry) Registerstelle* (Registration Unit) 
Institut für Medizinische Biometrie, Epidemiologie und Informatik  
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI 
Obere Zahlbacher Str. 69
55131 Mainz Telephone: 06131/17 67 13 Telefax: 06131/17 32 47 
 Email: krebsregister@imbei.uni-mainz.de
Vertrauensstelle* (Confidentiality Unit): 
Am Pulverturm 13
55131 Mainz Telephone: 06131/17 30 02 Telefax: 06131/17 32 47 
 Internet: www.krebsregister-rheinland-pfalz.de
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Epidemiologisches Krebsregister Saarland (Saarland Population-based Cancer Registry)
Ministerium fur Gesundheit und Verbraucherschutz (Ministry of Health and Consumer Protection)
Prasident-Baltz-Str. 5 
66119 Saarbrucken Telephone: 0681/501 59 82 (R) Telefax: 0681/501 59 98 (R) 
  0681/501 58 05 (V) 
 Email: krebsregister@gbe-ekr.saarland.de 
 Internet: www.krebsregister.saarland.de
Krebsregister Schleswig-Holstein (Schleswig-Holstein Cancer Registry)
Institut für Krebsepidemiologie e.V. (Institute of Cancer Epidemiology)
Ratzeburger Allee 160, Haus 50
23538 Lübeck Telephone: 0451/500 54 40 Telefax: 0451/500 54 55
Vertrauensstelle* (Confidentiality Unit) 
Ärztekammer Schleswig-Holstein
Bismarckallee 8-12
23795 Bad Segeberg Telephone: 04551/803 104 Telefax: 04551/803 188 
 Email: info@krebsregister-sh.de 
 Internet: www.krebsregister-sh.de
Deutsches Kinderkrebsregister (German Childhood Cancer Registry) 
Institut fur Medizinische Biometrie, Epidemiologie und Informatik  
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI 
55131 Mainz  Telephone: 06131/17 31 11 Telefax: 06131/17 44 62 
 Email: kinderkrebsregister@imbei.uni-mainz.de 
 Internet: www.kinderkrebsregister.de
Further contacts:
Zentrum fur Krebsregisterdaten im Robert Koch-Institut 
(German Centre for Cancer Registry Data at the Robert Koch Institute)
General-Pape-Str. 62 – 66
12101 Berlin  Telephone: 030/18 754 33 42  Telefax:  030/18 754 33 54 
 Email:  krebsdaten@rki.de 
 Internet:  www.krebsdaten.de
Bundesministerium fur Gesundheit (Federal Ministry of Health)
53107 Bonn
Referat 311  Telephone: 0228/99 441 15 10  Telefax: 0228/99 441 49 31 
Referat 315  Telephone: 0228/99 441 31 08 Telefax: 0228/99 441 49 38 
 Email:  poststelle@bmg.bund.de 
 Internet:  www.bmg.bund.de
Cancer Information Service 
German Cancer Research Centre
Im Neuenheimer Feld 280
69120 Heidelberg Telephone: 06221/42 28 90 
 Email:  krebsinformationsdienst@dkfz.de 
 Internet:  www. krebsinformationsdienst.de
*  To protect patients’ confidentiality, responsibility for cancer registration in Germany is often divided between Confi-
dentiality Units (Vertrauensstellen, V) and Registration Units (Registerstellen, R). Cancer morbidity and mortality 
notifications are sent to the Confidentiality Units, where personal information is anonymized. Along with the corres-
ponding medical data, these anonymized data are then sent to the Registration Units, which are responsible for main-
taining and analyzing the registry database.
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Sources for comparing country-specific cancer incidence and mortality rates
(for the years 2007/2008 if not otherwise stated)
Netherlands: Netherlands Cancer Registry    http://www.cijfersoverkanker.nl/?language=en
Denmark, Finland, Sweden: Association of the Nordic Cancer Registries 
 http://www-dep.iarc.fr/nordcan/English/frame.asp
France: Institut de veille sanitaire    http://www.invs.sante.fr/surveillance/cancers/estimations_cancers/default.htm  
 (last available year: 2005)
Czech Republic: Institute of Health Information and Statistics of the Czech Republic 
 http://www.svod.cz/?sec=aktuality&lang=en
Poland: National Cancer Registry    http://85.128.14.124/krn/english/index.asp
England: Office for National Statistics:  
 http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-218569
United States: National Cancer Institute Surveillance Epidemiology and End Results    
 http://seer.cancer.gov/canques/incidence.html
Switzerland: National Institute for Cancer Epidemiology and Registration 
 http://www.nicer.org/default.aspx?NavigationID=5&SubNavigationID=35    
 (averaged rates for years 2004 to 2008) 
Belgium: Incidence: Belgian Cancer registry    http://www.kankerregister.org
 http://kankerregister.nettools.be/media/docs/StK_publicatie.pdf  
 http://kankerregister.nettools.be/media/docs/StK_appendices.pdf
 Mortality (for year 2008 only): 
 Belgium: Algemene Directie Statistiek en Economische Informatie  
  http://statbel.fgov.be/nl/statistieken/cijfers/bevolking/sterfte_leven/oorzaken/index.jsp
 Flemish region: Vlaams Agentschap Zorg en Gezondheid. Team Gegevensverwerking en 
  Resultaatsopvolging. Afd. Informatie en Ondersteuning 
  http://www.zorg-en-gezondheid.be/Cijfers/
 Brüssel, Bruxelles region: Observatoire de la Santé et du Social de Bruxelles.  
  Bulletins statistiques de décès
 Walloon region: Ministère de la Communauté francaise-Direction générale de la Santé-Cellule  
  desstatistiques des naissances et des décès Bulletins statistiques de décès 
  www.sante.cfwb.be
Austria: STATISTIK AUSTRIA, Österreichisches Krebsregister (Stand: 13.09.2011)
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08“Cancer in Germany” is published every two years by the Asso-
ciation of Population-based Cancer Registries in Germany e. V. 
(GEKID) and the Centre for Cancer Register Data (ZfKD) at the 
Robert Koch Institute. The results in this eighth edition are based 
on data from 15 out of 16 federal states through to 2008. Data 
was judged sufficiently complete for 10 federal states and also  
for large parts of North Rhine-Westphalia, which represents a 
considerably improved database.
For the first time, this edition covers cancers of the liver and gall 
bladder, as well as multiple myelomas. The key epidemiological 
parameters and current trends are presented for all cancers 
combined and individually for 24 types of cancer. In addition to 
details on incidence and mortality, with regional and internatio-
nal comparisons, the distribution of tumour stages at diagnosis 
and survival prospects are also included. As in previous editions, 
a separate chapter on cancer in children is provided by the Ger-
man Childhood Cancer Registry.
For 2008, the ZfKD estimates that there were some 470,000 new 
cases of cancer in Germany, about 70,000 more than in 1999. 
This increase is due mainly to the continuing increase in the pro-
portion of older people in the population. In addition there was 
the expected increase in the incidence of breast cancer following 
the start of the mammography screening programme in Germa-
ny between 2005 and 2008.
In 2008, breast cancer was still the most common form for wo-
men with some 72,000 new cases. For men the most common 
form was still prostate cancer with approx. 63,000 diagnosed 
cases.
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